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Abstract 
Multidrug resistance (MDR) is often the major cause for the failure of chemotherapy 
against cancers. Though the cancer cells can achieve MDR through various 
mechanisms, most common among them is the drug efflux mediated by ATP-binding 
cassette (ABC) transporters which utilizes energy derived from adenosine 
triphosphate (ATP) for the transport. These ABC transporters are ubiquitous and are 
involved in many physiological functions in various organisms. They also transport a 
diverse range of substrates across different cellular membranes. Some of these 
transporters have been found to be overexpressed in various cancer cell lines when 
treated with anticancer drugs. Multidrug resistance protein 3 (MRP3) is one of such 
ABC transporter in humans. This thesis aimed to characterize this transporter with 
respect to the functions of its different domains and the transport mechanism. 
Therefore various truncated versions of the protein lacking one or more of its 
functional and structural domains were designed. 
The transporter and its different truncated versions were successfully 
overexpressed into the yeast Pichia pastoris for their characterization. For 
purification, a poly-His tail and a Strep tag were incorporated in the recombinant 
proteins. It is shown here for the first time that the MRP3 transporter can 
successfully be expressed even after removal of TMD0 and the linker region L0 in 
yeast. The purification of the full transporter was analyzed on different affinity 
columns. While the binding and elution on the Ni-NTA column was successful, the 
purity of the protein was not sufficient for further reconstitution experiments to 
analyze the transport activity. Further purification on Strep-tactin and Reactive Red 
column led to insufficient results. 
The protein was unable to bind to the Strep-tactin column efficiently in its native or 
denatured state irrespective of the position of the tag. Though the protein was 
binding to the Reactive Red column, it could not be eluted even with high 
concentrations of salts. These results suggest that the choice of affinity tag for the 
heterologous expression and purification of the protein is of prime importance and 
the binding of the tag to the column material may vary from protein to protein.  
The present thesis demonstrates the successful expression of the MRP3 and its 
truncated versions in yeast. Membrane vesicles prepared from these expressing 
clones can be used to study the transport and ATPase activities of the full 
transporter and its truncated versions. The results obtained from such activity 
measurements can be useful in understanding the role of TMD0 and L0 in the drug 
specificity and the activity of the protein. However such a system of measurements 
needs to be optimized. 
In conclusion, this study has demonstrated a successful expression of truncated 
versions of MRP3 in yeast for the first time and opened the doors for further 
characterization of the protein.   
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1 Introduction 
Cell membranes are important for the life of the cell; it not only encloses the cell and 
defines its boundaries but also maintains the differences between the cytosol and 
the extracellular environment which is essential for its functions. (Bruce Alberts 
2002) The hydrophobic lipid membranes play a key role in the integrity of the cells 
by limiting the movement of substances across the living cells. However transport of 
specific substances across this barrier is essential for the survival of the cells. For 
this purpose, membranes have specialized proteins associated with the membrane 
transport systems. These transport systems allow uptake of specific molecules and 
removal of unwanted compounds from the cell. Such transport systems render the 
membranes selectively permeable for the substances (Jeremy M Berg 2002).  
Depending on the characteristics of the substance being transported and the 
direction of transport, there are two principal mechanisms by which molecules can 
pass though the boundary of cellular membranes. The transport mechanisms are 
passive (by simple diffusion or facilitated diffusion) and active transport. 
a. Simple diffusion 
Simple diffusion is the spontaneous movement of a substance down its concentra-
tion gradient from higher to lower concentration. In simple diffusion, small non 
charged molecules or lipid soluble hydrophobic molecules pass between the 
membrane lipids to enter or leave the cell, moving from areas of high concentration 
to low concentration. Small molecules like oxygen, nitrogen, carbon dioxide and 
most hydrophobic compounds are transported across the membrane by simple 
diffusion (Jeremy M Berg 2002). 
b. Facilitated diffusion 
Passive diffusion is a very slow process and hence not efficient enough for the 
transport of many substances across the lipid membranes which are necessary to 
sustain life processes (Reginald H. Garrett 2010).  Therefore, transport of inorganic 
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ions and small water-soluble organic molecules across the lipid bilayer is achieved 
by specialized transmembrane proteins called ‘Channels’. These channels provide an 
alternative path through the bilayer for specific solutes and transport them down 
their concentration gradient.  
In both, simple and facilitated diffusion the transport is driven solely by the 
concentration (or electrochemical) gradient, therefore no metabolic energy is 
required for both the processes (Bruce Alberts 2002).  
c. Active transport 
Simple and facilitated diffusion transport the substances down their concentration 
gradient. But in order to maintain this concentration gradient across the membranes 
and drive many cellular processes, molecules sometimes have to be transported 
against their concentration gradient (from low to high concentration). To carry out 
this type of transport, an external energy source is required. Thus referred to as 
active transport (David L. Nelson 2008). 
 In active transport, movement of molecules across membranes is mediated by 
specialized membrane proteins that are known as transporters. These transporters 
are further divided into different families and classes, based on the nature of 
transport, the substrates and the source of energy utilized to drive the transport. 
Although this energy can come from various sources like electron movement or 
from light, the most common energy input is ATP hydrolysis (Reginald H. Garrett 
2010). 
One of the largest protein families of integral membrane proteins that utilize the 
energy of ATP hydrolysis to translocate solutes across cellular membranes is formed 
by the ATP-binding cassette (ABC) transporters. 
1.1 ABC transporters 
ATP-binding cassette (ABC) transporters are a large superfamily of membrane 
proteins which includes a variety of active transporters with diverse functions 
(Higgins 1992). They are ubiquitous in biology and power the translocation of large 
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number of structurally different substrates across the membrane using the energy 
derived from ATP hydrolysis.  
ABC transporters are widespread in archaea, eubacteria and eukaryotes and play a 
wide variety of physiological roles in all species of living organisms such as 
maintenance of osmotic homeostasis, nutrient uptake, resistance to xenotoxins, 
antigen processing, cell division, bacterial immunity, pathogenesis and sporulation, 
cholesterol and lipid trafficking and in the development of stem cells (Jones and 
George 2004). Apart from these physiological roles, ABC transporters are also 
associated with a variety of clinical problems such as cystic fibrosis (a chronic, life-
threatening lung disease) and multidrug resistance (resistance to chemotherapy 
drugs) (Higgins 1992). 
The designation ‘ABC transporter’ recognizes a highly conserved ATP-binding 
cassette, which is the most characteristic feature of this superfamily. These 
transporters function as either importers or exporters. The importers bring 
necessary nutrients and other molecules into cells whereas the exporters pump 
toxins, drugs and lipids outside across membranes. Whereas exporters are found in 
both eukaryotes and prokaryotes, importers seem to be present exclusively in 
prokaryotic organisms (Rees, Johnson et al. 2009). 
Recently, two ABC transporters in yeast associated with transport of sterols were 
shown to promote either influx or efflux of a cholesterol derivative depending on the 
sterol context of the cell. This is a rare example of an ABC transporter mediating bi-
directional transport, suggesting that direction of transport is not a static inherent 
property of the transporter, but rather that it is mutable and influenced by 
surrounding sterols and proteins (Gulati 2011). 
Although most of the ABC transporters exhibit relatively tight substrate specificity, 
some are multispecific. The oligopeptide transporter for example, handles 
essentially all di- and tripeptides (Tame, Murshudov et al. 1994) while others have 
an extremely broad specificity for hydrophobic compounds, such as the multidrug 
transporter LmrA from Lactococcis lactis (van Veen, Callaghan et al. 1998). 
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1.1.1 Structure of ABC transporters 
Despite the large variety of substrates and physiological processes in which they are 
involved, ABC transporters comprise a conserved core structure of two highly 
hydrophobic transmembrane domains (TMDs) and two ATP-binding cassettes 
(ABCs), also commonly known as nucleotide-binding domains (NBDs). The TMDs 
normally consists of six membrane-spanning segments and the NBDs are 
peripherally located at the cytoplasmic face of the membrane. In prokaryotes, four 
separate subunits usually provide the four domains, whereas in higher organisms 
these domains are normally fused together (Schmitt and Tampe 2002).  
Eukaryotes only have ABC transporters that are involved in the export of substrates, 
which commonly have a single polypeptide for the core structure with each NBD 
being C-terminal localized to each TMD. Exceptions to this scheme are the half-
transporters found in both prokaryotes and eukaryotes. In these half transporters 
TMD is fused covalently to either C- or N-terminus of the NBD. The complete core 
structure for half-transporters can be homo- or heterodimers or sometimes a higher 
order oligomer. (Jones and George 2004). 
In prokaryotic ABC importers, the vital function of substrate translocation is carried 
out by a high-affinity binding protein. This protein specifically associates with the 
ligand in the periplasm for delivery to the appropriate ABC transporter. (Figure 1-1) 
(Ames 1986). These binding proteins are released following an osmotic shock. 
(Heppel 1969) 
Apart from this typical four domain structure, sometimes additional elements can 
fuse to the TMDs and/or NBDs of ABC transporters. The exact function of these extra 
domains is mostly unclear. Most of them are believed to be associated with some 
regulatory functions (Biemans-Oldehinkel, Doeven et al. 2006). 
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Figure 1-1: Molecular architecture of ABC transporters. A schematic representation of ATP-binding 
cassette (ABC) transporters, which are composed of two transmembrane domains (TMDs) and two ABC 
domains (or nucleotide-binding domains). The binding protein component that is required by importers 
is also shown. Two conformational states of the ABC transporter — outward facing and inward facing, 
with the substrate-binding site orientated towards the periplasmic (extracellular) and cytoplasmic 
(intracellular) regions, respectively — are depicted to show the alternating access mechanism of 
transport.(Rees, Johnson et al. 2009) 
The NBDs can be further divided into two constituent domains: a catalytic core 
domain and a more structurally diverse α-helical domain. The NBDs of all the ABC 
transporters irrespective of their origin, function and substrate share extensive 
amino acid sequence similarities and several conserved motifs. The catalytic core 
domain contains the conserved P-loop or Walker A motif (GXXGXGK(S/T) where X 
could be any amino acid residue), a Walker B motif (ϕϕϕϕD, of which ϕ is a 
hydrophobic residue), a Q-loop and an H-motif (or switch region). The α-helical 
domain contains a conserved LSGGQ sequence also known as “C” signature motif 
which is characteristic for the ABC ATPases. (Higgins and Linton 2004; Deeley, 
Westlake et al. 2006; Rees, Johnson et al. 2009) 
Unlike the NBDs, TMDs of the ABC transporters are not conserved. The primary 
sequences of ABC transporter TMDs are markedly variable compared to those of the 
NBDs. These membrane spanning α helical segments provide a translocation 
pathway through which the substrate crosses the membrane. Due to their variable 
sequences, these domains are also believed to be involved in the substrate binding of 
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the transporter, which explains the enormous substrate diversity of the ABC 
transporters. (Higgins 1992) 
Using the experimental data available for a number of ABC transporter studies and 
diferent computer-assisted algorithms, the topology of a typical ABC transporter is 
predicted. (Figure 1-2) 
 
Figure 1-2: The schematic representation of structure of a typical ABC transporter predicted using 
diferent computer-assisted algorithms. Most of the transporters consist of two membrane associated 
domains caled as transmembrane domains (TMDs) with six membrane-spanning regions each folowed 
by a cytoplasmic nucleotide binding domain (NBDs). Each NBD has several highly conserved motifs, 
which include the Walker A motif (GXXGXGKS/T), involved in the phosphate-binding, Walker B motif 
(ϕϕϕϕD, where ‘ϕ’is a hydrophobic residue) which maintains the geometry of the active site and a 
highly conserved ‘LSGGQ’ signature sequence or C-motif, involved in ATP hydrolysis. (Deeley, Westlake 
et al. 2006). 
Because of these structural similarities, it is generaly assumed that al ABC 
transporters bind and hydrolyze ATP in a similar fashion and use a common 
mechanism to power the translocation of the substrate though the transmembrane 
domains. 
1.1.2 Mechanism of substrate transport by ABC transporters 
In recent years, the ABC transporter research has gained high attention and the 
number of ABC transporters studied is drasticaly increasing. In spite of al the 
practical dificulties working with membrane proteins, crystalographic structures of 
many ABC transporters have been solved and many biochemical assays have been 
designed to study their transport mechanism. 
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Following the crystallographic structure and the biochemical studies many 
predictions have been made for the mechanism of transport. Some of these 
predictions are further supported by concrete experimental evidences and have 
helped to propose a model for substrate transport. 
Different models have been proposed for the transport mechanism of various ABC 
transporters studied so far. All of them share some common predictions owing to 
the structural similarities of all ABC transporters. 
The TMDs form the membrane spanning channel and are thought to contain the 
substrate binding sites, while the NBDs are molecular motors which drive the 
transport by transforming the chemical potential energy of ATP into protein 
conformational changes.  
The Walker A motif (GXXGXGKS/T) is involved in the phosphate-binding (hence 
called P-loop). This glycine rich loop is generally followed by an uncapped α helix. 
This structure binds the triphosphate moiety of ATP through electrostatic 
interactions. Walker B motif (ϕϕϕϕD, where ‘ϕ’ s a hydrophobic residue) assists in 
establishing and maintaining the geometry of the active site as the highly conserved 
aspartate residue at its C-terminus coordinates with the catalytic Mg2+ ion. Other 
ABC motifs like LSGGQ (C motif), Q-loop and the H-motif are known to coordinate 
with the bound nucleotide; their precise role in the transport mechanism is unclear. 
(Higgins and Linton 2004; Jones and George 2004) 
In a typical ABC transporter, the two NBDs assemble such that the Walker A (P-
loops) of one NBD and the LSGGQ motif of the other come closer and generate two 
ATP binding and hydrolysis sites. In the absence of a nucleotide, there is a gap at the 
domain interface and the nucleotide binding sites are accessible to free water 
molecules. When ATP is bound, the interface closes and the nucleotides are 
sandwiched between the NBDs. The gap between the NBD closes, which brings the 
coupling helices closer together. As a consequence, the TMDs are transformed from 
a facing inward to a facing outward conformation (Figure 1-3).  
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Figure 1-3: A proposed mechanism of ATP binding and transformation of TMDs from facing inward to 
facing outward conformation. This model proposes that the binding of ATP triggers the closing of a gap 
between the ABC domains, which moves the coupling helices, an architecturally conserved feature, 
closer together and flips the TMDs to an outward-facing conformation. Hydrolysis of bound ATPs results 
in the movement of ABC domains (and hence NBDs) away from each other, which in turn brings the TMDs 
to facing inward conformation (Locher 2009). 
It is believed that ABC importers as well as exporters use this mechanism to expose 
binding and extrusion sites, which are located in the TMDs to opposite sides of the 
membrane thus moving substrates across the bilayer unidirectionally. (Locher 
2009) 
It is generally assumed that during a single transport cycle two molecules of ATP are 
consumed, but the exact number may change from transporter to transporter.  
Though this model of substrate binding and transport is the most recent and widely 
supported by structural, biophysical, biochemical and physiological studies, there 
are several steps in the mechanism still to be understood. Moreover, this model is 
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not applicable to the ABC transporters consisting of ‘atypical’ structures, e.g. 
containing mutations in the conserved motifs.  
1.1.3 ABC superfamily in humans 
In humans, ABC transporters are widely distributed in every tissue and involved in a 
variety of physiological processes such as cholesterol and lipid transport, multidrug 
resistance, antigen presentation, mitochondrial Fe homeostasis and the ATP-
dependent regulation of ion channels (including the cystic fibrosis transmembrane 
conductance regulator and the sulfonyl urea receptors)(Dean, Hamon et al. 2001). 
The role of ABC transporters is sometimes so important to the system that it is 
difficult to characterize the physiological system in depth without identifying the 
role for a particular ABC transporter involved. Apart from the usual physiological 
processes, these ABC transporters also protect cells from cytotoxins and can confer 
resistance to antibiotics and anticancer drugs (Dean 2009) .  
In humans, the ABC transporter superfamily includes 49 genes that have been 
classified into 7 different subfamilies designated A to G depending on their substrate 
specificities and sequence similarities (Vasiliou, Vasiliou et al. 2009).  
Members of this diverse transporter family play pivotal roles in many cellular 
processes. Mutations in the ABC transporter genes cause many genetic disorders in 
humans, including Tangier disease (cardiovascular), persistent hyperinsulinemic 
hypoglycemia of infancy (pancreas), Stargardt disease (eye), Wegener's 
granulomatosis (immune system), cystic fibrosis (lung and gut) and Dubin-Johnson 
syndrome or hypercholesterolaemia (liver). (Higgins and Linton 2004) 
The details of each ABC subfamily in humans are listed here (Vasiliou, Vasiliou et al. 
2009). 
1. Subfamily A (ABCA) 
This subfamily contains 12 genes expressing some of the largest of the ABC 
transporters. Most of these appear to be involved in lipid trafficking in many diverse 
organs and cell types. Mutations in specific ABCA genes are associated with genetic 
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disorders such as Tangier disease T1, familial high-density lipoprotein (HDL) 
deficiency, Stargardt disease-1, retinitis pigmentosa (serious eye diseases), andage-
related mascular degeneration and (Oram and Lawn 2001; Koenekoop 2003; Ayuso 
and Millan 2010). 
2. Subfamily B (ABCB)  
This subfamily of 11 genes is unique to mammals and includes both full-transporters 
and half-transporters. Members of this subfamily are known to confer multidrug 
resistance in cancer cells; hence, subfamily B has also been called the ‘MDR family of 
ABC transporters’. Mutations in ABCB genes are associated with diseases like 
ankylosing spondylitis (disease that involves inflammation of the joints between the 
spinal bones), diabetes type 2, coeliac disease, lethal neonatal syndrome, X-linked 
sideroblastic anaemia with ataxia (blood disorder with problems in movement) and 
several cholestatic liver diseases of infancy (Dean, Rzhetsky et al. 2001; Vasiliou, 
Vasiliou et al. 2009). 
3. Subfamily C (ABCC) 
Subfamily C includes 13 other genes which include transporters associated with 
multidrug resistance, cystic fibrosis (Cystic fibrosis transmembrane conductance 
regulator (CFTR), also called ABCC7) and ATP-dependent potassium channel 
regulators such as the sulfonylurea receptors SUR1/ABCC8 and SUR2/ABCC9. 
Mutations in ABCC genes have been implicated in multidrug resistance, Dubin – 
Johnson syndrome, congenital bilateral aplasia of the vas deferens, diabetes type 2 
and paroxysmal kinesigenic choreoathetosis and autosomal recessive diseases such 
as cystic fibrosis, pseudoxanthoma elasticum (accumulation of deposits of calcium 
and other minerals in elastic fibers) and hyperinsulinaemic hypoglycaemia of 
infancy (low blood glucose caused by excessive insulin) (Le Saux, Urban et al. 2000; 
Yabuuchi, Takayanagi et al. 2002; Kapoor, Flanagan et al. 2011). 
This class is described further in detail under section 1.1.4. 
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4. Subfamily D (ABCD) 
This subfamily contains 4 genes that encode half-transporters which form 
homodimers or heterodimers to make a functional unit. These 4 human genes 
encode several distinct proteins by means of alternative splicing mechanism. 
Mutations in ADBD genes are known to cause adrenoleukodystrophy (ALD) and 
Zellweger syndrome (peroxisome biogenesis disorders), hence the members are 
also known as the peroxisomal or ALD transporters (Tanaka, Tanabe et al. 2002). 
5. Subfamily E (ABCE) 
ABCE subfamily contains a single gene that encodes ABCE1 which is an organic 
anion-binding protein (its trivial name is OABP). Because of alternatively spliced 
transcripts, the ABCE1 gene encodes five distinct proteins. This member of the ABC 
superfamily has an ATP-binding domain but lacks the transmembrane domain, thus 
making it unlikely to function as a transporter. ABCE1 functions indirectly to 
promote interferon activity. Recent studies have demonstrated the potential role of 
ABCE1 in human lung adenocarcinoma and in eukaryotic posttermination ribosomal 
recycling (Pisarev, Skabkin et al. 2010; Ren, Li et al. 2012). 
6. Subfamily F (ABCF) 
Subfamily F contains 3 ABCF genes which encode 26 distinct proteins. Just like 
ABCE1, ABCF members also have ATP-binding domains, but no transmembrane 
domains, rendering transporter function unlikely. The ABCF genes appear to be 
upregulated by tumour necrosis factor-α and therefore are believed to be involved 
in inflammatory processes (Ota, Katsuyama et al. 2007).  
7. Subfamily G (ABCG) 
Subfamily G comprises 5 genes that encode ‘reverse half-transporters’, meaning the 
NBDs precede to the TMDs. Due to alternative splicing, the 5 ABCG genes encode 18 
distinct subunit proteins. 
Members of this family are involved in diverse physiological functions which include 
regulation of cellular lipids, transport of steroids (cholesterol, estradiol, 
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progesterone and testosterone), chlorophyll metabolites, organic anions, peptides 
and multidrug resistance (Adachi, Suzuki et al. 2005; Sharom 2008). 
Mutations in ABCG genes have been implicated in sterol accumulation disorders and 
atherosclerosis (Higashikuni, Sainz et al. 2012). 
1.1.4 The ABCC (MRP) family  
The subfamily C is one of the largest of the 7 branches among the ABC families in 
humans, comprising of 13 ABC proteins. Along with 10 multidrug resistance-
associated proteins (MRPs) this family also includes CFTR and the sulfonylurea 
receptors SUR1 and SUR2A/B as mentioned previously. MRPs 1– 6 and MRPs 7–10 
have been designated ABCC1– 6 and ABCC10 – 13, respectively, while CFTR, SUR1 
and SUR2A/2B are designated ABCC7, ABCC8 and ABCC9, respectively(Dean, Hamon 
et al. 2001). 
1.1.4.1 Structure of ABCC family proteins 
Based on the predicted structure of the TMDs, the ABCC proteins (with the exception 
of MRP9) are divided into two groups. First group of ABCC proteins having a 
“typical” ABC transporter structure with two TMDs (TMD1 and TMD2), each of 
which is predicted to contain six TM helices (Figure 1-2), includes CFTR (ABCC7), 
MRPs 4, 5, 8 and the second group includes the remaining MRPs and the SURs 
(ABCC8 and ABCC9) that have an additional NH2-terminal region comprised of ~200 
amino acids termed as TMD0 (Figure 1-4). The TMD0 of the “long” ABCC proteins 
are relatively poorly conserved. However, they are all hydrophobic and predicted to 
contain from four to six transmembrane helices. The function of TMD0 in the “long” 
MRPs remains poorly defined (Deeley, Westlake et al. 2006).  
So far studies with different members of the ABCC family in different systems have 
led to sometimes contradictory results. While some postulated that the TMD0 region 
is not required for the transport function or proper routing to the plasma membrane 
(Bakos, Evers et al. 1998), others believe that it is important for transport activity 
(Gao, Yamazaki et al. 1998; Ito, Weigl et al. 2003; Leslie, Letourneau et al. 2003). In 
some members, TMD0 has been shown to interact with other proteins (Otonkoski, 
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Ammala et al. 1999; Babenko and Bryan 2003; Chan, Zhang et al. 2003), while in 
others it is required for localization to the membranes (Fernandez, Holo et al. 
2002). 
It could be possible that the functions of TMD0 are protein specific and may vary 
from transporter to transporter. 
 
Figure 1-4: Schematic structure of the “long” ABC transporters from ABCC subfamily. Apart from the 
typical two TMDs and two NBDs, some members of the ABCC family possess and extra N-terminal 
transmembrane region caled TMD0. The TMD0 containing 4-6 (usualy five) transmembrane helices is 
extended with the cytoplasmic linker L0 (Deeley, Westlake et al. 2006). 
The entire ABCC family shares certain highly conserved features in their NBDs, 
particularly in NBD1, regardless of whether the MRPs have two or the three TMDs 
suggesting a common ancestor of al members of the family (Deeley and Cole 1997; 
Dean, Hamon et al. 2001). 
The Walker A, Walker B motifs and the LSGGQ sequence (‘C’ motif) as wel as the 
signature of ABC NBDs are also present in ABCC proteins. However, these elements 
deviate in some cases from the form commonly found in other ABC proteins (Cole, 
Bhardwaj et al. 1992). 
For example, the glutamate residue folowing the Walker B motif in most ABC 
transporters is present at the appropriate location in NBD2 of the ABCC proteins, 
but in the NBD1 it is replaced either by aspartate (in MRP1 and other ABCC 
proteins) or serine residue (in CFTR). As the glutamate residue plays a critical role 
in cleavage of the γ-phosphodiester bond of ATP, this replacement of amino acid 
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residue has a profound effect on the ATP binding and hydrolysis characteristics of 
the NBD1 and as a consequence on the catalytic cycle of members of ABCC subfamily 
(Moody, Millen et al. 2002; Smith, Karpowich et al. 2002; Payen, Gao et al. 2003; 
Verdon, Albers et al. 2003).  
In addition, the ABC signature sequence LSGGQ is also modified in NBD2 of the ABCC 
proteins. While the two NBDs in most prokaryotic ABC transporters are identical, in 
many eukaryotic ABC proteins the two NBDs are at least very similar in their 
structure. Unlike this typical ABC protein scheme, the two NBDs of the ABCC family 
proteins are both structurally and functionally nonequivalent, supporting the 
concept of a different catalytic cycle for ABCC subfamily proteins. (Deeley, Westlake 
et al. 2006) 
1.1.4.2 Physiological role of ABCC family proteins 
The MRPs widely present in a number of tissue/blood barriers and are associated 
with distribution and elimination pathways for a wide range of both anti-cancer and 
non-anti-cancer drugs and metabolites. In addition, these MRPs can influence the 
pharmacokinetics of drugs and thereby affect their disposition in the body. Many 
drugs are detoxified by conjugation with glutathione, glucuronate or sulfate, which 
results in acidified conjugates that cannot diffuse though cell membranes. Members 
of the MRP family mediate the export of these conjugates (Borst and Elferink 2002). 
The subcellular localization and substrate specificities of different long and short 
MRPs are shown in Figure 1-5. 
Though it is widely accepted that multidrug resistance is multifactorial, several 
MRPs together with ABCB1 (P-gp/MDR1) and ABCG2 (BCRP) have been recognized 
as major components of multidrug resistance, especially at the blood-brain-barrier 
(BBB) (Eisenblatter, Huwel et al. 2003; Deeley, Westlake et al. 2006; Wittgen, van 
den Heuvel et al. 2011) 
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Figure 1-5: Subcellular localization and substrate specificities of long (left) and short (right) MRPs. The 
question marks indicate that the subcellular localization is not known. (Deeley, Westlake et al. 2006) 
1.1.5 The human ABCC3 (MRP3) transporter 
ABCC3 or MRP3 belongs to the “long” transporter group of the ABCC family, 
comprising the extra NH2-terminal domain. Though the transporter shares the 
highest (~56 %) sequence similarity with MRP1 (ABCC1), the well-studied member 
of the family although the substrate specificity of these two transporters varies 
drastically. On the other hand there is a large overlap in the substrate specificity of 
ABCC2, ABCC3 and ABCG2. Whereas ABCC2 and ABCG2 are expressed at the apical 
membranes of the cells, transporting their substrates into bile, feces and urine, 
ABCC3 is expressed basolaterally, especially in hepatocytes and enterocytes and it 
generally transports its substrates into the blood circulation. (Borst and Elferink 
2002; Vlaming, Pala et al. 2008)  
MRP3 is expressed in almost all the tissues in the body which includes the adrenal 
gland, pancreas, gut, gall bladder and placenta, with lower levels being found in liver, 
kidney and prostate. In contrast to MRP1 and MRP2, the in vivo functions of MRP3 
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are not yet clearly understood, though in many cellular models ectopic expression of 
human MRP3 has been shown to confer resistance to etoposide and methotrexate, 
which suggests its potential role in the protection of normal tissues against 
chemotherapeutic agents.(Belinsky, Dawson et al. 2005) 
Under cholestatic conditions, when the presence of ABCC2 in the canalicular 
membrane markedly decreases, ABCC3 is upregulated and allows increased 
basolateral efflux of bilirubin glucuronides from the liver. Thus there appears to be a 
reciprocal relationship between the two transporters which are presumed to protect 
the liver from accumulation of potentially toxic bile constituents. (Donner and 
Keppler 2001). Both transporters are expressed in various tumors and can transport 
a wide range of (anticancer) drugs.  
1.1.6 Transport mechanism of ABCC3  
ABC transporters are large membrane proteins and it has been technically difficult 
to get crystals suitable for X-ray crystallographic analysis. Therefore obtaining a 
crystal structure of an ABC transporter in different binding states is rather 
challenging. Moreover, only the crystal structure itself is not sufficient to predict the 
exact mechanism of the transport and various steps involved. A crystal structure 
always has to be supported by enough biochemical evidences in order to unravel the 
exact order of sequences in which the actual mechanism of transport takes place. 
Our present knowledge of the mechanism of transport of MRP3 is mostly based on 
comparative hypotheses. As the MRP3 possesses the highest sequence and 
structural similarity with that of MRP1, results obtained from the experiments done 
with MRP1 are usually generalized for MRP3 (and other MRPs consisting of the extra 
TMD).  
As mentioned earlier, the NBDs of most prokaryotic ABC transporters are identical 
and in many eukaryotic ABC proteins, the two NBDs are structurally and functionally 
equivalent and can be exchanged with little or no effect on function (Chen, Chin et al. 
1986; Beaudet and Gros 1995; Hrycyna, Ramachandra et al. 1999). However, the 
two NBDs of the ABCC family members are less conserved indicating that the two 
NBDs play distinct functional roles in the catalytic cycle of the ABCC proteins. 
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On the basis of some initial experimental evidence, Deeley in his review has 
proposed a hypothetical model of substrate transport cycle for MRP1 (and other 
MRPs), which possibly is applicable for MRP3 (and other proteins with non-identical 
NBDs) as well. (Figure 1-6) 
 
 
Figure 1-6: Model of the hypothetical transport cycle of MRP1 for the transport of LTC4. This model 
predicts the steps involved in the transport of substrate in which the transporter shuttles between the 
high affinity and low affinity states. (Deeley, Westlake et al. 2006) Step 1) Binding of substrate: it is 
assumed that the binding of substrate to a high-affinity site(s) induces conformational changes that 
stimulate binding of ATP to NBD1. It is also predicted that the ATP is already bound to the NBD1 and this 
binding is necessary to maintain the high affinity states of the transporter. Step 2) Binding of second 
molecule of ATP: The initial ATP binding of by NBD1 triggers the binding of a second molecule of ATP by 
stabilizing the interaction between NBDs. This stabilization is achieved by establishing contacts with the 
C signature of NBD2. Step 3) Release of substrate: Binding of ATP molecules on both the NBDs, causes the 
conformational changes in the TMDs thereby changing the state of the transporter from high affinity 
binding to low affinity binding state. These conformational changes release the substrate on the opposite 
side of the membrane. Step 4) Hydrolysis of ATP at NBD2: In order to retain the high affinity state, after 
the release of substrate, the ATP molecule bound at NBD2 is hydrolyzed. Step 5) Release of ADP from 
NBD2: After the hydrolysis of ATP, release of ADP from NBD2 drives the conformational changes 
necessary to regain the high affinity state. Step 6) Hydrolysis of ATP and release of ADP from NBD1: It is 
also postulated that the hydrolysis of ATP is also required to reset the high affinity state and onset of new 
transport cycle. 
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As seen from the Figure 1-6, in this hypothetical model, many steps are yet to be 
understood. The hydrolysis of ATP by NBD1 is still unclear though and mutations 
that increase ADP trapping at NBD1 are shown to lock MRP1 in a high affinity state 
for substrate, even when ATP is bound by NBD2 (Gao, Cui et al. 2000; Payen, Gao et 
al. 2003)  
But the questions still to be answered are; i) whether the substrate binding or the 
binding of first ATP is the initial step; ii) whether mere binding of both the ATP 
molecules to the NBDs or the hydrolysis of ATP molecule drives the transport by 
shifting the conformation from high to low affinity substrate binding state; iii) 
whether ATP hydrolysis is required to regain the high affinity substrate binding 
state or not. These and many other steps in the transport cycle of ABCC proteins 
remain speculative and need much more structural and functional evidences to be 
understood clearly. 
The ATPase activities of purified ABCC proteins are about two orders of magnitude 
lower than some prokaryotic ABC transporters and P-gp/MDR1. Consequently, 
performing different assays with the protein using crude membranes, in order to 
study the transport mechanism have proven to be difficult. 
After the successful heterologous expression and purification of MRP3 from the 
yeast P. pastoris in its active state by the working group of Prof. Urbatsch 
(Chloupkova, Pickert et al. 2007), the protein was available in sufficient quantities 
for the biochemical assays in order to understand the function of the protein in 
detail.  
In our working group, the heterologously expressed MRP3 was successfully 
reconstituted into artificial liposomes which are an adequate model for systematic 
characterization of substrate specificities and transport process of a protein 
(Zehnpfennig, Urbatsch et al. 2009). Using these artificial proteoliposomes, our 
group has recently shown that ATP hydrolysis and substrate translocation show 
positive cooperativity and are half-coupled in MRP3 (Seelheim, Wullner et al. 2013). 
Though initial results obtained from the studies in these artificial proteoliposomes 
support the model proposed by Deeley, there is still a lot to be done to understand 
the transport process completely.  
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1.2 Heterologous expression of proteins 
Functional characterization of any protein involves several biochemical assays, 
which in turn require large amounts of active protein in hand. But the protein being 
studied need not necessarily be a highly expressed protein in its native organism. 
 Expression of a particular protein can be sometimes induced by specific substances. 
But in most cases such increase in the protein expression is limited and sometimes 
toxic to the native host, thereby making the use of native host for overexpression 
unsuitable (Khlistunova, Biernat et al. 2006; Xie, Nair et al. 2008). In such cases 
expression of the desired protein in another suitable host system is the only choice. 
Several prokaryotic and eukaryotic expression systems have been developed over 
the last decades for such heterologous expression of proteins.  
The choice of the host for overexpression is of prime importance as the expressed 
protein must be in the right conformation and active after the purification. Here are 
some of the existing systems available for recombinant gene expression. 
1.2.1 Prokaryotic expression system 
Escherichia coli has been the most frequently used prokaryotic expression system 
for the high-level production of heterologous proteins (Makrides 1996; Baneyx 
1999). Easy methods for genetic manipulation, low cost of production, high yield of 
protein, ease of scaling and short turnaround time are the advantages that make this 
system a first choice for any recombinant protein expression (Sorensen and 
Mortensen 2005). However, most eukaryotic proteins such as large multimeric 
membrane proteins, are not correctly folded when expressed in E. coli (and other 
prokaryotic systems) (Baneyx and Mujacic 2004).  
Moreover, prokaryotic expression systems cannot perform the post-translational 
modifications like glycosylation (addition of sugars to the protein), phosphorylation 
(addition of phosphate group), lipidation (addition of lipid group), sulfation 
(addition of sulfate group) etc., which are essential for the activity and/or trafficking 
of the eukaryotic proteins. These facts limit the types of protein(s) that can be 
expressed heterologously in the prokaryotic systems (Brondyk 2009). 
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Prokaryotic homologues are frequently used for obtaining structural information on 
membrane proteins because they can easily be expressed in bacteria in large 
quantities (Doyle, Morais Cabral et al. 1998). However, this method cannot easily be 
applied to mammalian MPs, because when expressed in prokaryotes these proteins 
are mostly directed to inclusion bodies, from which they are usually impossible to 
purify without denaturation (Mus-Veteau 2002). 
1.2.2 Eukaryotic expression systems 
In order to overcome the disadvantages of the prokaryotic expression system, many 
eukaryotic expression systems have been developed having the capability of 
performing post translational modifications and expressing the protein in its active 
form. This include mammalian, insect and yeast expression systems. 
1.2.2.1 Mammalian cells 
Mammalian cell expression systems comprise a large number of different cell lines 
used for protein expression. Chinese hamster ovary (CHO) cells (Kim, Kim et al. 
2012), human embryonic kidney (HEK) 293 cells (Thomas and Smart 2005), murine 
erythroleukemia (MEL) cells (Needham, Gooding et al. 1992; Shelton, Davies et al. 
1993; Needham, Egerton et al. 1995), baby hamster kidney (BHK) cells (Wirth, Bode 
et al. 1988), mouse L-cells (Kavathas and Herzenberg 1983; Gopal, Polte et al. 1989) 
are few examples. 
Many mammalian cell lines have been used for large-scale commercial production of 
therapeutically important proteins. But the major disadvantages of mammalian cells 
are difficulties in achieving stable transfection, their lower production yield 
compared to other eukaryotic systems, their slow growth rate and the higher cost 
due to the need for complex growth media. 
Hence, the system is not very useful for the production of sufficient amounts of 
protein for structural and biochemical analysis. 
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1.2.2.2 Insect cells 
Protein production in insect cells such as Spodoptera frugiperda (SF9) using 
Baculovirus-mediated infections is another popular method for the production of 
proteins. Insect cells are grown in suspension in serum free media. Apart from the 
expression of intracellular, surface bound or secreted proteins, this system has been 
also successfully used for the production of membrane proteins (Possee, Thomas et 
al. 1999; Hitchman, Possee et al. 2009) .  
Many mammalian transporters and receptors are functionally overexpressed by 
using this system (Sievert, Thiriot et al. 1998). Optimized expression vectors, easy 
scale up and high yield of protein are the advantages. (Mus-Veteau 2002; Hitchman, 
Locanto et al. 2011) (Mus-Veteau 2002). 
But the post translational modifications done by the insect systems are not as 
complicated and precise as seen in human cells (Geisse, Gram et al. 1996). Moreover, 
the viral proteases present in the recombinant insect cells can sometimes degrade 
the protein of interest. 
To summarize, though the mammalian and insect cells ensure the expression of 
eukaryotic proteins with right folding and all the post translational modifications, 
requirement of a complex growth medium and culture conditions makes the system 
highly expensive. Moreover, comparatively difficult methods of genetic 
manipulations make it tedious.  
1.2.2.3 Yeast  
This simple eukaryotic cell combines the advantages of both, prokaryotic and 
eukaryotic expression systems. Like the prokaryotic systems, the yeast expression 
system also has a short turnaround time, can easily be scaled up and needs relatively 
simpler techniques for genetic manipulation. On the other hand, it can also perform 
many of the post-translational modifications seen in higher eukaryotic cells. 
(Romanos, Scorer et al. 1992) 
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A variety of studies like protein-protein interactions, mutagenesis or protein folding 
can be performed in yeast. Apart from that, yeasts are also used as a model for 
studies of membrane proteins (Petschnigg, Moe et al. 2011). But the most popular 
use of yeasts is for cloning and heterologous overexpression of eukaryotic proteins 
in large amounts sufficient for biochemical, biophysical and structural analysis. For 
this purpose, yeasts are studied and genetically modified to achieve optimized 
expression of foreign proteins (Choi, Bobrowicz et al. 2003; Hartner, Ruth et al. 
2008). Two yeast species have been most successfully used for heterologous 
expression of foreign proteins including large multi domain mammalian MPs: 
Saccharomyces cerevisiae and P. pastoris. 
Though Saccharomyces cerevisiae has been used as a heterologous expression 
system for many years, low production yield and the tendency of hyperglycosylation 
makes the system unfavorable in many instances (Sandy B. Primrose 2009). 
Secreted proteins expressed in S. cerevisiae are often retained in the periplasm 
thereby making the purification difficult (Buckholz and Gleeson 1991; Romanos, 
Scorer et al. 1992). Most importantly, S. cerevisiae produces ethanol when grown at 
high cell densities, which is toxic to the cells and lowers the quantity of recombinant 
protein being expressed. 
In order to solve these problems, P. pastoris is used as the alternative species for 
protein production. Simple methods of genetic manipulations, growth to higher 
densities, successful expression of secreted protein, strong inducible promoters and 
requirement of simple defined media for growth makes this system the most 
economical and useful for the foreign gene expression. 
Details of this system are discussed further in detail in 1.3. 
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1.3 Expression in the yeast P. pastoris  
The expression in yeast P. pastoris has many advantages over the other expression 
systems. As an eukaryotic systems expression in P. pastoris can perform the 
modifications like other eukaryotic expression systems, especially post-translational 
modifications such as protein processing, protein folding and protein secretion into 
the medium (Cregg, Tolstorukov et al. 2009). Isolation of secreted proteins is much 
easier from P. pastoris by the fact that it does not secrete a lot of its own proteins. 
(Bora 2012). 
Contrary to S. cerevisiae, P. pastoris does not produce toxic levels of ethanol when 
grown to high cell density cultures. Being a poor fermenter, it favors preference for 
respiratory growth and can be cultured at extremely high densities in the controlled 
environment (Gellissen 2006) .  
P. pastoris shares genetic manipulation methods and growth conditions to 
Saccharomyces cerevisiae, with the added advantage of higher levels of expression 
which leads to rapid development of this system (Cereghino and Cregg 2000). Easy 
maintenance, easy scale-up, inexpensive growth requirements and higher 
expression levels make P. pastoris a very useful protein expression system 
(Balamurugan 2006). 
Because of these and many other advantages, P. pastoris has been extensively used 
for large scale production of many human vaccines and therapeutic proteins.   Being 
unicellular yeast, the glycosylation pattern of the proteins expressed in P. pastoris 
differs in many respects to the higher organisms. This, in many instances can be 
antigenic (Sinclair and Elliott 2005; Jacobs and Callewaert 2009; Sola and Griebenow 
2009). In order to solve these problems, genetically engineered strains of P. pastoris 
have been developed, which impart humanized glycosylation to the proteins 
expressed (Li, Sethuraman et al. 2006; Jacobs, Geysens et al. 2009; Zha 2012). 
The other advantage of the P. pastoris expression system is the strong inducible 
promoter. As a methylotrophic yeast, it is capable of metabolizing methanol as its 
sole carbon source.  
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The enzyme alcohol oxidase (AOX), which catalyzes oxidation of methanol to 
formaldehyde using molecular oxygen, has a very poor affinity for oxygen.  This 
difficulty is compensated by generating large amounts of enzyme (Cregg, Cereghino 
et al. 2000). This enzyme is coded by two genes AOX1 and AOX2. However, the AOX1 
gene is responsible for the majority of alcohol oxidase activity in the cell when 
induced by methanol (Cregg, Madden et al. 1989). Among the two genes, AOX1 is 
tightly regulated at transcriptional level (Tschopp, Brust et al. 1987). The strong and 
highly regulated promoter of the AOX1 gene can be utilized for heterologous gene 
expression. 
In order to perform the genetic manipulations in P. pastoris using this strong 
promoter, many vector systems have been designed. Two of them which are used in 
this project, are discussed below. 
1.3.1 Autonomously replicating pPicholi vector 
pPicholi is a dual expression vector, designed for heterologous gene expression in 
the yeast P. pastoris as well as in the prokaryote E. coli. The vector contains the AOX1 
promoter from P. pastoris and an E. coli T7 promoter, allowing expression in both 
the systems. The vector also has sequences for autonomous replication in P. pastoris 
and E. coli. The integrated P. pastoris autonomous replication sequence (PARS) not 
only allows autonomous replication of the vector in the P. pastoris cells but also 
enables simple recovery of plasmids from yeast. 
This vector contains a Zeocin resistance gene which imparts resistance against the 
antibiotic Zeocin to the cells and could thus be used as a selection marker. 
As the vector can replicate autonomously, the copy number can be increased or 
decreased by simply changing the concentration of antibiotic Zeocin in the media. 
Moreover, only small amounts of DNA are sufficient and no vector linearization is 
required to successfully transform this vector into P. pastoris cells (MoBiTec 2003). 
A detail description of the plasmid’s clone chart is given in appendix 3.3. 
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1.3.2 Genome integrating pPICZ vector 
pPICZ vectors also comprise parts of the strong and highly regulated AOX1 gene 
with the  AOX1 promoter (5’AOX1) and transcription terminator (TT) along with 
other elements like Zeocin resistance gene and elements for replication in E. coli 
(details appendix 3.3). The gene of interest can be inserted into the multiple cloning 
site (MCS) which is placed in between the AOX1 promoter and terminator sequence 
(TT). 
 The AOX sequences in the vector can recombine with AOX1 gene from the 
P. pastoris genome, because of the sequence homology, resulting in the insertion of 
one or more copies of the vector into the genome (Cregg, Barringer et al. 1985; 
Cregg, Madden et al. 1989). 
This generates stable P. pastoris transformants expressing the desired protein. As 
the gene of interest is integrated inside the genome, addition of Zeocin is not 
required in the media to retain the plasmid inside the P. pastoris cels. Figure 1-7 
shows the mechanism of insertion of the vector into the P. pastoris genome 
(Invitrogen 2010). 
 
Figure 1-7: Schematic representation of the insertion of the pPICZ plasmid to the intact AOX1 locus from 
the P. pastoris genome. This insertion results in the integration of 5’PAOX1(AOX1 promoter sequence 
from plasmid), gene of interest, TT (transcription terminator sequence of AOX1 gene) and the Zeocin 
resistance gene. The 5’PAOX1 is induced by methanol and drives the transcription of the gene of interest 
(Invitrogen 2010). 
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1.4 Artificial liposomes as a tool for transport studies 
Biological membranes function as a barrier to define cell boundaries and to protect 
the integrity of the interior of the cell (Brown 1996). These fluidic bilayers of lipid 
sheets are associated with numerous peripheral and integral membrane proteins 
(Singer and Nicolson 1972). The integral membrane proteins perform numerous 
functions as transporters, channels, receptors, enzymes or as structural membrane 
anchoring domains.  
Despite their diverse cellular functions and roles in processes like multidrug 
resistance, these proteins remained the least studied owing to the fact that these 
membrane proteins are notoriously difficult to handle and to study because of their 
highly hydrophobic nature. Since they are designed to sit within the hydrophobic 
environment of the lipid bilayer, they tend to be unstable when extracted from their 
native environment and aggregate rapidly (Ryan, Souda et al. 2010). 
As the extraction of these proteins is difficult and tricky, most of the studies done so 
far are performed by overexpressing the protein of interest in a heterologous host 
and preparing vesicles from the host membranes to characterize the protein. Based 
on these vesicle preparation methods, different assay types have been developed to 
understand biochemical characteristics of a particular membrane protein and 
transport processes associated with it (Glavinas, Mehn et al. 2008). 
But use of these membrane vesicles could sometimes provide misleading results, as 
the activity or transport seen for a protein could be a result of some other intrinsic 
proteins of the host organism. In such cases, reconstitution of the protein into 
artificial membrane systems provides reliable information about the protein. 
Different methods are available for efficient reconstitution and solubilization of 
membrane proteins by using appropriate detergents (Seddon, Curnow et al. 2004). 
In our lab, reconstitution of MRP3 into artificial liposomes has been successfully 
performed with the use of the nonionic detergent n-dodecyl β-D-Maltopyranoside 
(DDM) (Zehnpfennig, Urbatsch et al. 2009). We aim to use this powerful tool to 
further analyze functions of this ABC transporter.  
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2 Objectives of the project 
The mechanism of ATP hydrolysis and transport of substrates by ABC transporters 
remains elusive even after intensive research. Recent developments in the 
crystallization combined with biochemical studies of some bacterial and eukaryotic 
ABC transporters led to the establishment of the most convincing model of 
transport, which indicate towards the equal affinity and binding of both the NBDs 
and the conserved domains in ATP binding followed by conformational changes to 
drive the transport (Jones and George 2012). However, these transport models 
cannot be applied to the members of the ABCC (MRP) family of human ABC proteins 
and other ABC transporters which comprises functionally nonequivalent NBDs (Gao, 
Cui et al. 2000). Apart from the non-identical NBDs, several members of the ABCC 
family also deviate from the typical ABC protein structure due to their extra TMD of 
which the exact role is still not clear. 
The aim of this thesis was to understand the role of the extra N-terminal TMD in the 
“long” MRPs and study the role of each domain of the transporter in the mechanism 
of substrate transport. For this, we focused on one member of the “long” ABC 
transporter group of the ABCC family, called ABCC3 (MRP3). 
Our group has successfully reconstituted purified MRP3 into artificial liposomes and 
hence provided a reliable model for systematic characterization of substrate 
specificities and transport process mechanism of the protein (Zehnpfennig, Urbatsch 
et al. 2009; Seelheim, Wullner et al. 2013). To study the function and mechanism of 
transport of MRP3 in detail, we aimed to express in addition to the full transporter 7 
different truncated versions (called constructs) into yeast P. pastoris. In order to 
enable the purification of the expressed proteins, a C-terminal sequence encoding a 
tandem affinity purification tag composed of a Strep tag II sequence and Poly-His tag 
was fused with the protein sequences.  
The following constructs comprising MRP3 as a full transporter and different 
truncated versions were considered (Figure 2-1). 
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Reconstitution of these MRP3 constructs into proteoliposomes would considerably 
help to understand the role of the diferent protein domains for the drug transport 
and the related ATP hydrolysis. 
MRP3 MRP3-ΔTMD2NBD2 
  
ΔTMD0-MRP3 ΔTMD0-MRP3-ΔTMD2NBD2 
  
ΔTMD0L01/2-MRP3 ΔTMD0L0-MRP3-ΔTMD2NBD2 
  
ΔTMD0L0-MRP3 ΔTMD0L0TMD1NBD1-MRP3 
   
Figure 2-1: Schematic representation of MRP3 ful transporter and its diferent truncated versions 
proposed for cloning and expression in P. pastoris. The pictures were modified using an original picture 
from (Deeley, Westlake et al. 2006). The truncated versions ΔTMD0-MRP3, ΔTMD0L01/2-MRP3, 
ΔTMD0L0-MRP3 (2nd ,3rd and 4th row on left side) were lacking the extra N terminal domain TMD0, TMD0 
and half of the linker region L0 and TMD0 and L0 complete respectively. In MRP3- ΔTMD2NBD2 (1st row 
on right side), the TMD2 and NBD2 (C-terminal TMD and NBD) were removed. ΔTMD0-MRP3-
ΔTMD2NBD2 (2nd row on right side) was the N terminal half of the core domain (TMD1NBD1) retaining 
the linker region L0. While ΔTMD0L0-MRP3-ΔTMD2NBD2 and ΔTMD0L0TMD1NBD1 -MRP3 (3rd and 4th 
row on right side) were half transporters expressing only a single TMD and NBD. 
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3 Results and Discussion 
3.1 Cloning and expression of hMRP3 using autonomously 
replicating pPicholi vector 
3.1.1 Aims and rationale 
The first step to achieve the heterologous gene expression in the yeast P. pastoris 
was to select the right vector for cloning and expression from a number of 
expression vectors available commercialy. 
In order to purify the recombinant protein after the expression in the heterologous 
host, the expression vector had to be modified so as to add a purification tag to the 
protein sequence. For this purpose, a tandem afinity purification tag containing poly 
histidine tag (8xHis) and a peptide sequence exhibiting intrinsic afinity towards 
Streptavidin (Strep tag I ) was designed. This dual afinity tag provides high purity 
of the protein after the purification procedure. The schematic representation of the 
expression cassette with the purification tag is shown in Figure 3-1. 
 
Figure 3-1: Schematic representation of the expression cassette for ligation of ABCC3 and its constructs 
in pPicholi for expression in P. pastoris. After cloning, the modified pPicholi plasmid encodes a protein 
bearing a C-terminal sequence consisting of Factor Xa protease cleavage site, Strep tag II afinity tag, site 
3C-protease cleavage site (3C) and Poly-His tag (8xHis). In addition, the vector contains Kozak-like bases 
(P. pastoris Kozak) in the region around the ATG start codon, which is important for high-level 
expression in P. pastoris. 
So, it was necessary to construct a library of E. coli cel lines containing the modified 
pPicholi vector with sequences encoding MRP3 protein or its truncated versions to 
generate a stable source of plasmids for transformation into P. pastoris. 
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The aim of this part was to construct a pPicholi vector library with different 
truncated forms and a full sequence of MRP3 gene to transform these pPicholi 
vectors containing different MRP3 sequences into P. pastoris and to choose the best 
expression clone for every MRP3 truncated form among the transformants. An 
expression clone showing the expression of the protein consistently and in sufficient 
quantities would then be used for large scale culturing and purification. 
3.1.2 Results 
3.1.2.1 Vector and hMRP3 sequence modification 
The modified pPicholi vector containing the C-terminal purification tag with Factor 
Xa-Strep tag II-3C Protease-8xHis sequence was a kind gift from Dr. Markus Seidl 
(Institute of Biochemistry, Muenster).  
The pGEM7-MRP3 vector containing cDNA insert encoding hMRP3 was kindly 
provided by Prof. P. Borst (The Netherlands Cancer Institute, Amsterdam). The clone 
chart of the pGEM7 vector containing the MRP3 sequence is shown in section 6.3.  
As given in Figure 3-1 for the ligation and cloning of MRP3 sequence, AscI and SacII 
restriction sites were chosen. But the hMRP3 cDNA sequence also has an intrinsic 
SacII site. So, it was necessary to mutate the SacII site inside the MRP3 sequence in 
order to achieve the successful cloning and ligation. 
The SacII site within the MRP3 sequence was eliminated by site directed 
mutagenesis (SDM) as described in section 0. The site CCGCGG was mutated to 
CTGCGG; which leads to a silent mutation in the MRP3 sequence without changing 
the amino acid sequence. This silent mutation was designed considering the codon 
usage of P. pastoris to ensure the optimal expression of the protein. The sequences of 
primer pairs used SDM in SacII site, labeled as MRP3_Mut_Sac_For and 
MRP3_Mut_Sac_Rev, are mentioned in Appendix 0.  
The SDM product was transformed into competent Top10F’ E. coli cells as described 
in 5.1.2.3 and the transformed clones were picked for plasmid isolation as described 
in section 5.2.1. The isolated plasmid from each clone was analyzed for the SacII 
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mutation. A virtual cutting of the pGEM7-MRP3 vector, before and after SDM in SacI 
site showed results as described in Table 3-1. 
 Fragments size in kb after restriction 
      
 +SacII +SacII +EcoRI  
+SacII +SacII 
+EcoRI     pGEM7-
MRP3 
original 
7757 7040 pGEM7-MRP3 
SacII site deleted 
7757 7757 
linear 717 Uncut linear 
Table 3-1: Expected size of pGEM7-MRP3 vector fragments when restricted with diferent enzymes, 
before and after deletion of SacII site. 
Plasmid DNA from the clones selected for SacI mutation analysis were restricted 
with SacI and EcoRI and the restricted samples were analyzed on 1 % agarose gel as 
described in sections 5.2.4 - 5.2.5. The comparison between positive and negative 
clones after mutagenesis is shown in Figure 3-2. 
 
 
Figure 3-2: pGEM7-MRP3 plasmid showing diferent restriction pattern before and after deletion of SacII 
site. The DNA bands were separated on 1 % agarose gel and 1 kb DNA ladder from NEB was used as a 
reference. –K designates a negative control for restriction without addition of any restriction enzymes. 
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As seen from the restriction analysis, the pGEM7-MRP3 plasmid before SDM was 
able to be restricted by both SacII and EcoRI enzymes. When restricted by the SacII 
enzyme alone, the circular plasmid migrated at a different rate than the plasmid 
without restriction (-K). On the other hand restriction with both SacII and EcoRI 
enzymes showed 2 distinct bands. 
 After the SDM and deletion of SacII site, the plasmid showed the same band pattern 
before and after restriction by SacII enzyme. The plasmid showed multiple 
conformations (open circular, supercoiled) on the agarose gel with or without 
restriction by SacII enzyme, indicating the deletion of this site. When restricted by 
both SacII and EcoRI enzymes together, the plasmids after SDM showed only a single 
band. This confirmed that the plasmid was linearized by EcoRI and had no SacII site 
anymore. The clones showing positive results by restriction pattern analysis were 
sent for sequencing to confirm the mutation (section 5.2.11). Results for the 
sequence alignment showing the point mutation in the SacII site are shown in Figure 
3-3. 
 
Figure 3-3: Screenshot of the sequence alignment done using BioEdit sequence alignment editor, after 
the sequencing of the positive clones from SDM of the SacII site within the MRP3 sequence. 
3.1.2.2 Amplification of insert and ligation into the vector 
After the SDM in the SacII site in the MRP3 sequence, the modified pGEM7-MRP3 
vector was used as a template for all the further PCR amplifications. The desired 
open reading frame (ORF) encoding specified domain(s) from hMRP3 cDNA 
template were amplified with appropriate pair of primers by polymerase chain 
reaction (PCR). The amplification was performed using the high fidelity polymerase 
as described in section 5.2.9.1. Sequences and combination of all the primers used 
for different MRP3 constructs are mentioned in 0. 
The amplified fragments were cleaned, restricted, ligated with modified pPicholi 
vector and transformed in Top10F’ E. coli (section 5.2.7.2, 5.2.4, 5.2.8 and 5.1.2.3). 
10 20 30 40 50 60 70 80
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
MRP3 in pGEM7 TTTACAGTGATGCCGATATTTTCTTGCTGGATGACCCACTGTCCGCGGTGGACTCTCATGTGGCCAAGCACATCTTTGAC
                                                                                
157mQ-3_M1_904_rev ...........................................T....................................
157mQ-4_M1_904_rev ...........................................T....................................
157mQ-5 M1 904 rev ...........................................T....................................
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Positive clones were selected by colony PCR (5.2.9.2). The results from a colony PCR 
performed after the ligation of modified pPicholi vector with the ful MRP3 sequence 
are shown in Figure 3-4. The same procedure was folowed for selection of positive 
clones for other constructs for the insertion into the empty vector (data not shown). 
 
Figure 3-4: Results from a colony PCR performed to select the clones after ligation of amplified MRP3 
fragments into modified pPicholi vector. The sequence between the AOX1 promoter and terminator was 
amplified using Taq DNA polymerase. The DNA bands were separated on 1 % agarose gel and 1 kb DNA 
TriDye™ ladder from NEB was used as a reference. –K designates a negative control for amplification in 
which the empty vector without any insert was used as a template. The numbers indicates the clones 
selected for colony PCR. 
  
DNA Protein 
No. Construct Insert pPicholi Plasmid Amino acids 
Size 
in kDa 
1 MRP3 4799 3355 8154 1567 174.06 
2 ΔTMD0-MRP3 4226 3355 7581 1379 152.80 
3 ΔTMD0L01/2-MRP3 4106 3355 7461 1336 147.77 
4 ΔTMD0L0-MRP3 3956 3355 7311 1284 141.72 
5 MRP3-ΔTMD2NBD2 2927 3355 6282 943 105.79 
6 ΔTMD0-MRP3-ΔTMD2NBD2 2369 3355 5724 757 84.86 
7 ΔTMD0L0-MRP3-ΔTMD2NBD2 2084 3355 5439 662 73.77 
8 ΔTMD0L0TMD1NBD1-MRP3 2090 3355 5445 664 73.04 
Table 3-2 : Size of the MRP3 and its truncated version genes after ligation with the vector (modified 
pPicholi). The constructs are referred by the numbers instead of ful names for convenience in the 
descriptions. The detail description of each construct is given in Figure 2-1. 
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The positive clones were sequenced and analyzed as described in 5.2.11. Positive 
clones without any mutation were used for transformation into P. pastoris (5.2). The 
sizes of al the 8 constructs generated are shown in Table 3-2. 
A gel picture showing the relative plasmid sizes of al the 8 constructs is given in 
Figure 3-5. 
 
Figure 3-5: Relative size of the plasmids containing diferent constructs of MRP3. The DNA bands were 
separated on 1 % agarose gel and 1 kb DNA TriDye™ ladder from NEB was used as a reference. Empty 
vector designates the modified pPicholi vector without any insert. Other bands indicate the construct of 
MRP3 inserted into this empty vector. The gel contains the 100 ng of plasmid in each wel. Al the 
plasmids were linearized with AscI restriction enzyme to compare the sizes. 
3.1.2.3 Transformation into P. pastoris and expression analysis of al 
constructs 
The plasmid for each MRP3 construct was isolated and transformed into electro 
competent P. pastoris cels without linearization as described in sections 5.1.1.2, 
5.1.1.2 and 5.1.1.3. The transformed P. pastoris cels were inoculated in the MGYH 
(minimal glycerol + histidine) media for culturing and induction on a smal scale 
(section 5.1.1.1). 
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A clone transformed with the empty vector was cultured as a negative control (-K) 
and a clone of P. pastoris KM71 expressing MRP3 was used as an internal control 
clone (+K) for all the experiments performed. The positive control clone was kindly 
provided by Prof. Urbatsch (Texas Tech University, USA).  
The OD600 and pH of these cultures were measured before starting the induction 
with methanol in order to equalize the relative cell densities of all the cultures and 
to compare the differences in pH. Results from one such culture measurements are 
summarized in Table 3-3. 
Cultures in Buffered MGYH 
media 
 
Cultures in Buffered MM 
media 
after 48 h incubation at 29 °C 
 
after 48 h incubation at 29 °C 
       Cultures OD600 of 
Culture 
pH of 
Culture  
Cultures OD600 of 
Culture 
pH of 
Culture 
 
  
 
   
-K 3.43 4.86 
 
-K 2.39 4.88 
+K 5.24 4.42 
 
+K 3.19 5.08 
1B-1 6.39 3.68 
 
1B-1 2.81 4.85 
1B-2 4.09 4.65 
 
1B-2 3.05 4.93 
2D-1 5.45 4.78 
 
2D-1 2.19 5.02 
2D-2 7.01 4.25 
 
2D-2 2.35 4.99 
4A-1 6.64 4.31 
 
4A-1 3.55 4.60 
4A-2 4.84 4.20 
 
5C-1 3.87 4.99 
5C-1 6.23 4.02 
 
5C-2 3.91 5.03 
5C-2 3.27 4.84 
 
6A-1 2.99 5.10 
6A-1 5.14 4.45 
 
6A-2 3.98 5.03 
6A-2 5.75 4.18 
 
7A-1 2.98 5.03 
7A-1 5.61 4.01 
 
7A-2 4.20 
 
5.07 
7A-2 7.21 4.38 
    8G-1 No growth 5.10 
    8G-2 No growth 5.10 
    
Table 3-3: Values of OD600 and pH for small scale cultures after 48 h of culturing in MGYH media and MM 
media. The culturing was performed in 3 ml media in culture tubes. The constructs are referred by the 
numbers as mentioned in Table 3-2, instead of full names for convenience. The letters A, B, C etc. refers 
to the E. coli clones used for plasmid isolation and last number designates the internal P. pastoris clone 
number. The cultures for construct 8 were discarded as they showed no growth in MGYH media.  
The cultures were harvested and the crude microsomes were prepared from the 
pellets as described in section 5.4.1. Total protein concentrations of each sample 
were measured by Bicinchoninic acid (BCA) assay (section 5.4.2). 
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Figure 3-6: Western blot analysis of smal scale (3 ml) microsomal preparations from diferent clones of 
P. pastoris expressing various constructs of MRP3. The protein expression was determined after 48 h 
after of methanol induction. Control (-K and +K) clones were cultured, induced and harvested along with 
the sample clones. Equal amount (20 µg) of total protein from each sample was used for loading on 8 % 
SDS gel for Western blotting. The proteins were detected using Anti-MRP3 antibody (1:1000). 
Equal amounts of protein samples from each clone were used for loading on SDS gel. 
Protein samples were separated by SDS-PAGE, transferred to nitrocelulose 
membranes via Western blot and detected by using a specific antibody against MRP3 
(sections 5.4.4 and 5.4.6). 
In Figure 3-6, it can be seen that the +K sample shows a band around 150 kDa, which 
is the expected size of MRP3 on Western blots when detected by Anti-MRP3 
antibody. The antibody also recognized a band around 130 kDa in samples 2D-1 and 
2D-2, which are the clones for construct-2 (refer Table 3-2). 
The same set of clones was cultured again by scaling up the culture volume (10 ml) 
to reproduce the expression (Culture data for OD600 for pH value not shown). 
Results obtained from two such smal scale (10 ml) independent culturing and 
induction experiments are summarized in Figure 3-7. Here the detection was 
performed with two diferent lots of Anti-MRP3 antibody (with same catalog 
number). 
 The results obtained for al the clones from three independent culturing and 
induction is shown in and Figure 3-8. 
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(a) 
 
(b) 
Figure 3-7: Western blot analysis of smal scale microsomal preparations from diferent clones of 
P. pastoris expressing various constructs of MRP3 from two independent culturing and induction 
experiments. The culturing was performed in 10 ml media in culture flasks .Equal amount (20 µg) of 
total protein from each sample was used for loading on 8 % SDS gel for Western blotting. The proteins 
were detected using Anti-MRP3 antibody (1:1000) (a) Constructs 1, 2 and 3 show overexpression of 
protein comparable to the positive control (+K). (b) New lot of Anti-MRP3 primary antibody showing 
unspecific bands at 150 kDa. 
As seen in Figure 3-7 (a), the clones expressing ful length MRP3, construct 2 and 
construct 3 (refer chapter 2), showed the protein expression on scaling up the 
cultures. The band intensities of 150kDa band in, 1B-1, 1B-2 and the 130 kDa band 
in, 2D-2, 3C-1 and 3C-2 samples were comparable to +K. 
But the comparative band intensities for the same set of clones changed in the next 
culturing and induction attempt. In Figure 3-7 (b), the band intensity of 150 kDa 
band seen in +K sample is much higher than the respective bands in 1B-1, 1B-2, 2D-
1, 2D-2, 3C-1 and 3C-1 samples. 
It was also seen that during the experiments diferent lots of the same Anti-MRP3 
primary antibody (1° AB) showed diference in the binding. As seen from Figure 3-7 
(a), one lot recognizes bands at ~70 and ~90 kDa. On the other hand, a new batch of 
the same AB with the same lot number showed unspecific bands at 150 kDa. So, 
further Western blotting was performed using Anti-6xHis 1° AB. Results from the 
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third attempt to reproduce the expression experiments from the same clones are 
shown in Figure 3-8. 
 
Figure 3-8: Western blot analysis of protein expression from diferent clones of P. pastoris expressing 
various constructs of MRP3. Equal amount (20 µg) of total protein from each sample was used for loading 
on 8 % SDS gel for Western blotting. The proteins were detected using Anti-6xHis antibody (1:1000). 
The expression of protein by P. pastoris clones under observation was not consistent 
and reproducible. Though clones expressing constructs 1, 2 and 3 showed the 
protein expression, only expression from a clone of construct 2 (2D-2) was 
reproducible to some extent. So the P. pastoris clone expressing 2D-2 was sub-
cloned on YPD-100 and YPD-1000 agar plates (containing of Zeocin concentration 
100 and 1000 µg/ml respectively) and used for expression analysis. 
3.1.2.4 Expression of MRP3 construct 2 on smal and large scale 
The sub clones of clone 2D-2 were used for smal scale (10 ml) culturing along with -
K and +K and expression analysis was performed again as described in section 
3.1.2.3. The results for the expression of protein from sub clones were as shown in 
Figure 3-9. 
As seen in the Figure 3-9, diferent sub clones of 2D-2 selected from YPD plates with 
diferent Zeocin concentration (100 and 1000 µg/ml), showed diferent band 
intensities, when equal amount (20 µg) of total protein from each sample was used 
for comparison. The bands for construct 2 are seen at 130 kDa while the +K band is 
at 150 kDa. 
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Figure 3-9: Western blot analysis of protein expression from the sub-clones clone 2D-2 expressing 
construct 2. The clone 2D-2 was plated on YPD agar plates with 100 and 1000 µg/ml Zeocin 
concentration and the sub clones were cultured and induced for protein expression. Same amount (20 
µg) of total protein from each sample was applied on 8 % SDS gel for comparison. The proteins were 
detected using Anti-6xHis antibody (1:1000). 
The sub clone 2D-2.5 was selected for culturing and fermentation on large scale. The 
fermentation was performed as described in section 5.5.1 with addition of Zeocin. 
Culture samples were taken during each phase of fermentation and the protein 
expression was analyzed from these samples by smal scale microsomal preparation 
and Western blotting as described in 5.4.1 and 5.4.6. A fermentation sample of 
internal control clone (+K), was used as positive control. The Western blotting 
results for the large scale fermentation are shown in Figure 3-10 
 
Figure 3-10: Western blot analysis of large scale fermentation of clone 2D-2.5. Large scale fermentation 
culture samples were taken during each phase of large scale fermentation after 4 h intervals. Same 
amount (20 µg) of total protein from each sample was applied on 8 % SDS gel for comparison. The 
proteins were detected using Anti-6xHis antibody (1:1000). 
. 
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3.1.3 Discussion 
As seen from Figure 3-2, Figure 3-4 and Figure 3-5, the modification in the hMRP3 
sequence and insertion of various DNA sequences encoding different domains of 
MRP3 into the modified pPicholi expression vector was successfully done. The 
expression vectors were transformed in P. pastoris for the expression of protein.  
As mentioned earlier, the autonomously replicating pPicholi vector comprises many 
advantages over the traditional genome integrating vectors used for cloning in 
P. pastoris (MoBiTec 2003). The expression of a protein is usually proportional to its 
gene copy number. As the pPicholi vector contains the P. pastoris autonomously 
replicating sequences (PARS), the plasmid copy number can be controlled by 
increasing or decreasing the selection pressure (Wittrup, Bailey et al. 1990). This 
eliminates the need of screening of large number of P. pastoris clones after 
transformation, in order to select the clone containing high copy number of plasmid. 
The selection pressure can be generated by addition of sufficient quantities of the 
antibiotic Zeocin to the culture media (Paulina Balbás 2004).  
However, results obtained from small scale cultures of different clones containing 
this expression vector were disappointing. The protein expression by these clones 
was not reproducible under exact culture conditions, which can be seen in Figure 
3-6, Figure 3-7 and Figure 3-8. Only a single clone (2D-2) showed a constant 
expression of protein in these three independent experiments. 
The reasons could be either failure to maintain the exact culture conditions or to 
load equal amount of protein on SDS gels for Western blotting.  
In order to maintain the similar conditions during induction, the MGYH cultures 
grown to different cell densities (measured by OD600 measurements) were diluted 
to equal OD600 values at the beginning of the induction. Probably, the measurement 
and adjusting the OD600 to equalize the number of cells was not enough to maintain 
constant culture conditions for methanol induction. This is because OD600 values 
give only a rough estimate of the number of cells present in the media, irrespective 
of their growth state or viability. So, the ‘health’ of the cultures before induction 
could not be measured by this method, which may vary for different cultures. Many 
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factors affect the viability and growth of the culture which include the age of the 
colony picked for culturing, number of viable cells from the picked colony, growth 
phase of the cells growing in the culture etc. These factors cannot be controlled with 
the OD600 measurements and equalizing the values for cultures leads to a difference 
in the methanol utilization among the cultures grown under similar culture 
conditions (Evans 1996).  
Another reason could be the incorrect loading of the samples for Western blot 
analysis. The protein amounts on each crude preparation of microsomes for 
different clones were measured by BCA assay. This assay provides better tolerance 
to commonly encountered interfering agents in the cell lysate preparations such as 
nonionic detergents and simple buffer salts (Smith, Krohn et al. 1985), but this assay 
is highly sensitive towards reducing agents and other commonly found sugars in the 
cells (Brown, Jarvis et al. 1989). Moreover, it is already shown that the presence of 
lipids in samples can cause a significant error in the analysis of proteins by this 
procedure (Kessler and Fanestil 1986). This reduces the accuracy of the method for 
the total protein concentration measurements from yeast cell lysates, which could 
be a possible reason for the non-reproducibility of the Western blot experiments 
performed for the detection of the protein of interest. 
Moving on with the single clone showing slightly reproducible results, the 
expressing clone 2D-2 was sub cloned on YPD agar plates with different 
concentration of Zeocin and these sub-clones were analyzed for protein expression. 
The sub-clones showed a large difference in the expression of protein, which was 
unexpected (Figure 3-9). As these sub-clones were obtained from a single parent 
clone, they were expected to show a similar expression profile of the protein under 
similar culturing conditions and selection pressure. But the large difference in the 
protein amounts expressed under similar conditions indicates that the copy number 
of this autonomously replicating vector may vary among the sub-clones as well.  
From Figure 3-9, it can also be concluded that the increasing selection pressure 
might not always maintain a high copy number of a plasmid. The sub-clones 2D-2.1 
and 2D-2.2 grown on an YPD plate containing 1000 µg/ml Zeocin were expected to 
show a high expression of protein like the other three (2D-2.3, 2D-2.4 and 2D-2.5) 
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clones. But surprisingly the expression levels in these two sub-clones were lower 
than the sub-clones grown on the same YPD agar plate. This may be because the 
plasmid might have been lost from the cells randomly during the growth on YPD 
plate or during the culturing in MGYH media.  
Even the clone 2D-2.5 from YPD-1000 plate which showed high expression of 
protein on small scale culturing, expressed no protein at all when scaled up (refer 
3.1.2.4). This may be because the 100 µg/ml concentration of Zeocin in the 
fermenter was not enough to retain the plasmid inside the P. pastoris cells grown to 
a high density in the fermenter. So the loss of this autonomously replicating plasmid 
from the cells was possible. It is known from the literature that the autonomously 
replicating plasmids are unstable when the selection pressure is not maintained 
(Stearns, Ma et al. 1990). Unfortunately, use of further higher concentrations of 
Zeocin in the fermenter is not possible for economic reasons.  
To summarize, the autonomously replicating plasmids were not suitable for the 
large scale protein expression in yeast. 
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3.2 Expression and purification of hMRP3 using genome 
integration method 
The expression of MRP3 and its constructs using the autonomously replicating 
pPicholi vector led to non-sufficient results, showing a non-reproducible expression 
pattern in small scale cultures and complete lack of expression in large scale 
fermenter cultures, even when fermented under controlled conditions. After the 
unsuccessful attempt to express the protein using autonomously replicating pPicholi 
vector, the next step was to test the expression using a genome integration method. 
The genome integration method was performed with two different vectors (pPicholi 
and pPICZ A) with the different positions of the purification tag. 
3.2.1 Expression and purification using C-terminal purification tag 
3.2.1.1 Aims and rationale 
As the expression of proteins using autonomously replicating vector was 
unsuccessful, it was absolutely essential to develop another method to express the 
protein. Because genome integration method is a routinely used method for 
expression of heterologous proteins in yeast, we decided to proceed with this 
method. 
Aim of this part was to integrate the existing autonomously replicating expression 
vector pPicholi into P. pastoris genome and generate clones which can express MRP3 
protein in detectable amounts and purify the expressed protein by affinity 
chromatography using the Strep tag II and 8xHis purification tags inserted in the 
protein sequence. 
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3.2.1.2 Results 
3.2.1.2.1 Linearization, genome integration of the pPicholi vector and 
selection of MRP3 expressing clones 
The modified pPicholi vectors with MRP3 sequence and its truncated versions were 
linearized with the FastDigest restriction enzyme MssI (Fermentas), cleaned and 
transformed into competent P. pastoris KM71H cells ( see appendix 6.3.3) following 
the steps described in 5.2.1, 5.2.3., 5.2.4, 5.2.7.2, 5.1.1.2 and 5.1.1.3. The restriction 
site for MssI (PmeI) lies in the AOX1 promoter sequence of the plasmid. Exact 
position of the restriction site is shown in the vector map in the appendix 6.3.  
From the many P. pastoris clones grown after transformation, clones from YPD 
plates with different Zeocin concentration were chosen and cultured for screening 
the expressing clones (section 5.1.1.1). A clone transformed with empty vector (-K) 
and the internal control clone (+K) were cultured as negative and positive controls 
for expression respectively. The culturing was performed without addition of Zeocin 
to the media. The OD600 values were adjusted to be equal for all cultures in order to 
keep methanol concentration fairly constant during the induction. 
The methanol induced cultures were harvested and crude microsomes were 
prepared as described in section 5.4.1. Total protein concentrations of each sample 
were measured by BCA assay (section 5.4.2). 
Protein samples were separated by SDS-PAGE, transferred to nitrocellulose 
membranes via Western blot and the proteins of interest were detected by using a  
specific antibody against the 6xHis tag (sections 5.4.4 and 5.4.6). The results for 
protein expression by different clones from three independent culturing 
experiments are summarized in Figure 3-11. 
As seen from the Western blot for three independent culturing experiments, the 
clones were able to express the protein even in absence of the selection pressure 
(Zeocin) in the MGYH media. 
The clone 1000-1 showed a light band at around 150 kDa in all the experiments, 
which was comparable to the size of the protein expressed by the +K. The clone 
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1000-1 showed reproducible results with respect to the expression, though the 
amount of protein expressed in equal amount of total protein was sometimes lower 
(Figure 3-11 a, c) and sometimes higher (Figure 3-11 b) than the positive control +K. 
Other two clones 1000-6 and 1000-7 also showed a band around 150 kDa in both 
the experiments in which they were tested (Figure 3-11 b, c). The intensities of the 
150 kDa band varied for al the clones in comparison to the +K in independent 
culturing, even when same amount of total protein (20 µg) was loaded. In al the 
blots the negative control –K did not show any band around 150 kDa. 
 
Figure 3-11: Western blot analysis of smal scale microsomal preparations from three independent 
culturing and induction experiments with diferent clones of P. pastoris. The clones were transformed 
with linearized pPicholi plasmids containing MRP3 gene insert. Total induction time and addition of 
0.5 % methanol for each cultured is mentioned on right side. Controls (-K and +K) clones were cultured, 
induced and harvested along with the sample clones. The number 1000 in the clone name refers to the 
concentration of Zeocin in µg/ml in the YPD agar plate from which the clone was selected. Same amount 
(20 µg) of total protein from each sample was applied on 8 % SDS gel for comparison. The proteins were 
detected using Anti-6xHis primary antibody. 
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3.2.1.2.2 Large scale fermentation of clone 1000-1 
As the clone 1000-1 showed a reproducible protein expression in smal scale 
cultures it was selected for culturing and fermentation on large scale. No Zeocin was 
added to the fermenter for selection pressure to check if the vector can stil be 
retained in the cels. 
 A large scale fermentation culture sample of the clone +K fermented under similar 
conditions was used as positive control (+K) for Western blotting. Crude 
microsomes were prepared from both the samples and total protein concentrations 
of each sample were measured by BCA test (section 5.4.1 and 5.4.2). Equal amount 
of total protein from each sample was used for loading on 8 % SDS gel and the MRP3 
protein was detected using anti-6xHis antibody by Western blotting as described in 
sections 5.4.4 and 5.4.6. 
 
Figure 3-12: Western blot analysis of large scale fermentation of clone 1000-1. The fermenter culture 
was induced for 24 h with 0.3 % methanol and the MRP3 expression was compared with the expression 
of MRP3 by control clone (+K) under similar conditions of large scale fermentation. Equal amount (10 
µg) of total protein from each sample was used for loading on 8 % SDS gel for Western blotting. The 
MRP3 was detected using Anti-6xHis 1° AB. 
Figure 3-12 displays a Western blot showing the expression of MRP3 on large scale 
by the internal control clone (+K) and clone 1000-1 under similar fermentation 
conditions. The clone 1000-1 showed a dark band around 150 kDa similar to the +K, 
which is the approximate size of the MRP3. Both the samples also showed a light 
band above 180 kDa with similar band pattern. The fermenter sample from 1000-1 
was then used for large scale protein purification on afinity columns. 
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3.2.1.2.3 Isolation, Solubilization and purification on Ni-NTA column 
The culture obtained from the large scale fermentation of yeast cels was harvested 
and disrupted with glass beads as described in section 0. The microsomal fractions 
after the disruption were solubilized and ultracentrifuged to get the soluble fraction 
(section 5.5.3). 
The soluble fraction was directly loaded on a Ni-NTA (nitrilotriacetic acid) column 
for afinity purification folowed by concentration on 100 kDa and 30 kDa exclusion 
size Amicon membrane filters (Section 0). 
Equal volumes of samples from ultracentrifugation and purification steps were 
analyzed by SDS-PAGE and subsequent silver staining (sections 5.4.4 and 5.4.5.2). 
 
Figure 3-13: Silver staining of SDS-PAGE for analysis of the colected samples during the ultrafiltration. 
The samples UC-S and UC-P (Ultracentrifugation – Supernatant and Ultracentrifugation – Pelet) are the 
soluble and insoluble fractions after ultracentrifugation of the solubilized microsomes. FT is the 
unbound fraction dripped from Ni-NTA column after overnight binding of the soluble fraction on the 
column. W1 and W2 are the samples from washing of the columns with washing bufer containing 30 mM 
and 40 mM Imidazole respectively. F-100 and F-30 are filtrates taken during the ultrafiltration with the 
100 kDa and 30 kDa Amicon membranes respectively. In the Elution lane is the final product of the Ni-
NTA purification process, the concentrated protein solution of MRP3. 
In Figure 3-13, lanes UC-S and UC-P (Ultracentrifugation – Supernatant and 
Ultracentrifugation – Pelet) show the fractions obtained after ultracentrifugation of 
the solubilized sample. The flow through in the third lane (FT) is the unbound 
protein from the UC-S loaded on the column. A subsequent washing step with 
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washing buffer containing 30 mM Imidazole W1 eluted proteins of various sizes, 
which can be seen as light bands around 120, 80 and 38 kDa. Next washing step W2 
(with 40 mM Imidazole) also eluted a single protein with a band of 38 kDa.  
The filtrate sample after ultrafiltration with the 100 kDa Amicon membrane (F-100) 
showed a light band around 150, 80 and 55 kDa while filtrate after ultrafiltration 
with the 30 kDa membrane (F-30) showed no visible band of protein. The elution 
fraction containing concentrated protein showed many protein bands including dark 
bands at around 80, 70, 55 and 40 kDa. This also showed a large band scattered 
between 130 and 150 kDa, which probably is the concentrated MRP3. 
The amount of MRP3 in the concentrated sample was calculated by measuring the 
absorption at 280 nm (A280) on Nanodrop and the elution sample was used for 
purification on a Strep-tactin affinity column. 
3.2.1.2.4 Purification on Strep-tactin column 
The expressed MRP3 protein also contained the purification tag Strep tag II which 
was used for the binding and purification on Strep-Tactin affinity column. 
The purification was performed by using spin columns and all the washing and 
elution steps were performed as described in section 5.5.5.  
Same volume from each fraction of purification was loaded on 8 % SDS gel and the 
proteins were separated by SDS-PAGE. The separated proteins were transferred to 
nitrocellulose membranes and MRP3 was detected in each lane by Western blotting 
with Anti-MRP3 antibody [M3II-9] Sections 5.4.4 and 5.4.6).  
The lane Ni-NTA elution is the concentrated protein sample obtained after 
purification on Ni-NTA column (Figure 3-13), which was used for loading on the 
Strep-tactin column. This lane shows a dark band spread over 70 to 200 kDa and 
also till the starting point of the SDS gel. FT is the unbound fraction, which also 
shows approximately same bands and intensity as the first lane. The samples W1-
W5 are the fractions obtained after washing the column with wash buffer. The lane 
W1 was also crowded with different bands of various sizes (70 to 200 kDa) while the 
sample W2 showed only 2 bands at 150 and around 200 kDa. The Elution sample is 
Results and Discussion 49 
 
the mixture of al the elution fractions. This elution fraction did not show any band 
for MRP3. 
 
 
Figure 3-14: Western blotting of the Strep-tactin purified MRP3 protein sample. The sample Ni-NTA 
Elution is the purified and concentrated protein after the Ni-NTA column purification, directly loaded on 
the Strep-tactin spin column for binding. FT is the unbound fraction after 2 h of incubation. W1 to W5 are 
the samples from washing of the columns with washing bufer. Elution is the mixed sample of al the 
eluted fractions. Same volume (20 µl) of each sample was applied on 8 % SDS gel for comparison. The 
proteins were detected using Anti-MRP3 antibody [M3II-9] (1:2000). 
3.2.1.2.5 Purification of a control protein on Strep-tactin column 
In order to solve the problem of purification on Strep-tactin column it was necessary 
to know the factors afecting the binding of protein to the column. To check, if the 
detergent n-dodecyl β-D-Maltopyranoside (DDM), used for solubilization of the 
protein, is the problem in binding, we decided to test the binding of a protein known 
to have a Strep tag I sequence under the similar detergent concentrations. 
For this purpose, a 40 kDa pure and soluble protein expressed in from E. coli was 
provided by Julian Matern (Prof. Mootz’s group, Institute of Biochemistry, 
Muenster). This protein also had Strep tag I. 
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This control protein was mixed with bovine serum albumin (BSA) in equal amount 
and dissolved in Ni-NTA elution bufer to mimic the final bufer composition and 
DDM concentration as the Ni-NTA eluted MRP3. This protein mixture was loaded on 
the same Strep-tactin spin column (regenerated before use as described in 5.5.5) 
purified exactly as described in 3.2.1.2.4. 
 The Strep-tactin column purification was analyzed by SDS-PAGE and subsequent 
Coomassie staining (sections 5.4.4 and 5.4.5.1.1) 
Figure 3-15 shows the SDS-PAGE analysis results of the purification of the control 
protein on Strep-tactin column. The sample is the mixture of the control protein and 
BSA. The lane loaded with this mixture showed an expected band at 40 kDa and 
around 67 kDa for control protein and BSA respectively. Apart from these two bands 
the lane also showed various bands around 70, 88, 140, 200 kDa and at the starting 
of the separating gel. The lane FT (flow through) shows two dark bands at 40 and 
68 kDa and a realy light band at 88 kDa. The bands seen in FT get lighter in W1 and 
W2 and completely disappear W3, W4 and W5 (W=Wash). The elution fraction 
shows only the dark 40 kDa band and a very light protein band around 80 kDa. 
 
Figure 3-15: Coomassie staining of SDS-PAGE analysis of Strep-tactin column purification of the control 
protein. The sample Protein mixture is the equal amount mixture of BSA and the control protein known 
to have Strep tag II. FT is the unbound fraction dripped from the spin column after incubation for 2 h. W1 
to W5 are the samples from washing of the columns with washing bufer. Elution is the mixed sample of 
al the eluted fractions. Same volume (20 µl) of each sample was applied on 8 % SDS gel for comparison 
.The control protein is seen in the elution fraction. 
Results and Discussion 51 
 
3.2.1.2.6 Purification on Strep-tactin column after removal of His tag 
In order to check if the middle position of the Strep tag I was afecting the 
interaction between the Strep tag I and the column material, we decided to cleave 
of the poly-His  tag from the MRP3 protein and check for the binding and 
purification again. 
As shown in Figure 3-1, the C-terminal purification tag contains a 3C protease 
cleavage site between Strep tag I and 8xHis sequence. So, the His tag could be 
removed from the protein by cleavage with 3C protease. 
The protease cleavage reaction was set up with diferent amounts of Protein purified 
on Ni-NTA column as described in section 5.4.7.1. 
The removal of His tag was checked by SDS-PAGE and subsequent Western blotting 
with Anti-MRP3 and Anti 6xHis antibody (5.4.4 and 5.4.6). 
 
Figure 3-16: Western blot analysis of the overnight 3C protease cleaved MRP3 protein samples. The 
values 5, 10, 20 and 50 µg indicates the amount of purified MRP3 used for cleavage of 3C protease in a 
100 µl reaction. –K represents the reaction mixtures except without 3C protease and 3C denotes the 
mixtures with the addition of proteases. In the picture same membrane was stripped after 6xHis 
antibody treatment and incubated with Anti-MRP3 antibody [M3II-9] (1:2000) afterwards to visualize 
the protein. 
In Figure 3-16 (a), al lanes labeled as 3C showed a single sharp band around 35 kDa 
when treated with Anti-6xHis antibody while the same samples without 3C protease 
treatment (labeled as –K) showed a distinct band at 150 kDa along with other bands 
around 55, 60, 65, 70,180 and 200 kDa. The band pattern was same in al the lanes 
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with 10, 20 and 50 µg of protein sample while no protein was detectable in the lane 
with 5 µg sample lane except the sharp band at 35 kDa. 
Figure 3-16 (b) shows the same blot stripped and incubated with Anti-MRP3 
antibody [M3I-9] to visualize the protein. Al the lanes in this blot show dark bands 
around 80, 130, 150 and 170 kDa. The band intensities increase from left to right as 
the concentration of the Ni-NTA purified MRP3 increases in the sample. At al the 
concentrations, lanes –K and 3C show the same band pattern and intensities. 
Al the samples used to load 3C lanes were mixed and diluted 1:1 with 2x Ni-NTA 
elution bufer applied to the Strep-Tactin spin columns and the purification was 
performed exactly as described in section 3.2.1.2.4. 
Equal volume of samples from various purification steps were analyzed by SDS-
PAGE and subsequent Western blotting by Anti-MRP3 antibody [M3I-9] (1:2000) as 
described in sections 5.4.4 and 5.4.6. 
 
Figure 3-17: Western blotting of the 3C protease cleaved MRP3 protein purified on Strep-tactin spin 
column. The sample after 3C protease cleavage was diluted 1:1 with 2x Ni-NTA elution bufers and 
directly applied to the Strep-tactin spin column for binding. FT is the unbound fraction after 2 h of 
incubation. W1 to W5 are the samples from washing of the columns with 1 CV washing bufer. E1-E3 are 
the elution fractions which are 4x concentrated compared to the sample used for loading. Same volume 
of each sample was applied on 8 % SDS gel for comparison. The proteins were detected using Anti-MRP3 
antibody [M3II-9] (1:2000). 
Figure 3-17 shows dark bands around 70, 90 and 150 kDa in the lane FT (flow 
through). Lanes W1, W2 (wash samples) also show similar bands, but less intense 
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than in FT. A 150 kDa band with almost equal intensity is seen in W3, W4, W5 and 
E1, E2, E3 sample. 
3.2.1.2.7 Purification on Strep-tactin column after mild denaturation by SDS 
In order to check if the mild denaturation of the expressed MRP3 could improve the 
purification on Strep-tactin column, we decided to denature the protein under mild 
denaturing conditions.  
To do so, the microsomal fractions after the disruption of the cels (section 0) were 
solubilized and ultracentrifuged as described in 5.5.3. In order to denature the 
protein, the solubilization was performed at room temperature (RT) with 1 % 
denaturing detergent sodium dodecyl sulfate (SDS). 
 
Figure 3-18: Western blotting of the denatured MRP3 protein purified on Strep-tactin spin column. The 
microsomal fractions of P. pastoris were solubilized at RT with 1 % SDS for mild denaturation. The 
soluble fraction of the denatured sample obtained after ultracentrifugation was loaded on Strep-tactin 
column for purification. FT is the unbound fraction after 2 h of incubation on Strep-tactin column at RT. 
W1 to W5 are the samples from washing of the columns with 1 CV (column volume) washing bufer. E1-
E3 are the elution fractions which are 4x concentrated compared to the sample used for loading. Same 
volume of each sample was applied on 8 % SDS gel for comparison. The proteins were detected using 
Anti-MRP3 antibody [M3II-9] (1:2000). 
The soluble fraction after ultracentrifugation was directly loaded on Strep-Tactin 
spin column and purification was performed at RT exactly as described under 
section 5.5.5 The results after SDS-PAGE and subsequent Western blotting analysis 
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by Anti-MRP3 antibody [M3II-9] (sections 5.4.4 and 5.4.6) after Strep-tactin 
purification are shown in Figure 3-18. 
In the Figure 3-18, dark bands around 75, 90, 130, 150 and 200 kDa can be seen in 
samples FT, W1 and W2. The bands in FT and W2 are much more intense and almost 
black. These three lanes also show light bands around 38, 40 and 55 kDa. Other 
lanes containing washing and elution samples (W3, W4, W5 and E1, E2, E3) show 
only very light bands at 200 kDa (may be just at beginning of wells). W3 lane also 
shows a very light band at 90 kDa. 
3.2.1.3 Discussion 
It was obvious from section 3.1.3, that the pPicholi vector is unable to express 
recombinant protein on large scale when allowed to replicate autonomously in the 
cells. This is probably because the vector is lost from the P. pastoris cells when the 
selection pressure is not high enough (Duret, Andre et al. 2005; Colin Ratledge 
2006).  
It is known from the literature that the genetic modification in the genome of any 
organism is possible by insertion of foreign DNA which contains a homologous 
region with the genomic DNA sequence(s). This allows the transfer of any 
modification of the cloned gene into the genome of a living cell (Stearns, Ma et al. 
1990; San Filippo, Sung et al. 2008). 
The pPicholi vector, though originally designed for autonomous replication, also 
contains elements which can drive the homologous recombination events with the 
P. pastoris genome. The AOX1 promoter sequence or the AOX1 transcription 
termination region (TT) from pPicholi vector can recombine with the aox1::ARG4 
gene sequence from the KM71H strain (details in section 6.3.3) of P. pastoris via 
single crossover or multiple event resulting in the insertion of one or more copies of 
the vector upstream or downstream of the aox1::ARG4 gene (Cregg, Barringer et al. 
1985; Cregg, Tolstorukov et al. 2009).  
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This recombination event may also occur with non-linearized plasmid, but at a lower 
frequency. Linearization of plasmids at a restriction enzyme site located in the AOX1 
sequence facilitates such gene insertion events (Invitrogen 2010).  
The plasmid was linearized by restriction at MssI (PmeI) enzyme site which lies 
inside the AOX1 promoter sequence (MoBiTec 2003). As seen from Figure 3-11 and 
Figure 3-12 the expression of MRP3 after linearization of the plasmid was successful 
and reproducible without addition of Zeocin to the media on both small and large 
scale. 
This supports the possibility of stable integration of the plasmid. In any case, the 
protein was now successfully expressed on large scale and was available for further 
purification steps. 
After the successful production on large scale (Figure 3-12), the next step was to 
solubilize and purify the protein for biochemical measurements. For the 
solubilization step the nonionic detergent DDM was selected as it was shown 
previously to solubilize the protein without affecting activity of the protein. 
Following the solubilization, the protein was purified on Ni-NTA column with a 
known protocol for purification. (Chloupkova, Pickert et al. 2007; Zehnpfennig, 
Urbatsch et al. 2009). 
Figure 3-13 shows the result for Ni-NTA column purification. It is seen in the picture 
that apart from the recombinant protein containing His tag, many other proteins 
were bound to the column, which were eluted either with mild washing steps (W1, 
W2) or with strong elution buffer (Elution lane). In the elution sample many bands 
were seen at different sizes showing that the protein was not pure and was 
contaminated with other proteins. So, further purification was mandatory to achieve 
highly pure protein needed for reconstitution in liposomes and ATPase activity or 
transport measurements.  
The subsequent purification on the Strep-tactin column was performed, but the 
purification led to disappointing results. In Figure 3-14, the dark bands seen in at 
150 kDa in FT, W1 and W2 lanes indicate that the MRP3 was lost in the flow through 
and subsequent washing steps. Other smaller bands recognized by antibody could 
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be the fractions of protein generated by action of proteases or by random 
disintegration during freeze thaw cycles. As no band was seen in the elution fraction, 
it was clear that the purification did not work indicating the incapability of protein 
to bind to the column.  
To confirm that the conditions like buffer composition and presence of detergent are 
not affecting the binding of protein to the column, purification was performed under 
similar conditions with a control protein expressing Strep tag II (Figure 3-15). The 
protein was mixed with BSA to ‘contaminate’ and then test the purification. The 
protein mixture on the gel shows the expected 40 kDa band for the protein and the 
69 kDa band for BSA. Other bands seen at 70 kDa, 140 kDa and 200 kDa could be 
impurities, dimers and aggregates of BSA respectively, as these bands are seen in FT 
and other washes (W1, W2), which indicates that these are not binding to the 
column. On the other hand, a band seen at 88 kDa in the protein mixture lane does 
not appear in the FT or washes, which implies that this could be a dimer of the 
control protein which bound to the column and did not wash away in the washing 
steps.  
The 40 kDa and 80 kDa bands reappeared in the elution fraction, concluding that the 
control protein was able to bind to the Strep-tactin column under similar conditions 
of buffer and detergent. A notable part of the control protein was also seen in in FT 
and W1 samples, showing a large unbound fraction. It is already known from the 
literature that the efficiency of the Strep-tactin column is around 50-60 % and so 
some protein loss was expected (De Giuseppe, Forti et al. 2010). 
In the literature, the combination of His and Strep tag II was often used successfully 
for the purification of many mammalian proteins (Li 2010). So, the possibility of His 
tag affecting the binding of Strep tag II with the Strep-tactin resin was almost 
negligible. Still in order to check if this could be a problem, the purification was 
repeated after successful removal of the His tag from the protein (Figure 3-16 and 
Figure 3-17).  
In Figure 3-16 (a), the blot was developed using Anti-6xHis antibody. In this blot all 
the samples labeled as 3C (in which the protein was treated with 3C protease) show 
a strong band at 35 kDa, which is the size of recombinant, His tagged HRV 3C 
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protease. The –K samples (without protease) show the expected MRP3 band at 
150 kDa which are not seen in 3C samples. This indicates that the His tag was 
removed from the MRP3 and was not detectable by the Anti-6xHis antibody 
anymore. Bands seen at 55 and 60 kDa could be other proteins from P. pastoris as 
these appear in both, 3C and –K lanes. However, the 65 kDa band seen in –K lane 
could be a degradation product of MRP3, as this band is not seen after the 3C 
protease treatment.  
In order to confirm that the failure to recognize MRP3 bands by the 6xHis antibody 
is caused by the removal of the tag and not by the absence of protein itself, the 
membrane was stripped and treated with Anti-MRP3 antibody [M3II-9] Figure 3-16 
(b)). The antibody is very strong and detects the protein even when present in 
smaller amounts. The antibody showed many smaller and larger bands than 
150 kDa (size of MRP3), which possibly could be various degradation and 
aggregation products of the protein caused by the storage at 4 °C for longer time. 
The possibility of unspecific cleavage by 3C protease is ruled out as both, –K and 3C 
samples, show the same the band pattern. The 65 kDa band seen in –K sample in 
Figure 3-16 (a) is also seen in Figure 3-16 (b), indicating this to be a degradation 
product and not another protein from P. pastoris. In summary, all the samples 
labeled as 3C contained MRP3 without His tag. 
The MRP3 samples with removed His tag were again purified on Strep-tactin column 
(5.5.5). The results shown in Figure 3-17 indicate that the removal of the His tag did 
not improve the binding of the protein to the Strep-tactin column. The lane FT shows 
a very dark band when treated with Anti-MRP3 antibody [M3II-9], showing the loss 
of protein. Subsequent washes (W1, W2) removed the protein completely from the 
column which can be seen as dark bands in the lanes. Remaining lanes (W1, W2, W3 
and E1, E2, E3) show only a small quantity of protein, which is seen as a light band at 
150 kDa. A slightly darker band in E2 compared to E1 indicates a very poor binding 
to the column. To summarize even the removal of His tag did not improve the 
binding. 
As it was confirmed that removal of His tag had no effect on the binding of protein to 
the Strep-tactin column, the protein was denatured with SDS. This treatment will 
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change the protein conformation and may expose the Strep tag II, if hidden inside 
and unavailable for the interaction with Strep-tactin column. As seen from the Figure 
3-18, even the denaturation of the protein did not improve the binding. This can be 
seen from dark bands in first three lanes FT, W1 and W2 in which most of the 
protein was seen. Again a slightly darker band in E2 fraction compared to E1 
indicates very little binding. But when compared to the amount of protein lost in FT, 
W1 and W2 the light band in concentrated E2 fraction had negligible protein, which 
means that the purification on the Strep-tactin column was unsuccessful even after 
denaturation of the protein. 
Further attempts were not performed with stronger denaturation conditions as this 
probably would lead to protein aggregation and even if it would be successful, such a 
purification product could not be used for further experiments. So, finding the 
reasons behind the non-binding of purification tag and solving the purification 
problem was essential to proceed.  
The Strep tag II is a small 8 amino acid peptides with no known effect on the 
trafficking, activity and/or the folding of the protein (IBA 2011). In the light of these 
facts, any conclusion made about the interactions would be futile. 
Considering the observations made so far, it was assumed, that the yield of protein 
after Strep tag II purification is different for different proteins. However, sometimes 
altering the position of the tag (C or N terminal) could help to improve the binding 
(Volkmann 2011). So the cloning strategy was changed for the constructs and it was 
decided to use an N- terminal Strep tag II for MRP3 purification. 
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3.2.2 Expression and purification using N and C-terminal purification 
tags 
3.2.2.1 Aims and rationale 
As the tandem afinity purification tag on C-terminus of the expressed protein did 
not work, a new system had to be designed for the expression and purification. 
From the experiments with pPicholi vector and literature it was clear that the 
genome integration method was a better choice for stable integration of the insert 
gene into the genome of P. pastoris (Romanos, Scorer et al. 1992). For the new 
cloning strategy, a more commonly used genome integrating vector pPICZ A was 
chosen for cloning which has been extensively used for expression of soluble and 
membrane protein expression (Obiezu, Soosaipilai et al. 2002; Chloupkova, Pickert 
et al. 2007; Wetterholm, Martinez Molina et al. 2008). 
 
Figure 3-19: Schematic representation of the expression cassette for ABCC3 and its truncated versions 
for expressing in P. pastoris. This strategy encodes Strep tag II afinity tag at N-terminal of the protein 
separated by a Factor Xa protease cleavage site. The C-terminal sequence consists of 3C-protease 
cleavage site (3C) and poly-His (6xHis) tag. In addition, the vector contains Kozak-like bases (P. pastoris 
Kozak), important for high-level expression in P. pastoris, in the region before Strep tag I sequence. 
Aim of this part was to perform al the cloning work by changing the vector and 
purification tag system and express the MRP3 and its truncated versions into 
P. pastoris again. The expressed protein would then be purified with a Ni-NTA and a 
Strep-tactin column. To achieve this expression, the pPICZ A vector had to be 
modified in order to insert the Strep tag I and the protease cleavage sites. 
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3.2.2.2 Results 
3.2.2.2.1 Modification of pPICZ A vector and ligation of MRP3 gene sequences 
into new vector 
As the cDNA sequence of MRP3 and its truncated versions were already cloned and 
sequenced in pPicholi vector, this time a new strategy was utilized for modification 
of vector and transfer of constructs from pPicholi to pPICZ A vector. 
The multiple cloning site (MCS) in the commercial pPICZ A vector has the c-myc 
epitope and a 6xHis tag for the addition of a tandem afinity tag at the C-terminal 
end of the protein (Figure 3-20). To replace the c-myc epitope by Strep tag I 
sequence along with the protease cleavage sites designed for the cloning (Figure 
3-19), a custom oligonucleotide pair was used (Figure 3-20). 
 
Figure 3-20: Schematic representation of the modification of in the multiple cloning site (MCS) of the 
pPICZ A vector. A complementary oligonucleotide pair containing Kozak-like bases (P. pastoris Kozak), 
Strep tag II afinity tag, a Factor Xa protease cleavage site and the 3C-protease cleavage site was used for 
the modification. Annealing of the two complementary oligonucleotide would result in a dsDNA fragment 
with KpnI restriction like cohesive end at 5’ and SalI restriction like cohesive end at 3’. These cohesive 
ends can be used for the replacement of the c-myc epitope of the pPICZ A vector with the new 
oligonucleotide sequence. The AscI and SacII restriction sites in the oligonucleotide, between Factor Xa 
site and 3C protease site would alow the cloning of MRP3 sequences from old vector (pPicholi) into new 
vector. 
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The two single stranded DNA oligonucleotides were annealed and phosphorylated 
as described in 5.2.12. The pPICZ A vector restricted with KpnI and SalI enzymes, 
cleaned as described in 5.2.4 and 5.2.7. The restricted plasmid was ligated with the 
annealed oligonucleotides and was transformed into TOP10F’ E. coli cells (5.2.8 and 
5.1.2.3). 
The positive clones with modified vector were selected by colony PCR as described 
in section 5.2.9.2. After modification, the vector was sequenced (5.2.11) before using 
it for further experiments. 
The pPicholi vectors containing old sequenced MRP3 DNA sequences and the 
modified pPICZ A vector were restricted with AscI and SacII enzymes (5.2.4). The 
restricted samples were cleaned, ligated and transformed in Top10F’ E. coli 
(sections 5.2.5 , 5.2.6, 5.2.4, 5.2.7.2, 5.2.8 and 5.1.2.3). The positive clones with 
modified vector were selected by colony PCR (section 5.2.9.2) and were transformed 
into P. pastoris as described in 3.2.2.2.1 and 5.1.1.3. A primer pair of ‘Strep tag II For’ 
and ‘AOX1 3’ Rev’ was used for all colony PCRs performed in order to differentiate 
from the old vector. 
3.2.2.2.2 High throughput screening of P. pastoris clones for expression of 
MRP3 
The high throughput screening of clones was performed as described in section 
5.4.2. A constitutively expressed protein, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), was detected by a GAPDH specific antibody and used as 
loading control. Results from two independent high throughput screening 
experiments are summarized in Figure 3-21.  
Figure 3-21, shows the results from two independent culturing and induction 
experiments performed in 24 well plates for high throughput screening of clones 
expressing MRP3 (5.4.2). After running of the samples on SDS gel and wet transfer, 
the membranes were cut at 90 kDa horizontally; the upper and lower halves were 
treated with different antibodies (Sections 5.4.4 and 5.4.6).  
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In both, the upper blots of figures (a) and (b), many clones show a band around 
150 kDa, similar to a band shown by control protein (+K), which is the expected size 
of MRP3. The GAPDH antibody recognized a band around 72 kDa. 
 
Figure 3-21: Western blot analysis of high throughput screening of diferent clones of P. pastoris 
transformed with modified pPICZ A plasmids with MRP3 gene insert. The protein expression was 
determined after 24 h of methanol induction. The controls -K and +K (as described in 3.1.2.3), clones 
were cultured, induced and harvested along with the sample clones in the same 24 wel plate. The 
numbers 100 or 500 refers to the concentration of Zeocin in µg/ml in the YPD agar plate from which the 
clone was selected. 15 µl samples from each cel lysate were loaded on 8 % SDS gel and analyzed by 
Western blotting. The MRP3 was detected using either Anti-6xHis AB (1:1000) (a) or Anti-MRP3 antibody 
[M3II-9] (1:2000) (b) (both upper blots) and GAPDH was detected by Anti-GAPDH antibody (1:4000). 
The amount of MRP3 expressed per cel was calculated by comparing the intensities 
of bands shown by MRP3 and GAPDH antibodies with ImageJ software and 
normalized to the MRP3 expressed by the internal control clone (+K) (data not 
shown). The amount of protein expressed by identical clones varied in independent 
cultures, so the clone showing moderate expression in al the cultures (100-5) was 
chosen for large scale fermentation. 
3.2.2.2.3 High throughput screening of P. pastoris clones for expression 
truncated versions of MRP3 
Apart from the ful length MRP3, the other truncated versions were also checked for 
expression using high throughput screening method (sections 5.4.2, 5.4.4 and 5.4.6). 
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Even after screening a large number of clones for expression, only three truncated 
versions showed a detectable expression of protein (Figure 3-22). 
 
Figure 3-22: Western blot analysis of high throughput screening of diferent clones of P. pastoris for the 
expression of ful transporter and its various truncated forms. The protein expression was determined 
after 24 h of methanol induction. The controls -K and +K (as described in 3.1.2.3), clones were cultured, 
induced and harvested along with the sample clones in the same 24 wel plate. The number 500 refers to 
the concentration of Zeocin in µg/ml in the YPD agar plate from which the clone was selected. 15 µl 
samples from each cel lysate were loaded on 8 % SDS gel and analyzed by Western blotting. The 
proteins were detected using Anti-MRP3 antibody [M3II-9] (1:2000). 
From the Figure 3-22 it can be seen that the truncated versions of MRP3, ΔTMD0-
MRP3 (Construct 2), ΔTMD0L01/2-MRP3 (Construct 3) and ΔTMD0L0-MRP3 
(Construct 4) also show bands recognized by Anti-MR3 antibody at 130 kDa. Though 
the sizes of constructs are diferent (Table 3-2), the smal diference of 5 kDa 
between construct 2 and 3 and 6 kDa between construct 3 and 4 is dificult to see on 
the blots. The size diference of 20 kDa between ful length MRP3 and construct 2 is 
clearly seen in Figure 3-22 (a). 
It is also notable, that the truncated versions showed a sharp band around 170 kDa 
when present in large quantities (clone 500-4, 5 from ΔTMD0-MRP3 and clone 500-
3 from ΔTMD0L01/2-MRP3), while no such band was detected for the internal 
control clone or the ful length MRP3, even when loaded in high quantities (Figure 
3-21).  
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3.2.2.2.4 Large scale fermentation and purification of clone 100-5 on Ni-NTA 
column  
The MRP3 expressing clone 100-5 was fermented on a large scale under controled 
conditions as described in section 3.2.1.2.2 Culture samples were taken during 
diferent time intervals of induction and the protein expression was analyzed from 
these samples by smal scale microsomal preparation and Western blotting as 
described in 5.4.1 and 5.4.6. A large scale fermentation culture sample of an internal 
control clone induced for 24 h was used as positive control (+K). 
 
Figure 3-23: Western blot analysis of large scale fermentation of clone 100-5. Culture samples from the 
fermenter were taken during induction after 4 h intervals and analyzed for protein expression. Equal 
amount of wet cel mass was used for smal scale microsomal preparation. 15 µl samples from each cel 
lysate was loaded on 8 % SDS gel and analyzed by Western blotting. The proteins were detected using 
Anti-MRP3 antibody [M3II-9] (1:2000). 
As seen from Figure 3-23, the clone 100-5 overexpressed the protein in suficient 
quantities for purification. 
The large scale fermentation samples were harvested and lysed as described in 
5.5.2.2. A smal amount (10 g) from the cel lysate was solubilized and 
ultracentrifuged as described in 5.5.3. The Figure 3-24 (a) shows the result after 
solubilization with DDM. The soluble fraction after ultracentrifugation was loaded 
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on a smal Ni-NTA column and the purification was performed as described in 
5.5.4.1. 
The Figure 3-24 (b) shows the Ni-NTA column purification of solubilized fraction 
(UC-S). It can be seen that the concentration of unbound MRP3 decreases in the flow 
through (FT1 to FT5) fraction with increasing incubation time on the column. The 
10x concentrated elution fractions (E1-E5) showed higher concentrations of the 
protein, as expected. The elution fractions E2-E5 were combined and used for 
further purification on Strep-tactin column. 
(a)  
(b) 
 
 
 
Figure 3-24: Western blotting pictures showing Solubilization and purification MRP3 expressed by 
P. pastoris clone 100-5 in fermenter culture. (a) DDM solubilized samples of the crude cel lysates from 
fermenter culture. The samples UC-S and UC-P (Ultracentrifugation – Supernatant and 
Ultracentrifugation – Pelet) are the soluble and insoluble fractions after ultracentrifugation of the 
solubilized samples. (b) Purification of UC- S samples on smal (5 ml) Ni-NTA column. FT1-FT5 are the 
unbound 5 ml fractions after 5, 10, 15, 20 and 25 min incubation on the column respectively. W1 and W2 
are the samples from washing of the columns with 1 CV (column volume) washing bufer containing 
30 mM and 40 mM Imidazole respectively. E1-E5 are the elution fractions of 500 µl each. Same volume 
(15 µl) of each sample was applied on 8 % SDS gel for comparison. The proteins were detected using 
Anti-MRP3 antibody [M3II-9] (1:2000). 
66 Results and Discussion 
 
 
3.2.2.2.5 Purification on Strep-tactin column 
The protein purified on Ni-NTA column was loaded on a Strep-tactin spin column 
and the purification was performed as described in 5.5.5. 
 
Figure 3-25: Western blotting of purification of the Ni-NTA purified MRP3 on Strep-tactin spin column. 
800 µl of the purified protein (Ni-NTA lane) was directly applied to the Strep-tactin spin column for 
binding. FT1-FT5 are the unbound fractions after 5, 10, 15, 20 and 25 min incubation on the column. W1-
W3 are the samples after washing the column with 800 µl of washing bufer. E1-E5 are the elution 
fractions of 200 µl each. Same volume of each sample was applied on 8 % SDS gel for comparison. The 
proteins were detected using Anti-MRP3 antibody [M3II-9] (1:2000). 
The blot shows a slight diference between the band intensities of the 150 kDa of Ni-
NTA eluted samples loaded on the Strep-tactin column and the flow through samples 
(FT1-FT5). Elution of the first washing step (W1) also shows the dark band at 
150 kDa, while al the other samples show almost no detectable amount of protein. A 
light band in the elution sample (E3) indicates a weaker binding of the protein to the 
column. But the elution samples were 4x concentrated (as the elution was 
performed in 200 µl of elution bufer) and a lighter band in this concentrated 
fraction indicates realy smal amount of protein. 
3.2.2.2.6 Purification on Strep-tactin column after mild denaturation 
In order to check the binding of the N terminal Strep tag I from the MRP3 to the 
Strep-tactin column after denaturation of the protein, the preparation of crude 
microsomes (cel lysate from section 3.2.2.2.4) was solubilized with 1 % SDS and 
ultracentrifuged at RT to separate the soluble and insoluble fractions (section 5.5.3). 
The soluble fraction was diluted 1:5 with Strep wash bufer and purified on the 
Strep-tactin columns at RT exactly as described in 5.5.5. 
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Figure 3-26: (a) Western blotting of the SDS solubilized sample of the crude cel lysates of P. pastoris 
clone 100-5 from fermenter culture. The samples UC-S and UC-P (Ultracentrifugation – Supernatant and 
Ultracentrifugation – Pelet) are the soluble and insoluble fractions after ultracentrifugation of the 
solubilized microsomes. (b) Purification of the 1:5 diluted UC- S sample on 1 ml Strep-tactin column. FT is 
the unbound 25 ml fraction let run slowly from the column to alow eficient binding. W1, W2, W3 are the 
samples from washing of the columns with 800 µl of washing bufer. E1-E5 are the elution fractions of 
800 µl each. Same volume (10 µl) of each sample was applied on 8 % SDS gel for comparison. The 
proteins were detected using Anti-MRP3 antibody [M3II-9] (1:2000). 
Figure 3-26 shows the results after purification on the Strep-tactin column. In Figure 
3-26 (a) the dark band at 150 kDa is visible in UC-S (Ultracentrifugation – 
Supernatant) samples, which is the soluble fraction after SDS solubilization and 
ultracentrifugation. The insoluble fraction from the pelet (UC-P) shows no band at 
150 kDa. Figure 3-26 (b) shows the purification of the UC-S samples on the Strep-
tactin column. UC-S 1:5 is the 5x diluted UC-S sample with Strep washing bufer in 
order to dilute the protein sample for direct purification on Strep-tactin column. FT 
is the flow through containing unbound proteins from the loaded sample on the 
column using a slow flow for eficient binding. This lane shows a dark band at 
150 kDa with similar intensity as the UC-S 1:5. W1-W3 are the washes with washing 
bufer. A band at 150 kDa can also be seen in the W1 and W2 samples, which 
disappears in W3. E1-E5 are the elution fractions, in which elution was performed in 
very smal quantities of the elution bufer. The concentrated elutions E1 and E2 
show a weaker band at 150 kDa. 
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3.2.2.2.7 Purification on diferent Strep-tactin resins and detection of Strep tag 
II with antibody 
In order to check if the resin used for the purification is the problem for the low 
afinity of the binding, the purification was also performed on diferent resins from 
the Strep-Tactin® Mini-Column Evaluation Set (IBA), as instructed by the 
manufacturer. Apart from the afinity to check if the capacity of the resin is the 
problem, purification was performed on Strep-Tactin Superflow High Capacity resin 
from IBA, in Prof. Tampé’s Laboratory of the University of Frankfurt under the 
guidance of Dr. David Parcej. 
In al the cases, the purification on diferent Strep-tactin columns yielded results 
similar to those shown in Figure 3-26, with very little binding to the column. 
To check, if the Strep tag has been modified by yeast, the protein was detected on 
Western blots by Strep tag I specific antibody. The detection was performed as 
described in 5.4.4 and 5.4.6. 
 
Figure 3-27: Western blotting picture showing the detection of MRP3 expressed in P. pastoris with Strep 
tag II at N terminal and C terminal positions. In the left picture, sample Ni-NTA elution from N terminal 
Strep tag II protein is a smal scale preparation sample purified on 5 ml Ni-NTA column. Sample FT in the 
next lane is the flow through from Strep-tactin column when Ni-NTA elution was loaded and let run after 
incubation for 2 h. On the right side the sample Ni-NTA elution is taken from a large scale Protein 
purified on Ni-NTA column concentrated on 100 and 30 kDa membranes. Same volume (20 µl) of each 
sample was applied on 8 % SDS gel for comparison. The proteins were detected by Anti Strep tag II 
primary antibody (Strep MAB classic, IBA). 
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Figure 3-27, shows a light band around 150 kDa in the samples containing MRP3 
with N terminal Strep tag I. These are the samples prepared by smal scale 
purification on the Ni-NTA column (section 3.2.2.2.4). Both Ni-NTA protein, (sample 
purified on Ni-NTA column) and FT (flow through from Strep-tactin column) showed 
light bands around 150, 70 and 40 kDa. On the right side of Figure 3-27, a WB is 
given for a sample of MRP3 with C terminal Strep tag I, purified and concentrated 
on large scale (section 3.2.1.2.3). This sample shows many dark bands of diferent 
sizes like 170, 100, 70, 55 and 40 kDa. 
3.2.2.2.8 Purification on Reactive red column 
As the purification on Strep-tactin columns was unsuccessful, the protein was 
attempted to be purified on a Reactive Red column which has afinity towards al the 
ATPases. 
 
Figure 3-28: Western blotting of purification on reactive red column. The sample UC-S 
(Ultracentrifugation – Supernatant) is the soluble fraction after Solubilization and ultracentrifugation 
used for purification. FT is the unbound fraction which came out of the column after incubation. W1, W2 
are the samples from washing of the columns with 1 CV washing bufer. E1, E2 are the fractions eluted in 
0.5 CV elution bufer with 500 mM NaCl. E3, E4 and E5 are the fractions eluted in 0.5 CV elution bufer 
with 1 M NaCl. Same volume (15 µl) of each sample was applied on 8 % SDS gel for comparison. The 
proteins were detected using Anti-MRP3 antibody [M3II-9] (1:2000). 
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The purification of protein was performed as described in 5.5.6. Same amount of 
samples from each purification steps was taken and analyzed by SDS-PAGE and 
subsequent Western blotting to monitor the purification (sections 5.4.4 and 5.4.6). 
Figure 3-28 shows the Western blot of the purification performed on the Reactive 
Red column. The sample UC-S is the soluble fraction obtained after 
ultracentrifugation, which was loaded on the column to check the binding and 
elution. This lane shows a dark band scattered around 70 kDa until 220 kDa and 
above (the starting of the gel). Lanes FT, W1-W2 and E1-E5 are the flow through, 
wash and elution fractions of the purification, which show no band of any size. 
3.2.2.3 Discussion 
For the screening of large numbers of P. pastoris clones for the detection of protein 
expression, a high throughput screening method was used. In this, all the clones are 
cultured in 24 well plates, in smaller amount (3 ml) of media. Advantage of this 
method is that it enables screening of a large number of clones at once (Boettner, 
Prinz et al. 2002). Detection of GAPDH has been used in P. pastoris as a loading 
control (Wan, Cai et al. 2008). This eliminates the need of protein measurements by 
BCA test before loading thereby minimizing the errors due to unequal loading of 
samples. 
But even the high throughput method did not lead to a reproducible pattern of 
expression of protein by identical clones (Figure 3-21). Probably because this 
method only ensures equal physical parameters of culture (Rotation speed, culture 
volume, size of vessel (well) etc.) but does not provide any tool to maintain the 
culture’s intrinsic parameters for each clone (like methanol concentration per cell, 
cell viability, pH etc.) which affect the protein expression (Mayson, Kilburn et al. 
2003; Zhao, Xue et al. 2008; Ling, Ithoi et al. 2010; Sreekrishna 2010). This leads to a 
variable expression of protein by identical clones in independent cultures. 
The same high throughput screening was performed in order to find expressing 
P. pastoris clones for truncated versions of MRP3 (Figure 3-22). As seen from the 
results, many clones chosen for constructs 2, 3 and 4 (ΔTMD0-MRP3, ΔTMD0L01/2-
MRP3 and ΔTMD0L0-MRP3 respectively) showed expression in small scale cultures. 
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The dark bands at around 120-130 kDa, which was the expected size of these three 
truncated versions, were recognized by MRP3 antibody. This indicates that these 
were the expected proteins.  
The expression of the truncated versions lacking TMD0 (ΔTMD0-MRP3), lacking 
TMD0 and only half of the linker region L0 (ΔTMD0L01/2-MRP3) and lacking TMD0 
and linker region L0 (ΔTMD0L0-MRP3) indicates that the TMD0 and the L0 region in 
the MRP3 are not necessary, at least for the proper folding. Because it is known from 
the literature that any misfolded protein in P. pastoris is not tolerated and is 
subjected to proteasomal degradation (Gasser, Saloheimo et al. 2008). So, if the 
protein was misfolded after removal of TMD0 and the L0 region, it would have been 
degraded by the P. pastoris cells. 
It would be very interesting to purify these expressed, truncated versions and study 
the transport activity and substrate recognition for each truncate in artificial 
liposomes.  
It is notable, that all the three truncated versions showing protein expression so far 
exhibited the ‘core region’ of the protein (refer section 2). While the other truncated 
version expressing only the ‘half transporter’ form of MRP3 did not show any 
expression even after multiple attempts of culturing and induction and screening of 
large number of clones. 
There could be many reasons behind the missing expression of these truncated 
versions. Firstly, it could be that the clones selected so far for the expression were 
unfortunately the ‘non-expressing’ ones. As it is already known that it is often 
necessary to screen a large number of transformants of P. pastoris to find a well 
expressing clone (Brooks, Morrison et al. 2013). 
Another possibility could be weak binding of the antibody. The Anti-MRP3 antibody 
[M3II-9] recognizes the amino acids 830-949 of hMRP3, which lie somewhere in the 
TMD2 region. Thus an Anti-6xHis tag antibody was used for the screening of 
constructs lacking TMD2 region of the protein. As seen from Figure 3-16, the Anti-
6xHis tag antibody is much weaker than the Anti-MRP3 antibody [M3II-9]. The Anti-
MRP3 antibody [M3II-9] (1:2000) could detect even a small amount of protein like 5 
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µg on the same membrane, while the Anti-6xHis tag antibody could not recognize 
even 20 µg of protein on the same blot. So it is possible that the clones selected for 
the other truncated versions expressing only ‘half’ of the MRP3 yielded protein 
expression but below the detection level of Anti-6xHis tag antibody. 
In the case that the clones were actually not expressing the truncated forms, the 
problem could also be found at transcriptional level. It is already known that the 
stability of the mRNA is crucial for the expression of a protein. The transcriptional 
regulation of mRNAs in eukaryotes is a complex process which sometimes involves 
extracellular signaling (Mitchell and Tollervey 2000). Moreover, specific sequence 
elements in mRNA are known to modulate the stability of different mRNAs (Shim 
and Karin 2002). It could be possible that the shortening of MRP3 gene would have 
led to removal of these specific sequences. Also short mRNAs are shown to have less 
stability than average (Hoen, Hirsch et al. 2011). Keeping all these points in mind, 
the reason for the low expression could be the instability at transcriptional level. 
Moving on to the expressed truncates, it can be seen from Figure 3-22 that the MRP3 
truncates without TMD0 and TMD0L01/2 showed a sharp band detectable by Anti-
MRP3 antibody [M3II-9] at around 170 kDa. This band was only detectable when the 
samples were overloaded (clone 500-4, 5 from ΔTMD0-MRP3 and clone 500-3 from 
ΔTMD0L01/2-MRP3). These bands were not seen in any sample from internal 
control clone or full length MRP3 even when loaded in high quantities (Figure 3-21).  
These bands cannot be random protein aggregates seen during SDS-PAGE, as the 
random aggregates are generally smeared and stuck at the beginning of the 
separating gel. Moreover, aggregates could have been seen in all the wells, as the 
other wells were also loaded with high amount of cell lysate.  
The other possibility could be dimerization, but the size of the band (170-180 kDa) 
was too small to be a dimer of these truncated proteins (120-130 kDa). It could also 
be possible that the truncated forms of MRP3 interact with native P. pastoris 
proteins, but this cannot be confirmed without further work.   
As the expression of MRP3 full transporter and at least some of its truncated forms 
was successful, the next attempt was to express them on large scale and to purify 
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them for further biochemical analysis. The large scale expression was started with 
the full transporter. 
From the MRP3 expressing P. pastoris clones a clone showing moderate expression 
in all the high throughput experiments (clone 100-5, Figure 3-21) was chosen for 
fermentation. This approach lead to an expected high protein expression in large 
scale fermentation under controlled conditions (Figure 3-23). This protein was 
subjected to further solubilization and purification procedures (3.2.2.2.4). 
Attempts to solubilize and to purify the protein on Ni-NTA column were successful 
on small scale (Figure 3-24). The decreasing concentration of protein in the flow 
through sample with increasing time of incubation (sample FT1-FT5, Figure 3-24 
(b)) confirms the binding of protein to the Ni-NTA column. The bound protein was 
eluted successfully which can be seen in the lanes E1-E5. These results were 
expected as similar protocols were used by other workers for MRP3 expressed in 
P. pastoris. (Chloupkova, Pickert et al. 2007; Zehnpfennig 2008) 
However purification of the protein obtained from the Ni-NTA, on Strep-tactin 
column again led to disappointing results. In Figure 3-25, the concentration of 
unbound protein seems to be decreasing with increased incubation time on the 
column (FT1-FT5) as the bands get lighter with increasing incubation time. But a 
significant amount of protein was lost after the first washing step (W1) and a 
negligible amount of protein was found in the concentrated elution fraction (E2). 
Repeated attempts of the experiments led to the same results, indicating that the 
Strep tag II at the N-terminus was not able to bind to the column under native 
conditions. 
In order to check if the protein binds to the column under denaturing conditions, the 
SDS solubilization was performed followed by purification on Strep-tactin column at 
RT (Figure 3-26). Similar band intensities in lane 1 and 2 (UC-S 1:5 and FT) indicate 
that almost all protein was unbound and was lost in the flow through. 
Purification performed with altered conditions of buffer and detergents and 
different resins (data not shown) also led to similar results confirming that the 
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problem was not the implication of the experiment, but seems to be intrinsic to the 
protein structure of this transporter. 
As Strep tag II has been used previously in P. pastoris by many workers (Boettner, 
Prinz et al. 2002; Parcej and Eckhardt-Strelau 2003), we assumed that P. pastoris 
does not modify the Strep tag II. To rule out the possibility of any modification by 
P. pastoris, the Strep tag II was detected using a Strep tag II specific antibody (Figure 
3-27). Since the antibody was able to recognize the protein (seen at 150 kDa), it 
must be concluded, that there was no modification in the Strep tag II sequence by 
P. pastoris. Other bands in the blot could be the degradation products of the protein 
as the protein samples used for the loading went through many freeze thaw cycles.  
As it was confirmed that the Strep tag II was neither modified nor deleted from the 
protein, it was assumed that some internal interactions within the protein makes the 
Strep tag II unavailable for binding. Despite the manufacturers claim that the Strep 
tag II does not interact with proteins (IBA 2011), it must be taken into consideration 
that the highly hydrophobic and charged tag might have some internal interactions 
with this protein. Such interactions are more likely for large membrane proteins 
thereby the tag  becomes unavailable for binding to the column (Parcej 2012). Thus 
further attempts to purify the protein on Strep-tactin were stopped and search was 
started for some other method of purification. 
Such an alternative method might be the Reactive Red column which has been used 
for the purification of many ATPases including ABC transporters (Urbatsch, al-Shawi 
et al. 1994; Ambudkar, Lelong et al. 1998). As seen from Figure 3-28, the protein was 
able to bind to the column but the elution was not possible, even at salt 
concentrations as high as 1 M sodium chloride. Also slight changes in the pH did not 
improve the elution. In summary,  the Reactive Red seems not to be useful for 
purification of this protein. 
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4 General discussion 
MRP3 is a member of the ABCC subfamily of human ABC transporters and is 
involved primarily in the export of bile acids and glucuronides from cholestatic 
hepatocytes (Belinsky, Dawson et al. 2005). Its ability to confer resistance e.g. 
against etoposide and methotrexate indicates, that the transporter is involved in 
protection of normal tissues against chemotherapeutic agent making it 
therapeutically important (Kool, van der Linden et al. 1999; Zeng, Liu et al. 2000; 
Jiang, Chen et al. 2009).  
The MRP3 possesses the extra N-terminal transmembrane domain (TMD0) which is 
characteristic for some of the members of the ABCC subfamily. The function of this 
domain is highly debated and thus not clear. Studies with truncated versions of 
MRP1 in various systems showed contradictory results. While some believe that the 
TMD0 region is neither required for the transport function of MRP1 nor for its 
proper routing to the plasma membrane (Bakos, Evers et al. 1998) others have 
shown that point mutation or deletion in TMD0 either decrease or completely 
eliminate the transport activity of MRP1 (Gao, Yamazaki et al. 1998; Ito, Weigl et al. 
2003; Leslie, Letourneau et al. 2003). On the other hand the function of TMD0 for 
other members of the ABCC family has been already characterized. The interaction 
between TMD0 of SUR1 and the potassium channel Kir6.2 is known to be required 
for the function of KATP-channel. (Otonkoski, Ammala et al. 1999; Babenko and Bryan 
2003; Chan, Zhang et al. 2003). The TMD0 in MRP2 is involved in the localization of 
the protein to the apical membranes in MDCKII cells (Fernandez, Hollo et al. 2002). 
The TMD0 in MRP3 remains poorly studied for its functions and localization. The 
fact that many of the other ABCC family proteins (MRP4, 5, 8, 9) lacking the TMD0 
makes the prediction of its function in MRP3 even more difficult.  
Apart from the functions of TMD0, the role of each domain of the protein in the 
transport mechanism is also unclear, which is true for the entire ABCC subfamily. 
Among the other closely related members of this family, MRP3 remains least 
studied, because the protein expression level in the normal cells is relatively low 
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(Zeng, Bain et al. 1999) but the transporter expression is upregulated in the 
cancerous tissue (Konig, Hartel et al. 2005). 
Recently, overexpression and purification of this protein in yeast P. pastoris in an 
active form provided sufficient amounts of protein for its biochemical and 
biophysical analyses (Chloupkova, Pickert et al. 2007). The successful reconstitution 
of MRP3 into artificial liposomes provided a reliable and powerful tool to analyze its 
substrate specificity and transport activity (Zehnpfennig, Urbatsch et al. 2009; 
Seelheim, Wullner et al. 2013). 
This thesis aimed to continue the work with this transporter by heterologous 
expression of designed truncated versions of the protein to characterize each 
domain in detail (Figure 2-1). The reconstitution and measurement of ATPase and 
drug transport activity by each truncated domain would have helped to predict the 
probable function of each domain and thereby provide evidence for the mechanism 
of transport cycle. However a prerequisite is the successful isolation and purification 
of the corresponding proteins in amounts that allow successful reconstitution. 
In order to express the protein in P. pastoris, we selected an autonomously 
replicating plasmid pPicholi. Though the clones containing this plasmid were able to 
express the protein and its truncated forms on small scale, the large scale cultures 
lacked protein expression completely, even when cultured under controlled 
conditions. We assume that this is because of the instability of the autonomously 
replicating plasmids under insufficient selection pressure (Romanos, Scorer et al. 
1992). 
The genome integration of the plasmid proved to be a better method for expression 
of the protein, being more reproducible. However, the amount of protein expressed 
per cell varied for identical clones in independent culturing experiments. This made 
selection of the ‘best’ expression clone among P. pastoris transformants too time 
consuming. 
For rapid detection of clones with multiple gene copies, Real-Time (quantitative) 
PCR can be used. This method would detect the clones with highest number of 
copies of a heterologous gene. But it is known, that in P. pastoris the gene copy 
number has no significant effect on the production of the protein (Sreekrishna 
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2010). In many cases a single copy expression cassette is sufficient for optimal 
production (Cregg, Barringer et al. 1985), while sometimes multiple copies are 
necessary for high level expression (Clare, Rayment et al. 1991; Romanos, Makoff et 
al. 1991). In some cases, an increase in copy number has even a negative effect on 
the protein level (Higgins 2001).  
It became clear that selection of suitable clones is possible only by protein 
expression analysis. Thus a high throughput screening method was used in order to 
screen large numbers of clones at once. Identical clones showing relatively constant 
protein expression in multiple attempts were thought to be the ideal clones for large 
scale expression.  
Large scale protein expression was successful with genome integrated plasmids. 
Attempts to solubilize the expressed protein and to purify it on Ni-NTA columns 
were successful, but the purity was not high enough for further experiments. 
Subsequent purification on Strep-tactin columns showed insufficient binding of 
Strep tag II-protein to the column material. The binding was poor irrespective of the 
position of the tag either on the C or the N-terminal end. Moreover it was 
independent from the structure of the protein in a native or denatured state.  
The reasons for the inability of the Strep tag II to bind to the column material 
remained obscure. The interaction between the Strep tag II and the column resin 
(engineered Streptavidin) is highly specific and involves a salt bridge formation 
between the free carboxylate group of the glutamate side-chain of the tag 
(WSHPQFEK) and an arginine of Streptavidin (Strep-tactin) (Schmidt, Koepke et al. 
1996). The small eight amino acids long tag is said to be non-interacting with any 
protein. It is also claimed that the Strep tag II is able to purify any protein including 
large membrane proteins (IBA 2011). 
We then tested the possible factors affecting this interaction in the buffer conditions 
that we were using. The addition of low concentrations of detergents n-dodecyl β-D-
maltopyranoside (DDM) or sodium dodecyl sulfate (SDS) in the binding and washing 
buffers should not affect this interaction, as the detergents mostly disrupts the 
hydrophobic interactions. SDS to some extent disrupts the electrostatic interactions 
in a protein owing to its ionic nature. But both these detergents do not affect the salt 
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bridge formation necessary for binding of the Strep tag II to the column resin. So the 
addition of these detergents into the buffers used for the purification cannot be the 
reason for the inefficient binding. 
The possibility of modification of Strep tag II by P. pastoris was ruled out as the tag 
was detectable by an antibody specific for Strep tag II. 
Because of these findings, we assume, that in contrast to the manufacturer’s claim 
the Strep tag II might have some strong internal interactions with our protein, 
irrespective of its position. But further presumptions about the details of this 
interaction cannot be made as the crystal structure of the protein is not known. 
Purification of the protein on another affinity column named Reactive Red was also 
not successful, as the protein could not be eluted from the column even using high 
salt concentrations upto 1M. Further increased concentrations of salt for elution 
would have a detrimental effect on the protein stability and activityand thus were 
not tested. 
In summary the expression of the MRP3 and its truncated versions with intact core 
domain was successful indicating that TMD0 and L0 are not necessary for at least 
structural stability of the protein. However, the purification step became the 
bottleneck for subsequent reconstitution experiments. Thus the transport and 
ATPase activity could not be further investigated and is a challenge for future work. 
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5 Experimental 
5.1 Cell Biology 
All the equipment used for cell biology experiments were sterilized by routine 
sterilization procedures.  
5.1.1 Pichia pastoris 
P. pastoris strain KM71H was used for all the experiments. 
5.1.1.1 Cell culturing and induction 
Frozen stocks or newly transformed cells of the prepared cell lines were streaked on 
YPD agar plates containing 100 mg/ml Zeocin and incubated at 30 °C for 3-4 days. A 
single distinct colony was picked and grown in 2, 10 or 25 ml of MGYH media, 
depending on the type of experiment. After 24 or 48 h of culturing at 29 °C and at a 
shaking speed of 250 rpm, the culture was centrifuged at 3000 g for 15 min at RT. 
The cell pellet was then resuspended in equal amount of MM media and the culture 
was induced with 0.5 % methanol for 24 or 48 h, with further occasional addition of 
0.5 % methanol after 12 h of induction occasionally. Shaking speed was increased to 
350 rpm during induction phase for better aeration. 
The composition of different media used was as listed in the following tables. 
YPD agar plates 
1 % (w/v)  Yeast extract 
2 % (w/v)  Peptone 
2 % (w/v)  Dextrose 
2 % (w/v)  Agar 
100 µg/ml Zeocin 
Autoclave glucose separately from yeast extract/peptone and aseptically combine 
the solutions. Let cool to less than 50 °C before aseptically adding Zeocin. [Pour 
into petri dishes and let cool.] Store upto 1 month in the dark at 4 °C 
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MGYH media (pH 5.0) 
0.34 % (w/v)  Yeast nitrogen base 
2 % (w/v)  Glycerol 
1 % (w/v)  (NH4)2SO4 
0.0004 % (w/v)  Biotin 
0.05 % (w/v)  Histidine 
0.1 M Phosphate buffer 
Autoclave and  store up to 6 months at 4 °C 
  
  MM media (pH 5.0) 
0.34 % (w/v)  Yeast nitrogen base 
1 % (w/v)  (NH4)2SO4 
0.0004 % (w/v)  Biotin 
0.05 % (w/v)  Histidine 
0.1 M Phosphate buffer 
0.5 % Methanol 
Autoclave and  store up to 6 months at 4 °C 
  
5.1.1.2 Competent cell Preparation 
Competent P. pastoris cells for transformation were prepared by two different 
methods. 
5.1.1.2.1 Conventional Protocol 
10 ml YPD media was inoculated with frozen glycerol stock or with a single fresh 
colony from an agar plate of P. pastoris KM71H and incubated overnight at 30 °C in a 
shaking incubator. Next day the culture was diluted to an OD600 of 0.1-0.2 with 
500 ml of freshly prepared YPD media and the culturing was continued in a 2000 ml 
culture flask at 30 °C in a shaker incubator. When the OD600 reached between 1.3-
1.5, the culture was centrifuged at 2000 g for 4 °C. The supernatant was discarded 
and the pellet was resuspended in 100 ml YPD media supplemented with 2 ml 
sterile-filtered 1 M HEPES (pH 8.0) and 2.5 ml 1.0 M dithiotheitol (DTT) was added 
dropwise. The cells were incubated for 15 minutes at 30 °C with gentle shaking. The 
suspension was diluted with 400 ml of sterile, ice cold water and centrifuged at 
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2000 g for 10 min at 4 °C. Subsequent washings were done with 400 and 250 ml ice 
cold water at 2000 g for 10 min at 4 °C. The pellet after the third wash was dissolved 
in 20 ml of ice cold 1 M sorbitol and centrifuged at 2000 g for 10 min at 4 °C. The 
supernatant was decanted carefully and the pellet was resuspended in 1 ml of ice 
cold 1 M sorbitol solution. The competent cells concentrated in 1 M sorbitol were 
divided into 50 µl aliquots in 0.5 ml microcentrifuge tube and stored at -70 °C in a 
styrofoam box. 
5.1.1.2.2 Condensed Protocol 
5 ml YPD media was inoculated with frozen glycerol stock of P. pastoris KM71H and 
incubated overnight at 30 °C in a shaking incubator. Next day the culture was diluted 
to an OD600 of 0.15-0.20 with 50 ml of freshly prepared YPD media and the 
culturing was continued in a 500 ml culture flask at 30 °C in a shaker incubator. 
When the OD600 reached between 0.8-1.0, the culture was centrifuged at 500 g for 
5 min at RT. The supernatant was discarded and the pellet was washed with 9 ml of 
ice cold BEDS solution supplemented with 1 ml 1.0 M dithiotheitol (DTT). The cell 
suspension was incubated at 30 °C for 5 min in a shaker incubator at 100 rpm and 
centrifuged again at 500 g for 5 min at RT. The supernatant was decanted carefully 
and the pellet was resuspended in 1 ml of ice cold BEDS solution without DTT. The 
competent cells concentrated in BEDS solution were divided into 50 µl aliquots in 
0.5 ml microcentrifuge tube and stored at -70 °C in a styrofoam box.  
YPD media 
1 % (w/v)  Yeast extract 
2 % (w/v)  Peptone 
2 % (w/v)  Dextrose 
BEDS solution (pH 8.3) 
10 mM Bicine-NaOH 
3 % (v/v) Ethylene glycol 
5 % (v/v) Dimethyl sulfoxide 
1 M Sorbitol 
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5.1.1.3 Transformation 
The competent cells stored at -70 °C were thawed on ice just before the 
transformation. 1 µg of the desired DNA, linearized and cleaned, was mixed with 
50 µl of the competent cells in a precooled 2 mm electroporation cuvette and 
incubated on ice for 2 min. The cells were electroporated at 1.5 kV for 4-5 ms in ECM 
399 Electro cell manipulator. Immediately after transformation 500 µl 1 M Sorbitol 
was added to the electroporation cuvette and the cells were collected in a sterile 
1.5 ml microcentrifuge tube. 500 µl YPD media was added to the cell suspension in 
sorbitol and incubated at 30 °C for 30 or 60 min with gentle shaking. 100 or 200 µl 
from the sorbitol-YPD culture was plated on YPD agar plates containing increasing 
concentrations of Zeocin (100, 250, 500, or 1000 µg/ml) for the selection of 
multicopy integrants. 
5.1.1.4 Cell storage 
A fresh back up of each P. pastoris clone into consideration was taken on YPD agar 
plate containing 100 mg/ml Zeocin and incubated at 30 °C for 3-4 days. The plate 
was sealed with parafilm and stored at 4 °C for short term storage. 
For long term storage, each clone was cultured in freshly prepared YPD media 
containing 100 mg/ml Zeocin and incubated at 30 °C overnight in a shaker 
incubator. Cultures in their exponential growth phase were mixed with sterile 
glycerol at a final concentration of 15 % and stored at -70 °C. 
5.1.2 Escherichia coli 
E. coli TOP10F’ strain was used for all the experiments. 
5.1.2.1 Cell culturing  
In order to isolate plasmid DNA or to make glycerol stocks, a single distinct colony of 
the desired clone was picked and inoculated into 5 ml LB-medium. Antibiotics were 
added to the media at a concentration of 25 or 50 µg/ml. Concentration of the salt 
was reduced when antibiotic Zeocin was used in the media (Low salt LB). The 
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cultures were grown overnight at 37 °C and at shaking speed of 180 rpm until the 
culture was saturated. 
 
 
 
 
 
5.1.2.2 Competent cell preparation 
A frozen stock culture of TOP10F’ E. coli cells was streaked on a pre-warmed LB agar 
plate (without any antibiotic) and incubated overnight at 37 °C. A distinct colony 
was picked from the plate, the next day and inoculated into 20 ml LB media. The 
culture was incubated at 37 °C in a shaker incubator for 5-6 h, till all the cells were in 
exponential phase. After 6 h of incubation, the 20 ml culture was diluted with 800 ml 
of freshly prepared LB media and incubated at 18 °C overnight. When the OD600 
reached between 0.4-0.6, the culture was centrifuged at 4500 g using a JA-10 rotor 
for 30 min at 4 °C. The supernatant was discarded and the pellet was dissolved in 
400 ml of sterile, ice cold water and centrifuged at 4500 g using a JA-10 rotor for 
15 min at 4 °C. Subsequent washings were done with 200 and 100 ml ice cold water. 
The pellet after the third wash was dissolved in 40 ml of ice cold 10 % glycerol and 
centrifuged at 3000 g for 30 min. The supernatant was decanted carefully and the 
pellet was resuspended in 1 ml of ice cold 10 % glycerol. The resuspended pellet was 
divided into 50 µl aliquots in 0.5 ml microcentrifuge tube and blast frozen in liquid 
nitrogen immediately. The frozen competent cells were then stored at -70 °C in a 
plastic box. 
5.1.2.3 Transformation 
The competent cells stored at -70 °C were thawed on ice just before the 
transformation. 100 ng of the desired DNA was mixed with 50 µl of the competent 
cells in a precooled, 2 mm electroporation cuvette and the cells were electroporated 
immediately at 2.5 kV for 4-5 ms in ECM 399 Electro cell manipulator. After 
LB media 
1 (w/v)  Tryptone 
0.5 (w/v)  Yeast Extract 
1 (w/v)  Sodium Chloride  
1.5 (w/v)  Agar (only for plates) 
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transformation 500 µl LB media was added to the electroporation cuvettes 
aseptically and the cells were collected in a sterile 1.5 ml microcentrifuge tube. The 
cell suspension is then incubated at 37 °C for 30 or 60 min with gentle shaking. 100 
or 200 µl from this culture was plated on LB agar plates containing appropriate 
antibiotic at a concentration of 25 or 50 µg/ml. The plates were incubated at 37 °C 
overnight and the colonies were screened for the positive clones. 
5.1.2.4 Cell storage 
For long term storage, freshly prepared cultures, grown overnight at 37 °C were 
mixed with sterile glycerol at a final concentration of 30 % and stored at -70 °C. 
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5.2 Molecular Biology 
5.2.1 Isolation of plasmid-DNA from E.coli 
Colonies from the desired clones were cultured in 5 ml LB medium supplemented 
with 50 µg/ml of appropriate antibiotic. After culturing overnight at 37 °C in a 
shaker incubator, the saturated cultures were centrifuged at the maximum speed in 
a table top centrifuge for 2 min. The supernatant was discarded and plasmid 
isolation was performed using GeneJET Plasmid Miniprep Kit from Thermo Scientific 
according to manufacturer’s instructions. Pelleted bacterial cells were resuspended 
in 250 µl of the Resuspension Solution (supplemented with RNase A) by vortexing 
until no cell clumps remain. The bacterial suspension was then subjected to 
SDS/alkaline lysis to liberate the plasmid DNA by adding 250 µl of the Lysis Solution 
and mixing thoroughly by inverting the tube 4-6 times. 350 µl of the Neutralization 
Solution was added to the viscous and slightly clear lysate and immediately mixed 
thoroughly by inverting the tube 4-6 times. This neutralization step creates 
appropriate conditions for binding of plasmid DNA on the silica membrane in the 
spin column. Cell debris, chomosomal DNA and SDS precipitate were pelleted by 
centrifugation at 12000 g for 5 min and the supernatant containing the plasmid DNA 
was loaded onto the spin column membrane. The columns were centrifuged for 
1 min and the flow though was discarded. The adsorbed DNA was washed twice 
with 500 µl of the Wash Solution to remove contaminants and the flow though was 
discarded. The columns were centrifuged for 1 min at 12000 g to remove the 
residual Wash solution. The spin columns were transferred into a fresh 1.5 ml 
microcentrifuge tube and 50 µl of the ultrapure water added to the spin column 
membrane to elute the plasmid DNA. This was then incubated for 2 min at room 
temperature and centrifuged at 12000 g for 2 min. The isolated plasmids were 
stored at -20 °C. 
5.2.2 Isolation of genomic DNA from P. pastoris 
Isolation of genomic DNA was performed from P. pastoris for subsequent PCR and 
sequencing. The conventional heat shock, Chelex and glass bead methods were 
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combined to get better for DNA isolation. A large, distinct colony was picked from 
YPD-agar plate and dissolved in 200 µl ultrapure water in a 1.5 ml microcentrifuge 
tube. 150 µl of 10 % Chelex suspension and 50 µl of Proteinase K was added to the 
cell suspension. 100 µl of 0.45 mm glass beads were added to the tube and vortexed 
at the maximum speed for 2-3 min at RT. The supernatant was collected in a new 
microcentrifuge tube. The glass beads were washed with 100 µl of Chelex 
suspension and the wash was collected in the same tube. These tubes were then 
incubated at -70 °C for 10 min and transferred to the heating block at 99 °C for 
2 min. The sample was centrifuged at 12,000 g for 2 min and the supernatant was 
collected and stored at -20 °C. This crude genomic DNA was used as a template for 
PCR. 
5.2.3 Quantification of nucleic acids 
The concentration and purity of DNA for all the experiments was measured with 
NanoDrop™ Micro Volume Spectrophotometer (Nanodrop ND-2000, Peqlab). The 
NanoDrop spectrophotometer uses short path lengths between 1.0 mm to 0.05 mm 
to enable measurement of concentrated samples without dilution. The Nucleic Acid 
application absorbance values are then normalized by the software automatically to 
a 1.0 cm (10.0 mm) path for all the measurements. The device accurately measures 
the concentration of DNA in a given sample using UV/Vis analysis at 260 nm which 
is the most suitable for RNA/DNA quantification due to the absorbance of purine 
and pyrimidine bases. The optical density at 260 nm (OD260) corresponds to 50 
μg/ml of double stranded DNA. The purity of isolated DNA was determined by 
measuring the optical density at 280 nm where the aromatic amino acids of proteins 
show the highest degree of absorbance. The ratio OD260/OD280 is supposed to be 
around 1.8 for DNA dissolved in buffer with pH > 7. Sample volumes as low as 0.5 µl, 
can be used for the measurement. 
5.2.4 Enzymatic Restriction of DNA 
1 to 5 µg of either plasmid DNA or amplified PCR fragments were restricted either 
by 1 µl (1 FDU) of FastDigest restriction enzymes from Thermo scientific for 15-
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20 min or by 10 U of restriction enzymes from National England Biolabs for 60-
90 min, with gentle shaking and at a temperature specific for a given enzyme. The 
reaction mixtures were prepared in 0.5 ml, thin walled microcentrifuge tubes as 
mentioned in the table.  
In case of plasmid DNA, the restriction was monitored by agarose gel 
electrophoresis and the fragments of right size were extracted by the method 
mentioned in section 2.6 whereas the restricted PCR fragments were directly 
cleaned by one of the methods mentioned in section 2.7. 
Restriction reactions with NEB enzymes 
DNA x µl x µl 
NEB enzyme y µl y µl 
10 x NEB buffer 2 µl 5 µl 
Ultrapure water 18-(x+y) µl 45-(x+y) µl 
Total 20 µl 50 µl 
30-60 min at specified temperature 
Restriction reactions with FastDigest enzymes 
DNA x µl x µl 
FastDigest enzyme 0.5 µl 2 µl 
10 x FD green buffer 2 µl 5 µl 
Ultrapure water 17.5-x µl 43-x µl 
Total 20 µl 50 µl 
15-20 min at specified temperature 
5.2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis is used to separate nucleic acids according to their size 
in a solid matrix under the influence of electric field. The gel electrophoresis was 
used routinely to visualize isolated plasmids, monitor restriction of DNAs and to 
analyze the PCR reactions. To ensure the movement of negatively charged DNA to 
the anode, the electrophoresis must be performed at pH close to neutral. Therefore, 
0.5 x TAE buffer was used for gel preparation and electrophoresis. In order to obtain 
optimal separation, variable concentration of agarose was used for gel preparation 
as per the table.  
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The calculated amount of agarose was dissolved in 50 ml 0.5 x TAE buffer by directly 
heating microwave for 1-2 min until the agarose is completely melted, poured into a 
casting tray containing a sample comb and allowed to solidify at room temperature. 
The samples were diluted with loading buffer to increase the density of the solution 
for better loading and tracking the running front. Apart from 10 x loading buffer 
prepared in lab, commercial loading buffers, like 6X orange loading dye from 
Thermo Scientific, 6 x blue loading dye from National England Biolabs were also 
used to treat the samples. Sometimes 10 x FastDigest green buffer from Thermo 
Scientific was used for this purpose. To determine size of the separated DNA 
fragments, a ready-to-load TriDye™ 1 kb DNA Ladder from National England Biolabs 
was also loaded in one of the wells.  
Gel electrophoresis was performed at 100 V. After the electrophoresis the gel slab 
was bathed in ethidiumbromide solution (1 ml of 0.5 mg/ml stock solution in 
1000 ml of 0.5 x TAE buffer) for 20-30 min and the bands were visualized under UV-
light (254 nm). 
Table: Concentration of standard agarose used for separating DNA of different size 
       
Agarose concentration (% w/v) 0.5 0.7 1.0 1.2 1.5 2.0 
Nucleic acid fragment range (kb) 1.0-30 0.8-12 0.5-10 0.4-7 0.2-3 0.1-2 
50 x TAE buffer (pH 7.4) 
2 M Tris 
2 M Sodium acetate 
0.05 M EDTA 
10 x DNA loading buffer 
0.25 % (w/v) Bromophenol blue 
0.25 % (w/v) Xylene cyanole 
15 % (v/v) Ficoll 
5.2.6 Extraction of DNA from agarose gel 
The extraction of desired DNA fragments from agarose gels was performed by using 
Zymoclean™ Gel DNA Recovery Kit from Zymoresearch. The DNA fragment was 
excised from the agarose gel using a scalpel and transferred into a 1.5 ml 
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microcentrifuge tube. The excised gel slice was weighed (1 mg ≈ 1 µl) and dissolved 
in 3 volumes of ADB (agarose digestion buffer) by heating at 55 °C for 10 min, until 
the gel slice was completely dissolved. The melted agarose solution was then 
transferred to a Zymo-Spin™ Column in a collection tube and centrifuged for 30-
60 seconds. DNA is adsorbed to the silica membrane in the presence of a high 
concentration of chaotropic salts and at acidic pH while contaminants pass though 
the column and are washed away. The flow though was discarded and the column 
was washed twice with 200 µl DNA Wash Buffer. 10-20 µl ultrapure water was 
added to the column and incubated for 1-2 min. The column was placed into a 1.5 ml 
tube and centrifuged for 30-60 seconds to elute pure DNA. 
Concentration of purified DNA was determined as described in section 2.3. 
5.2.7 Cleaning of DNA for ligation  
The restricted or gel extracted DNA was cleaned before ligation. The cleaning was 
performed by one of the following methods. 
5.2.7.1 Using a commercial cleaning kit 
For quick cleaning of samples, DNA Clean & Concentrator TM kit from Zymoresearch 
was used. All the steps were performed according to the manufacturer’s instruction 
except the last step where the elution was always done in sterile, ultrapure water. 
However the amount of DNA in the eluted samples was always lower than the other 
method. 
5.2.7.2 Precipitation with sodium acetate and ethanol 
In order to get large quantities of purified DNA for transformation, the samples were 
cleaned by this method. To the ‘dirty’ DNA sample, appropriate quantities of 3 M 
sodium acetate and ice cold, 100 % Ethanol were added so that the final ethanol 
concentration was 70 % and the final salt concentration was 0.3 M. The 
microcentrifuge containing the sample was vortexed briefly and centrifuged at 
12000 g for 10 min at RT. The supernatant was aspirated with a vacuum pump and 
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the pellet was dissolved in 1 ml of ice cold 70 % ethanol and then centrifuged again 
at 12000 g for 10 min at RT. The supernatant was decanted and last traces of ethanol 
were drawn out using vacuum pump. The pellet was resuspended in 50 or 100 µl of 
ultrapure water, after drying and used for further experiments. 
5.2.8 Ligation  
Before the ligation Concentration of restricted and purified DNA was measured 
using the method described in section 2.3. A vector/insert ratio of 1:3 was used for 
routine ligations but sometimes it was changed to 1:5 when the ligation efficiency 
was low and no positive clone was detected even after repeated attempts. Following 
formula was used to calculate the amount of vector and insert sample to be used for 
ligation. 
             
                                     
                                            
 
Ligation with T4 DNA ligase from 
NEB  
Insert x µl 
Vector y µl 
10 x Liagse buffer 2 µl 
T4 DNA ligase 1 µl 
10 mM ATP 2 µl 
Ultrapure water 15-(x+y) µl 
Total 20 µl 
15-20 min at specified temperature 
 
The ligation was carried out at room temperature for 30 min using T4 DNA Ligase 
from National England Biolabs. The reaction mixture was prepared in 0.5 ml, 
microcentrifuge tubes as mentioned in the table and the ligation mix was either used 
immediately or stored at 4 °C until transformation in E. coli cells. 
5.2.9 PCR methods 
The Polymerase Chain Reaction (PCR) was used for the amplification of specific 
region of the template DNA, insertion of restriction sites, rapid screening of ligation 
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reactions for positive clones, mutation at specific bases, amplification of genome 
integrated plasmid for sequencing and quick screening of plasmid inserts in 
transformed E. coli and P. pastoris cells. The PCR reaction was set up according to 
the nature of the experiment. Sequences of all the primers used for various reactions 
are enlisted in section. Annealing temperatures and secondary structures, for the 
different primer pairs used were calculated by using NetPrimer, free primer analysis 
software from Premier Biosoft. For the primers used for insertion of restriction site 
i.e. those containing non complementary regions, the optimum PCR conditions were 
found experimentally by performing a gradient PCR.  
5.2.9.1  Preparatory PCR reactions 
High fidelity polymerases like Pfu and Phusion from Thermo Scientific were used 
when the PCR was performed for amplification of insert and further cloning or for 
sequencing. The enzymes exhibit lower processivity but high accuracy resulting in 
much lower error rates during amplification. The PCR was set up according to 
manufacturer’s instruction. The reaction mixtures were prepared in 0.5 ml or 0.2 ml, 
thin walled PCR tubes and the reaction was performed according to the program 
mentioned in the tables. The amplicon was then restricted, purified, quantified and 
ligated into the vector as described previoiusly. On the other hand, if the PCR was 
performed for sequencing, the product was cleaned and sent for sequencing. 
Phusion Polymerase reaction 
mixture 
5x Phusion Buffer 10 µl 
10 mM dNTPs 1 µl 
MgCl2 1 µl 
10 µM Forward Primer 0.5 µl 
10 µM Reverse Primer 0.5 µl 
Template 2.5 µl 
Phusion Polymerase 0.5 µl 
Ultrapure water 34 µl 
Total 50 µl 
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Pfu Polymerase reaction mixture 
10x Pfu Buffer with MgSO4 10 µl 
dNTP mix (2 mM each) 1 µl 
10 µM Forward Primer 0.1 µl 
10 µM Reverse Primer 0.1 µl 
Template 0.2 µl 
Pfu Polymerase 1 µl 
Ultrapure water 37.6 µl 
Total 50 µl 
Pfu Polymerase PCR reaction 
1 Initial Activation 95 °C 30 sec 
2 Denaturation 95 °C 10 sec 
3 Annealing x°C 30 sec 
4 Extension 72 °C y*2 min 
5 Final Extension 72 °C 10 min 
 
Hold 4 °C 
 
 
repeat 2-4 for 18 cycles  
 
    
 
x= calculated/ found experimentally 
 
 
y= size of the target in kb 
 
5.2.9.2 Analytical PCR reactions 
The PCR method was also used to screen the transformed E. coli colonies for 
plasmids containing a desired insert, thereby checking if the ligation was successful. 
Individual colonies from a transformation plate were picked using a sterile 
toothpick and dipped into separate microfuge tubes containing 20 µl of ultrapure 
water. The cloudy suspension was heated at 99 °C for 2 min and centrifuged at the 
Phusion Polymerase PCR reaction 
1 Initial Activation 98 °C 30 sec 
2 Denaturation 98 °C 10 sec 
3 Annealing x °C 15-20 sec 
4 Extension 72 °C y*30 sec 
5 Final Extension 72 °C 5 min 
 
Hold 4 °C 
 
 
repeat 2-4 for 18 cycles  
 
    
 
x= calculated/ found experimentally 
 
 
y= size of the target in kb 
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maximum speed for 2 min in a table top centrifuge. 5 µl of of the supernatant was 
used as a template for PCR. Transformants from P. pastoris were also sometimes 
screened by colony PCR. The template for PCR was prepared by the method 
described in section 1.3.2. 
Taq Pol PCR components 
10x ThermoPol® Buffer 2 µl 
10 mM dNTPs 0.4 µl 
10 µM Forward Primer 0.4 µl 
10 µM Reverse Primer 0.4 µl 
Template 5 µl 
Taq DNA Polymerase 0.4 µl 
Ultrapure Water 11.4 µl 
Total 20 µl 
Taq Polymerase PCR reaction 
1 Initial Activation 95 °C 30 sec 
2 Denaturation 95 °C 10 sec 
3 Annealing x°C 10-20 sec 
4 Extension 68 °C y*1 min 
5 Final Extension 68 °C 10 min 
 
Hold 4 °C 
 
 
repeat 2-4 for 30 cycles  
 
    
 
x= calculated/ found experimentally 
 
 
y= size of the target in kb 
  
Taq DNA Polymerase from National England Biolabs was used for all the pure 
analytical PCRs. The PCR was set up according to manufacturer’s instruction. The 
reaction mixture was prepared in 0.5 ml or 0.2 ml thin walled PCR tubes and the 
reaction was performed according to the program mentioned in the table in a 
Mastercycler gradient thermocycler from Eppendorf. The amplified products from 
different colonies were then analyzed on agarose gel as mentioned previously. 
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5.2.10 Site-Directed Mutagenesis 
Site directed mutagenesis was used to make point mutations in hMRP3 sequence 
and in the 3C protease site sequence from the purification tag. The mutations were 
designed to match the codon usage in P. pastoris for optimal expression. 
All the site directed mutagenesis methods were performed using QuikChange site-
directed mutagenesis kit from Stratagene. The method was performed according to 
the manufacturer’s instruction. The reaction mixtures were prepared in 0.5 ml or 
0.2 ml thin walled PCR tubes and the reaction was performed according to the 
program mentioned in the tables. 
The kit includes a high fidelity PfuTurbo® DNA polymerase which replicates both 
plasmid strands without displacing the mutant oligonucleotide primers. The 
oligonucleotide primers containing desired mutation, each complementary to 
opposite strands of the vector, are extended during temperature cycling by 
PfuTurboDNA polymerase. Incorporation of the oligonucleotide primers generates a 
mutated plasmid containing staggered nicks. High fidelity of the polymerase and the 
low number of thermal cycles all contribute to the high mutation efficiency and 
decreased error rate during the reaction. 
After the temperature cycling, the product is treated with DpnI endonuclease which 
is specific for methylated and hemimethylated DNA (target sequence: 5´-GmATC-3´). 
The enzyme is used to digest the parental DNA template, which is susceptible to 
DpnI digestion and to select for mutation-containing synthesized DNA. 
The nicked vector DNA containing the desired mutations is then transformed into 
Top10F’ competent E. coli cells as mentioned in section 1.1.1.2. 
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QuickChange Mutagenesis PCR 
components 
10x reaction buffer 10 µl 
 dNTP Mix 1 µl 
10 µM Forward Primer 0.5 µl 
10 µM Reverse Primer 0.5 µl 
50 ng of dsDNA template x µl 
PfuTurbo® DNA polymerase  1 µl 
Ultrapure water 36-x µl 
Total 50 µl 
  
QuickChange Mutagenesis PCR reaction 
1 Initial Activation 95 °C 30 sec 
2 Denaturation 95 °C 30 sec 
3 Annealing 55 °C 1 min 
4 Extension 68 °C y*1 min 
5 Final Extension 68 °C 10 min 
 
Hold 4 °C 
 
 
repeat 2-4 for 12 cycles  
 
    
 
y= size of the target in kb 
 
5.2.11 DNA sequencing 
DNA samples (~ 100 ng/μl) diluted in ultrapure water were submitted for 
sequencing to the company GATC, biotech. The obtained sequencing data was 
analyzed using BioEdit biological sequence alignment editor (Version BioEdit v7.0.9) 
from NCBI. 
5.2.12 Annealing and Phosphorylation of oligonucleotides  
The Lyophilized samples obtained after upon arrival were dissolved in sterile 
ultrapure water and stored at -20 °C in 50 µl aliquots. The complementary 
oligonucleotides were mixed in equimolar proportions and heated and cooled 
together as mentioned in the table for the generation of a dsDNA fragments with 
cohesive ends. 
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Annealing of single stranded 
oligonucleotides 
Conc. in nM 1 nM 
  oligonucleotides x µl 
oligonucleotides x µl 
10x Ligase buffer 20 µl 
Ultrapure water 200-2x µl 
Total 200 µl 
Incubate at 99 °C, 400 rpm for 10 min 
Switch off the incubator 
Let the samples cool gradually to RT 
Store the samples at -20 °C 
 
The amount of oligonucleotides used for the final concentration of 1 nM in the 
reaction mixture was calculated using following formula 
  
           
                                          
 
The double stranded oligonucleotides after annealing were then phosphorylated as 
follows for further ligation reaction. 
Phosphorylation of annealed 
oligonucleotides 
Conc. in nM 1 nM 
  Annealed oligonucleotides x µl 
10x Ligase buffer 2 µl 
T4 polynucleotide kinase 1 µl 
10 mM ATP 2 µl 
Ultrapure water 15-x µl 
Total 20 µl 
Incubate at 37 °C for 1 h 
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5.4 Protein biochemistry 
5.4.1 Small scale preparation of microsomes from P. pastoris 
The harvested or frozen yeast cells, after culturing and induction were thawed on ice 
and resuspended in 500 µl- 1 ml homogenization buffer (~1 g cells /ml), 
supplemented with protease inhibitors (PI) Pepstatin A (PepA), Leupeptin (Leu), 
Chymostatin (Chym) and Phenylmethylsulfonylfluorid (PMSF). The concentrations 
of the PI are as mentioned in the table. Two-third volume of 0.45 mm cold glass 
beads were added to the resuspended cells and were vortexed in the 4 °C room for 
15 minutes at the maximum speed using Vibrax VXR mixer vortexer from IKA. The 
crude lysate was taken in a new 1.5 ml microcentrifuge tube and the glass beads 
were washed with 200 µl-500 µl homogenization buffer and the wash collected in 
same tube. 500 µl from each crude lysate was taken in a new microcentrifuge tube 
and 500 µl of 2 % SDS was added to it. The sample was heated at 65 °C for 15 min 
700-1000 rpm and centrifuged at 1000 g for 10 min. The supernatant was treated 
with SDS sample buffer and used for Western blotting. 
Homogenization buffer (pH 7.4) 
  
    330 mM Sucrose 
  300 M Tris 
  1 mM EGTA 
  1 mM EDTA 
  100 mM 6-Aminocaproic acid 
 2 mM DTT (add fresh)  
 
    
Protease inhibitor  Concentration 
in 100 ml Homogenization 
buffer 
Leupeptin (Leu) 10 mg/ml in Ultrapure water 80 µl 
 Pepstatin A (PepA) 10 mg/ml in DMSO  80 µl 
 Chymostatin (Chym) 2,5 mg/ml in DMSO 40 µl 
 Phenylmethylsulfonychlorid 
(PMSF)  1 M in DMSO 200 µl  
  
98 Experimental 
 
 
5.4.2 High throughput screening of P. pastoris clones for protein 
expression 
For the high throughput screening of clones for the protein expression, after 
transformation 20 clones from each YPD plate were picked and cultured in 2 ml 
MGYH media in a 24 deep well plate (HJ-Bioanalytik GmbH). Two sub-clones of the 
internal control clone and two clones transformed with Empty vector were also 
cultured in the same plate. The 24 well plate was covered with two layers of sterile 
Kim wipes and a tight fitting perforated lid and incubated at 29 °C at 250-350 rpm 
for either 24 or 48 h (till the cultures are dense enough for induction). After 24 or 
48 h the plates the perforated lid and the Kim wipes were removed and the plate 
was sealed with a cellophane tape. The sealed plate was centrifuged at 3200 g for 
20 min in Eppendorf centrifuge 5415 D. The supernatants from the wells were   
aspirated under ascetic conditions and the pellets were redissolved in 2 ml MM 
media with 0.5 % methanol. The plate was again covered with the Kim wipes and 
perforated lid and incubated at 29 °C at 350-400 rpm for 24 h. Occasionally, the MM 
media with 0.5 % methanol was supplemented with 0.5 % methanol after 12 h of 
culturing if the cultures were too thick.  After the induction, the plate was again 
sealed and centrifuged as mentioned earlier and the supernatant was aspirated. The 
plate containing the cell pellets was either stored at -20 °C or directly used for the 
cell lysis. The subsequent cell lysis was performed in the same plate as described in 
5.4.1 
5.4.3 Determination of protein concentrations 
The protein concentrations in the samples were determined by one of the following 
methods. 
5.4.3.1 Absorbance Assay (280 nm) 
Quantitation of the amount of protein in a solution is possible by measuring the 
absorbance of the light at 280 nm (A280). Absorbance assay is a rapid and 
convenient method for the measurement of amount of protein as no additional 
reagents or incubations are required and no protein standards need to be prepared. 
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The absorption at 280 nm depends on the aromatic acids like Tyr and Trp content of 
the protein (and to a lesser extent on the amount of Phe and disulfide bonds). 
Because different proteins have different amino acid compositions, the A280 value 
varies greatly between different proteins. Hence there may be considerable errors in 
the measurement of unknown proteins or protein mixtures. However this assay 
provides reliable results for the purified protein solutions such as fractions from 
chromatography columns.   
To measure the A280 of the protein sample on the Nanodrop (NanoDrop 2000, 
Peqlab), 1 µl of the buffer solution in which protein was diluted was placed on the 
pedestal and set as blank. The blank sample was removed from the pedestals using a 
Kimwipe before making the measurement. 1 µl of the sample (usually elution 
fractions from a chromatography column) was placed on the pedestal and the A280 
of the sample was measured. The concentration of protein in the sample was 
determined using following formula. 
                        
                                   
                                           
 
5.4.3.2 Bradford assay 
The Bradford assay uses a colorimetric reagent Coomassie Brilliant Blue G-250 dye 
for the detection and quantitation of total protein (Bradford 1976). The assay is 
based on the specific binding properties of the dye to the arginine, tryptophan, 
tyrosine, histidine and phenyl alanine residues in proteins. In solution the dye is in 
the cationic form (see Figure 5-1) and has an absorption maximum at 470 nm (red 
region). In the acidic environment of the reagent, protein binds to the Coomassie 
and renders the dye anionic which shifts the absorption maximum to 595 nm. This 
results in a spectral shift causing a visible color change from reddish/brown form of 
the dye to the blue form. Thus the protein concentration of the sample can be 
assayed by measuring the absorption in the spectrophotometer at 595 nm.  
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Figure 5-1: Structure of Coomassie Briliant Blue G-250 
This assay was performed in order to determine the protein concentration of the 
solubilized proteins in the samples obtained after purification on Ni-NTA column. 
For the determination of protein concentrations, 100 μL Bradfords reagent (Sigma 
Aldrich) was mixed with add 10 μL of the protein sample. The samples were 
incubated for 5 min and the absorbance measured at 595 nm using a 
spectrophotometer. For blank, a paralel assay was performed by addition of a same 
bufer without any protein. 
5.4.3.3 Bichinchoninic acid solution (BCA) test 
In order to determine the protein concentration of the isolated solubilized proteins, 
the highly sensitive BCA assay was used, which provides linearity over a broad range 
of protein concentration, as wel as compatibility with detergents and a wide range 
of common bufer components. The protein concentrations were determined by the 
Bicinchoninic acid (BCA) assay The assay is based on the reduction of Cu2+ to Cu+ by 
proteins in alkaline conditions (Biuret reaction). The cuprous ion formed during the 
reduction reaction is chelated by two molecules of BCA and the result is a purple-
colored product showing an absorption maximum of 562 nm. The macromolecular 
structure of the protein, the number of peptide bonds and the presence of specific 
amino acids (cysteine, tryptophan and tyrosine) are responsible for the color 
formation with BCA. The assay solution was prepared by a mixture of CuSO4 (4 %) 
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and BCA (1:50). A BSA dilution series (1 mg/ml-0 mg/ml) was used as a standard 
calibration to quantify the protein concentrations of the samples.  
20 μl of the protein samples and 20 μl of BSA solutions in serial dilutions used as 
standard calibration were applied into a 96-well microtiter plate in duplicates. 200 
μl of the CuSO4-BSA-reagent was added to each well and the reaction was allowed to 
proceed at 60 °C for 30 min. Subsequently the extinction was determined by means 
of a microplate reader MR700 from Dynatech. The protein concentration was 
calculated by comparing the optical density (OD) with the standard.  
The protein samples were treated with 2 % SDS and diluted with 10 times if the 
samples to be quantified contained a reducing agent.  
5.4.4 SDS-Polyacrylamide gel electrophoresis 
The separation and detection of expressed proteins was performed by means of 
discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) in combination with staining or Western blot analysis, using the Mini-Protean 
3 system (BioRad). Discontinuous gels contain a short stacking gel with a low 
percentage of acrylamide and low pH (6.8) to concentrate the sample followed by a 
resolving gel with a higher percentage of acrylamide and pH (8.8). The 
concentration of acrylamide used for the resolving gel depends on the size of the 
proteins to be analyzed. The SDS in the sample buffer denatures the proteins to a 
random-coil conformation and the reducing agent β-mercaptoethanol disrupts the 
tertiary structure of proteins by breaking the disulfide bonds. SDS also masks the 
intrinsic protein charge and gives all proteins a net negative charge which is 
proportional to their molecular weight. Hence, the proteins migrate towards the 
anode and are separated solely by a molecular sieving effect. 
A separating gel of desired thickness and percentage of acrylamide was poured in 
the gel cassette and layered with 70 % ethanol. Before casting the stacking gel, the 
residual ethanol was poured off and blot dried using a paper towel. The polymerized 
gels were stored in humid filter papers for a maximum of 7 days. 
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The chamber and gels were assembled as described by the manufactures protocol. 
Before loading, the protein samples were denatured for 15 min at 65 °C. 5 µl of 
prestained PageRuler Protein Ladder from Fermentas was loaded on each gel as a 
molecular weight standard and to monitor electroblotting. A maximum of 25 μl 
denatured protein sample was loaded in a single well. The electrophoresis was 
performed in 1x electrophoresis buffer at 80 V per gel. The voltage was increased to 
130-150 V when the proteins arrived at the resolving gel. The composition of the 
SDS gels is listed in the table: 
 
Stacking gel 4 % Resolving gel 8 %  
ddH2O 1.85 ml  2.9 ml 
Stacking gel buffer (pH 6.8) 
0.75 ml - 
0.4 % (w/v) SDS 
  0.5 M Tris/HCl 
  
Resolving gel buffer (pH 
8.8) 
- 1.5 ml  
0.4 % (w/v) SDS 
  1.5 M Tris/HCl 
  30 % (w/v) acrylamide / 
  0.8 % (w/v) biSacrylamide 
  TEMED 20 µl 20 µl 
10 % APS 12 µl 12 µl 
Electrophoresis buffer 
  0.1 M Tris 
 0.1 M Glycine  
 0.1 % (w/v) SDS 
 
4x Sample buffer 
  252 mM Tris/HCl 
  8 % (w/v) SDS 
 4 mM EDTA 
 40 % (v/v) Glycerol 
 0.01 % (w/v) Bromphenol blue 
 5 % (v/v) β-ME (add fresh)  
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5.4.5 Protein staining 
In order to detect the proteins in the polyacrylamide gels or on the membranes, the 
following staining procedures were used. 
5.4.5.1 Coomassie staining 
The Coomassie dyes bind to proteins though ionic interactions between sulfonic acid 
groups of the dye and positive amine groups of the proteins as well as though Van 
der Waals interactions. This staining procedure can be used for detection of proteins 
in a gel or on a membrane. 
5.4.5.1.1 Gel staining 
The polyacrylamide gel with separated proteins was rinsed for 3-5 minutes with 
ultrapure water to remove SDS and buffer salts, which interfere with binding of the 
dye to the protein and then stained in the staining solution with gentle agitation till 
the bands were visible (usually overnight). The gel was washed in a destaining 
solution until the background of the gelwas fully destained. The destaining solution 
was replenished several times. When the background was clear, the gel was washed 
once with ultrapure water, transferred in a clear polypropene cover, scanned and 
analyzed. 
Staining solution  
50 % (v/v) Methanol 
10 % (v/v) Glacial acetic acid 
0.1 % 
(w/v)  
Coomassie Brilliant Blue R-
250 
Destaining solution  
15 % (v/v) Methanol 
10 % (v/v) Glacial acetic acid 
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5.4.5.1.2 Membrane staining 
The blot transfer membranes were placed in a plastic box and washed with 
ultrapure water 3 times for 5 min each. The membrane was stained with the 
membrane staining solution for 5-20 min until the protein bands were visible. Once 
the bands were visible and dark, the membrane was washed in destaining solution 
until the background of the membrane was fully destained. The membrane was 
washed several times with ultrapure water, transferred in a clear polypropene 
cover, scanned and analyzed. 
Membrane Staining solution  
40 % (v/v) Methanol 
7 % (v/v) Glacial acetic acid 
0.025 % 
(w/v)  
Coomassie Brilliant Blue R-
250 
Membrane Destaining solution  
50 % (v/v) Methanol 
7 % (v/v) Glacial acetic acid 
5.4.5.2 Silver staining 
Silver staining is about 50 to 100 times more sensitive than Coomassie blue staining. 
Silver staining relies on the binding of silver to amino acid side chains, primarily 
sulfhydryl and carboxyl groups of proteins. After electrophoresis the gels were 
placed in a plastic container and washed with ultrapure water for 5 min on a 
platform shaker with continuous, gentle agitation. The water was removed and gel 
was fixed by incubating in 10 to 20 gel volumes of fixing solution for 10 min. After 
the fixation step, the gel was washed with 50 % methanol for 10 min and briefly 
immersed in a freshly prepared 0.02 % sodium thiosulfate solution (~1 min). The 
solution was removed and the gel was washed 2 times in ultrapure water for 5 min 
each and incubated in 0.2 % silver nitrate solution in dark at 4 °C for 30 min. the gel 
was then washed 3 times for 1 min with ultrapure water and incubated in the 
developing solution till the protein bands were visible. The gel was washed with 
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ultrapure water for 1 min and transferred to the stopping solution for 2 min. The gel 
was covered in a clear polypropene bag, scanned and analyzed. 
Fixing solution  
 50 % (v/v) Methanol 
5 % (v/v) Glacial acetic acid 
Developing solution  
3 % (w/v)  Sodium carbonate 
0.01(v/v) Formaldehyde 
Stopping solution  
5 % (v/v) Glacial acetic acid 
5.4.6 Western blot 
For Western blot analysis, the protein samples separated by SDS-polyacrylamide gel 
electrophoresis were transferred onto either nitrocellulose membranes (HybondTM 
ECL, GE Healthcare Biosciences) or PVDF membranes (Roth) by wet blotting 
method. This method is applied to transfer the proteins on the gels to the membrane 
and to ensure their accessibility for antibodies.  
For wet blotting, the membrane, gel and 2 layers of WhatmanTM paper were soaked 
with wet blot transfer buffer and placed between a platinum-coated titanium anode 
and a stainless steel cathode of the Trans-Blot® Electrophoretic Transfer Cell (Bio-
Rad) with the membrane facing the anodic side. A horizontal electrical field (80 V) 
was applied for 1.5 h to transfer the proteins from the gel to the membrane. 
After the transfer, the membranes were washed with tris buffered salin (TBS) and 
then fixed with Ponceau-S fixing solution or 3 % (w/v) TCA in ultrapure water for 
10-15 min. Thereafter, the membranes were washed 3 times with ddH2O, once with 
TBS and blocked with 5 % (w/v) milk powder in TBS or TBS-T (TBS with 0.1 % 
(v/v) Tween20) buffer for 30-60 min to cover unspecific binding sites. After the 
blocking step, the membranes were washed twice with TBS-T and TBS for 5 min 
106 Experimental 
 
 
each and were subsequently incubated with the primary antibody diluted in TBS 
with 0.5 % (w/v) milk powder overnight at 4 °C. 
In order to determine the protein loading GAPDH expression was analysed on each 
blot in addition. The list of primary antibodies used for various experiments is 
shown in the following table. 
Primary antibodies 
His tag 1:1000 Anti-6X His tag® antibody ab14923 Abcam 
MRP3 1:2000 Anti-MRP3 antibody [M3II-9] ab3375 Abcam 
 
1:1000 Anti-MRP3 antibody ab84887 Abcam 
Strep tag II 1:500 StrepMAB-Classic 2-1507-001 Iba 
GAPDH 1:2000 GAPDH Antibody (1D4) NB300-221 Novus Biologicals 
Next day, the membranes were washed again 2 times for 10 minutes with TBS-T and 
2 times with TBS for 5 min each and incubated (1-2 h) with an appropriate 
secondary horseradish peroxidase-conjugated antibody diluted in TBS containing 
0.5 % (w/v) milk powder. The secondary antibodies used and their concentrations 
in various experiments are listed the tables. 
Secondary antibodies 
mouse 1:2000 Rb anti Mouse Immunoglobulins / HRP P026002-2 Dako  
rabbit 1:1000 Sw anti Rabbit Immunoglobulins / HRP P021702-2 Dako   
 
For Strep tag II primary antibody, instead of Milk powder 3 % (w/v) BSA in TBS was 
used as a blocking reagent. As the 3 % (w/v) BSA solution poorly covers unspecific 
binding sites, the secondary antibody was diluted in TBS containing 5 % (w/v) milk 
powder for simultaneous blocking and binding. 
After the treatment with secondary antibody, the washing step with TBS-T and TBS 
(3 washing steps, each 5 min) was repeated and the proteins were detected by 
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enhanced chemiluminescence with the ECL Kit (Amersham Biosciences) according 
to the manufacturer’s instructions and exposed to Hyperfilms (GE Healthcare 
Biosciences). 
Densitometric analysis was performed by means of the Argus XI program (Biostep 
GmbH) and quantification was carried out with the ImageJ Software (NIH).  
Wet blot transfer buffer  
25 mM Tris 
192 mM Glycine 
20 % (v/v) Methanol 
TBS buffer (pH 8) 
10 mM Tris 
150 mM NaCl 
Ponceau S fixing solution 
0.25 % (w/v)  Ponceau S 
3 % (w/v)  TCA 
5.4.7 Proteolytic cleavage of peptides 
The protein purified on Ni-NTA column was subjected to one of the following 
proteolytic cleavage. 
5.4.7.1 Cleavage by 3C protease 
In order to keep the protein in soluble state, it was necessary that a minimum 
concentration of 0.1 % DDM was maintained in the buffers. So, the 10x buffer 
supplied by the manufacturer was diluted to 5x as follows. 
This diluted buffer was then used for the further protease reactions. The 
composition of buffer A used for the dilution of DDM was as follows. 
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Dilution of 3C protease buffer 
 10x 3C protease buffer 5 ml 
10 % (w/v) DDM in buffer A 500 µl 
Ultrapure water 4.5 ml 
Total 10 ml 
Buffer A 
 50 mM Tris 
20 % Glycerol 
50 mM NaCl 
 
The protein purified on Ni-NTA column was quantified for its protein concentration 
as described in section 5.4.3.1 and used for the cleavage by the 3C protease. The 
reaction was set up in a 1.5 ml microcentrifuge tube as mentioned in the table.  A 
negative control of the reaction was set up with only 5x buffer (with 0.5 % DDM) 
and the protein. 5 µl of ultrapure water was added to the negative control instead of 
3C protease.  
3C protease reaction 
Protein x µl 
5x buffer (with 0.5 % DDM)  40 µl 
HRV 3C protease 5 µl 
Ultrapure water 155-x µl 
Total 200 µl 
Incubated at 4 °C overnight at 200 rpm 
  x = volume of protein sample used for the 
reaction 
 
The protease cleavage was performed using 5, 10, 20, 50 and 100 µg of protein 
purified on the Ni-NTA column. The volume of protein used in the reaction was 
calculated using following formula. 
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The cleavage by 3C protease was monitored by subsequent western blotting as 
described in 5.4.6, by using a suitable antibody which can differentiate the protein 
before and after the cleavage. 
5.4.7.2 Cleavage by Factor Xa 
The 10x buffer supplied by the manufacturer was diluted to 5x with ultrapure water 
and 10 % DDM in buffer A, as mentioned in the table. This dilution was made to 
maintain 0.1 % DDM in the final protease reaction   in order to keep the protein in 
soluble state. 
Dilution of Factor Xa protease buffer 
10x  Factor Xa protease buffer 5 ml 
10 % (w/v) DDM in buffer A 500 µl 
Ultrapure water 4.5 ml 
Total 10 ml 
 
The protein purified on Ni-NTA column was used for the cleavage by the Factor Xa 
protease. The amount of protein in the sample was quantified as described in section 
5.4.3. The reaction was set up in a 1.5 ml microcentrifuge tube as mentioned in the 
table.  A negative control of the reaction was set up with only 5x buffer (with 0.5 % 
DDM) and the protein. 5 µl of ultrapure water was added to the negative control 
instead of Factor Xa protease. 
Factor Xa protease reaction 
Protein x µl 
5x buffer (with 0.5 % DDM)  40 µl 
HRV 3C protease 5 µl 
Ultrapure water 155-x µl 
Total 200 µl 
Incubated at 4 °C overnight at 200 rpm 
  x = volume of protein sample used for the reaction  
The volume of protein used in the reaction was calculated as mentioned in section 
5.4.7.1 
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5.5 Large scale fermentation, Protein Isolation and 
purification 
5.5.1 Large scale fermentation of P. pastoris  
The large scale fermentation was performed under control conditions in Infors HT 
Minifors bench top fermenter. The clones which have shown reproducible 
expression of high amounts of protein in small scale cultures were used for the large 
scale production of protein. The fermentation involved following steps. 
d. Creating the pre-culture 
The selected clone plated on a fresh YPD agar plate supplemented with 100 µg/ml 
Zeocin and was incubated at 30 °C for 3-4 days. A distinct colony from this plate was 
picked and inoculated in 50 ml MGY medium in a 250 ml baffled flask. The culture 
was incubated for 24 h at 29 °C at 200 rpm. The OD600 of 1 for a 50 ml culture 
refers to a mass of about 1.32 g of yeast cells. The culture was grown till the OD600 
reached at least 2.5 as the inoculation with 3 g of viable cells was found to be 
optimal for the fermentation (Spruth 2011 ). 
e. Fermentation process 
For the large scale fermentation and production of the protein, a protocol 
established by our working group for MRP3 expressing clone obtained from Prof. 
Urbatsch (Texas Tech University, USA) was used.  
The fermentation process involved three different phases. The first phase, also 
known as glycerol-batch phase, involved the exponential growth of yeasts. For the 
production of biomass, glycerol was used in the growth media as a carbon source. 
When the glycerol from the media was consumed, the linear feeding of glycerol was 
continued to generate a large amount of biomass. This second phase of feeding 
glycerol was referred to as the glycerol –feed phase. This is followed by the third so-
called methanol-feed phase. The methanol is provided at constant rate in order to 
induce the culture for the expression of MRP3.  
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The bench top fermenter Infors HT Minifors used for the fermentation includes a 
cooling jacket for the reaction vessel, probes for pH, temperature, dissolved oxygen 
and foam control. To ensure the optimal fermentation, these parameters were 
monitored and controlled using a computer program.  The time periods and volumes 
of glycerol-batch phase, glycerol-feed phase and the methanol feed phase were 
calculated by Monod model and simulated with software IRIS V5.2 (Infors HT). The 
computer program and the protocol were established by our coworker Patrick 
Seelheim.  
f. Preparation 
The fermenter was assembled and the fermenter vessel was filled with 1 L of non-
sterile fermentation medium. The composition of the media used was taken from 
Current Protocols in Protein Science (Romanos et al., 2001) and have been slightly 
modified. The appropriate reagent flasks labeled as feed and AF (Antifoam) was 
filled with 50 % (w / v) glycerol and antifoam agent respectively. The reagent flask 
labeled as base was filled with 170 ml of ultrapure water while the reagent flask for 
methanol (labeled as acid) was kept empty. Then all the electrodes, filters and the 
rotor were covered with aluminum foil and the fermenter was steam-sterilized at 
121 ° C for 30 min.  
The sterile fermenter assembly of the fermenter vessel and the reagent flasks were 
then connected to the base unit and the fermenter was switched on. The heat shield, 
tempertaure sensor and all the electrodes were connected.  After the temperature 
reached the set point, 50 ml of sodium hexametaphosphate solution of (2.5 % (w/v)) 
and 4.35 ml sterile PTM (Pichia trace metals) were aseptically added to the 
fermenter vessel. The reagent flasks labeled as base and acid were filled with 30 % 
(v / v) solution of ammonia and methanol (pa) under sterile conditions respectively. 
The reagent flasks with glycerol and methanol were supplemented with 12 ml /L 
PTM aseptically. 
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g.  Fermentation 
The 50 ml pre-culture was inoculated in the fermenter vessel when the fermentation 
medium showed a constant pH value of 5 and a temperature of 
29 ° C.  Immediately after the inoculation the glycerol-batch phase starts which takes 
around 12–18 h. The glycerol feed phase automatically started after the completion 
of glycerol-batch phase. During the feed phase 200-250 ml of glycerol (20 ml / h) 
was added to the culture to generate the biomass (about 24-28 h). Subsequently, 
after the generation of biomass, the culture was supplemented with methanol at a 
constant rate (3 ml/h). This methanol feed phase was continued for 24, 36 or 48 h 
and the culture was harvested after this induction phase. 
After the completion of fermentation, the yeast suspension from the fermenter was 
collected and culture was centrifuged for 15 min at 6,000 rpm (3500 g) in a JA14 
rotor (Beckman) at 4 °C. The supernatant after this centrifugation step was 
discarded and the pellet was dissolved in ultrapure water. The resuspended pellet 
was again centrifuged for 15 min at 6,000 rpm (3500 g) and the pellet containing 
yeast cells was stored at -70 °C until further processing. The composition of different 
solutions and media used for the fermentation are listed in the following tables. 
MGY media (pH 5.0) 
0.34 % (w/v)  Yeast nitrogen base 
2 % (w/v)  Glycerol 
1 % (w/v)  (NH4)2SO4 
0.0004 % (w/v)  Biotin 
0.1 M Phosphate buffer 
Autoclaved and  stored up to 6 months at 4 °C 
  
Fermentation media (1 L) 
1.14 g CaSO4.2H2O 
18.2 g K2SO4 
14.9 g MgSO4·7 H2O 
9.0 g (NH4)2SO4 
40.0 g Glycerol 
ad 1 L Ultrapure water 
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Sodium hexametaphosphate solution 
25 g Sodium hexametaphosphate 
50 ml Ultrapure water 
 
 
PTM 
 24 mg/ml CuSO4·5H2O 
0.32 mg/ml NaI 
12 mg/ml MnSO4·H2O 
0.8 mg/ml Na2MoO4·2 H2O 
0.08 mg/ml H3BO3 
2 mg/ml CoCl2 
80 mg/ml ZnCl2 
260 mg/ml FeSO4·7 H2O 
0.8 mg/ml D-(+)-Biotin 
0.02 ml/L H2SO4 
Autoclaved and stored indefinitely at room 
temperature. 
 
5.5.2 Preparation of microsomes from P. pastoris 
For the isolation and purification of the expressed protein, it is necessary to disrupt 
the yeast cells. But the yeast cells are difficult to lyse due to the highly complex and 
stable yeast cell wall. Mild methods such as chemical lysis or osmotic shock are not 
sufficient for efficient lysis of the cells o large scale. On the other hand, enzymatic 
digestion of the cell wall generates the protoplasts which usually require lysis with 
detergents that denatures the proteins and render them inactive. Therefore, 
mechanical cracking/fracturing of the yeast cell is most commonly used to break the 
rigid cell wall.   
 The mechanical cell lysis of the MRP3 expressing Pichia pastoris cells from the 
fermenter was performed by one of the following methods. In order to protect the 
expressed protein from denaturation and proteolytic degradation, all the steps were 
performed at 4 °C and different protease inhibitors were added to the buffers at 
various steps. 
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5.5.2.1 Disruption using BeadBeaterTM 
A mass of 70-80 g of wet cells from the MRP3 expressing Pichia culture harvested 
from the fermenter was dissolved in 100 ml of ice cold homogenization buffer 
supplemented with protease inhibitors (PIs) and DTT. The composition of 
homogenization buffer and concentration of the various PIs was as described in 
section 5.4.1. The cell suspension was mixed with 130 ml of cold glass beads (∅ = 
0.45 mm, BioSpec Products) and transferred into BeadBeater chamber 
(BeadBeaterTM, Model 1107900, BioSpec Products). The chamber filled with the cell 
suspension and glass beads was assembled in the cooling jacket and in the jacket a 
mixture of isopropanol and dry ice was filled.  
The cells were agitated in the BeadBeater 1 5 times for 1 minute, each time keeping 
the cells on ice for 1 minute in between. After the complete disruption for 15 min the 
lysed cell suspension was transferred to a 250 ml centrifuge bottle and 200 μL fresh 
PMSF was added to it. The glass beads were washed with approximately 100 ml of 
homogenization buffer and the wash was collected in the same centrifuge bottle. The 
lysed cell suspension was centrifuged at different rotation speeds as described in 
section 0 in order to obtain the microsomal fraction. 
5.5.2.2 Disruption using Emulsifier 
The mechanical disruption was performed in high pressure emulsifier (EmulsiFlex-
C5, Avestin) in order to get better yield of disruption. The homogenizer (emulsifier) 
has an air/gas driven high pressure pump and lyses the cells by pressurizing the cell 
suspension and suddenly releasing the pressure. This sudden change in the pressure 
creates a liquid shear which is capable of lysing the yeast cells. For yeast cell lysis 
operating pressure of 20,000 psi was used.  
The wet cells from the MRP3 expressing Pichia culture harvested from the fermenter 
were dissolved in ice cold homogenization buffer supplemented with protease 
inhibitors (PIs) and DTT at a concentration of 1.2-1.5 ml homogenization buffer/g 
cells. The cells were suspended carefully till the solution was free of any cell clumps 
or the ice crystals. The homogenizer was cleaned and precooled by flushing through 
10 ml of ice cold ultrapure water 2x by releasing the pressure. The apparatus was 
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also rinsed with 10 ml of ice cold homogenization buffer supplemented with PIs 
(section 5.4.1) before applying the cell suspension.  The homogenous cell suspension 
(10-20 ml) was then poured into the homogenizer and passed through the dynamic 
homogenizing valve under high pressure (20,000 psi). The high operating pressures 
resulted in a rise in the temperature of the cell suspension after lysis. The lysed cells 
were collected and cooled on ice. The cell suspension was passed through the 
homogenizing valve multiple (at least 3) times in order to achieve a reasonable 
degree of lysis.  The lysed cell suspension was then centrifuged at different rotation 
speeds as described in section 0 to separate the membrane fractions. 
5.5.2.3 Centrifugation after mechanical disruption 
The disrupted cells were centrifuged at 4 °C using various rotors and different 
rotation speeds in order to separate the membrane fractions.  The first step of 
centrifugation was performed with JA14 rotor (Beckman) at 6000 rpm (5,520 g) for 
15 min for the removal of cell debris, nuclei and of other large cell components. The 
turbid and slimy supernatant obtained after the first centrifugation step was 
separated and centrifuged again for 30 min at 12000 rpm (22,100 g). The 
supernatant obtained after the second centrifugation step was clear and contained 
the membrane fractions. In order to pellet down the microsomal fractions, the 
supernatant was centrifuged for 60 min at 48000 rpm (278,400 g) in Ultracentrifuge 
L-70 (Beckmann) with Ti 50.2 rotor. The pellet obtained after ultracentrifugation 
was dissolved in 1-3 ml of washing buffer supplemented with PIs (25 μL Pepstatin A, 
Leupeptin and Chymostatin and 75 μL of Phenylmethylsulfonylfluorid was added to 
30 ml washing buffer). The composition of washing buffer was as mentioned in the 
table and concentrations of PIs as similar to as mentioned in section 5.4.1.  
Washing buffer  
 50 mM Tris 
10 % Glycerol 
  
The resuspended pellets were diluted with washing buffer to fill up the tubes and 
ultracentrifuged again for 60 min at 48000 rpm (278,400 g) in Ultracentrifuge L-70 
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(Beckmann) with Ti 50.2 rotor. The supernatant after this washing step was 
discarded and each pellet was resuspended in 1-3 ml of buffer A supplemented with 
PIs and homogenized 10x in a Dounce homogenizer (30 ml of buffer A supplemented 
with 25 μL Pepstatin A, Leupeptin and Chymostatin and 75 μL of 
Phenylmethylsulfonylfluorid). The composition of buffer A was as mentioned in the 
table. 
Buffer A 
 50 mM Tris 
20 % Glycerol 
50 mM NaCl 
  
The resuspended and homogenized microsomal fractions from all the pellets were 
collected. The microsomal fraction was either directly used for solubilization or 
blast-frozen in liquid nitrogen and stored at -70 °C. 
5.5.3 Solubilization of microsomal membrane vesicles 
Chromatographic purification requires the protein of interest to be in a soluble state. 
The solubilization involves extraction of the protein of interest from its native 
membranes which can be performed by using various detergents. The dissociation 
of the membrane by using suitable detergent results in formation of small protein-
lipid clusters. The micelles formed by the aggregation of detergent molecules are 
analogous to the biological membranes and can incorporate the proteins by 
hydrophobic interactions. In these clusters the hydrophobic regions of membrane 
protein, which are normally embedded in the membrane lipid bilayer, are 
surrounded by a layer of hydrophobic tails of detergent molecules and the 
hydrophilic portions are exposed to the aqueous medium. This property allows the 
protein-lipid clusters to stay soluble in aqueous solutions. This soluble protein can 
then be used for purification and further analysis.  
The MRP3 was solubilized using a mild, non-ionic detergent n-dodecyl β-D-
maltopyranoside (DDM). The frozen microsomal fractions from section 5.5.2.3 were 
carefully thawed at 29 °C in a water bath and then kept on ice. The microsomal 
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fraction was diluted with buffer A to get a final concentration of ~4 mg microsomal 
protein/ml. Equal volume of solubilization buffer was added to the microsomal 
suspension and carefully stirred twice at RT for 15 min with incubation on ice for 
1 min in between. The composition of solubilization buffer was as follows. 
Solubilization buffer  
 
Buffer A 
0. 5 % (w/v) DDM 
0.5 mM β-ME  
  
The solubilized protein was centrifuged in Ultracentrifuge L-70 (Beckmann) with Ti 
50.2 rotor at 28000 rpm (94,700 g) for 30 min at 4 °C, in order to remove undesired 
components. The supernatant containing soluble protein was used for purification 
on affinity columns. 
5.5.4 Ni (II)-NTA Affinity Chromatography 
The Ni (II)-NTA Affinity Chromatography is based on the concept of immobilized-
metal affinity chromatography (IMAC). It uses the affinity of transition metal ions 
such as Cu2+, Zn2+ or Ni2+ to histidine and cysteine in aqueous solutions.  
In the Ni (II)-NTA affinity resin, the Ni2+ is immobilized on agarose beads by 
chelation using nitroloacetic acid (NTA). The poly His sequence from the 
recombinant protein binds to the immobilized Ni2+cations from the column and 
other proteins pass through the matrix (Figure 5-2). The bound protein can be 
eluted from the column under mild conditions by adding 100–250 mM imidazole or 
by reducing the pH. 
The purification of MRP3 on Ni-NTA column was performed either on small scale or 
large scale. In both the cases all the steps were carried out at 4 ° C. The compositions 
of different buffers used for the purification are mentioned in a table after the 
description of both small and large scale procedures. 
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Figure 5-2: The complex formation between the poly-His tag of the protein and the immobilized a Ni2+ 
cations on from the Ni-NTA agarose (Block, Maertens et al. 2009). 
5.5.4.1 Purification on small scale 
For small scale purification, 1 or 5 ml of the Ni (II)-NTA Agarose (Qiagen) was filled 
in a column and used under gravity flow. The column material was washed several 
times with 1 column volume (CV) of equilibration buffer before loading the 
solubilized protein onto the column. This was necessary to prevent the aggregation 
of the protein on the column. After the equilibration, the 1-5 CV of the solubilized 
sample was loaded and incubated on the column for 5 min. The unbound fraction 
called flow through (FT) after 5 min was let run from the column under the influence 
of gravity. The FT was again reloaded on the column and incubated again. This 
process was repeated 4x for efficient binding of the protein. After the binding step, 
the column with the bound protein fraction was washed with different washing 
buffers (WB). Following the washing steps with 1 CV of WB1 and WB2, 0.5 CV of 
elution buffer was loaded on the column and incubated for 5 min. The sample after 
5 min incubation was collected and labeled as elution fraction (E). The elution step 
was repeated 3-5x in order to elute all the bound protein from the column. The 
column was washed and regenerated as described in section 5.5.4.3.  
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5.5.4.2 Purification on large scale 
The large scale purification was performed by using 25 ml Ni (II)-NTA-Agarose 
(Quiagen) in glass columns operated by a High-precision multi-channel (IPC, 
Ismatec).  
Before loading the sample, the column was washed 2x with 75 ml ultrapure water (3 
CVs), let drip at maximum pump speed. The column was equilibrated with 50 ml (2 
CVs) of equilibration buffer and let drip until liquid level is 2 mm above resin. The 
solubilized protein sample was loaded onto equilibrated Ni-NTA resin column and 
let circulate overnight at a pump speed of 60. Next day the overnight incubated 
sample was let drip at maximum pump speed and labeled as FT. The column was 
washed with 6 CVs of WB1 and 4 CVs of WB2 at maximum pump speed and the 
samples were collected as W 1 and W2. After the washings, 2 CVs of the 
elution buffer (EB) was loaded on the column and two fractions of 0.2 CV were 
collected at a pump speed of 60. The EB was incubated for 15 min and next fraction 
of 0.2 CV was collected. The elution fractions were collected till the EB from the 
column was over. The amount of protein in different elution fractions was 
determined by Bradford’s assay as described in section 5.4.3.2. The fractions 
containing highest amount of protein were collected and concentrated by 
ultrafiltration by using membrane filters with different cut off size (Amicon). 
The collected elution fractions from the Ni-NTA purification were transferred in an 
ultrafiltration cell (Model 8200, Millipore) and concentrated using Amicon 
membrane filter of 100 kDa cut off size. The sample was concentrated to 10 ml by 
ultrafiltration under a pressure of maximum 2 bars from a nitrogen pressure source. 
The concentrated sample was diluted to 25 ml with buffer A supplemented with 
0.1 % DDM and again concentrated to 5 ml. The process was repeated 2x. The 
concentrates sample was collected and transferred to ultrafiltration cell assembled 
with Amicon membrane filter of 30 kDa cut off size. The sample was diluted to 25 ml 
with buffer A containing 0.1 % DDM and concentrated to 5 ml under a pressure of 
maximum 4 bars. The dilution and ultrafiltration was repeated 3x and the protein 
was concentrated to 1-2 ml. The concentration of the protein was determined by 
measuring the absorption at 280 nm as described in section 5.4.3.1. The 
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concentrated protein was stored in liquid nitrogen at -196 °C or used for further 
purification. 
Composition of  buffers for Ni-NTA 
purification 
Equilibration buffer  
Buffer A with 0.1 % DDM 
  
Washing buffer 1 
 50 mM Tris 
10 % Glycerol 
0.1 % DDM 
1 mM β-ME  
30 mM  Imidazole 
  
Washing buffer 2 
 50 mM Tris 
10 % Glycerol 
0.1 % DDM 
1 mM β-ME  
40 mM  Imidazole 
  
Elution buffer  
 50 mM Tris 
10 % Glycerol 
0.1 % DDM 
1 mM β-ME  
200 mM  Imidazole 
5.5.4.3 Regeneration of Ni (II) NTA column 
After the purification, the Ni (II) NTA column was regenerated for next round of 
purification. The washings were performed at maximum pump speed for large scale 
columns and under gravity flow for small scale. The column was washed with 2 CVs 
of ultrapure water and 2 CVs of 0.5 M NaOH. The column was then washed with 5 
CVs of 100 mM EDTA and 2 CVs of ultrapure water to wash off all the Ni2+ cations 
Experimental 121 
 
bound to the resin. The column was recharged for next round of purification by 
washing with 2 CVs100 mM NiSO4 and drained until close to surface. The recharged 
column was washed with 10 CVs of ultrapure water and 2 CVs of 30 % ethanol and 
stored at 4 °C in 30 % ethanol. 
5.5.5 Strep tag II Affinity Chromatography 
The Strep tag II affinity purification is based on the principle of the well known 
binding of biotin to streptavidin. The Strep tag II peptide is capable of binding to the 
biotin binding pocket of streptavidin and hence serves as purification tag. The 
column resin uses an engineered streptavidin called Strep-Tactin which has high 
affinity to the Strep tag. The Strep-tagged proteins bind to the column with high 
affinity and specificity while other proteins pass through the matrix. The bound 
proteins are eluted using low concentrations of biotin or desthiobiotin (a stable, 
reversibly binding biotin analog) in the elution buffer. 
The purification on Strep-tactin column was performed on small scale by using 
either 200 µl, 500 µl or 1 ml of Strep-tactin resin (Strep-Tactin Superflow®, IBA). 
The purification with 200 µl of resin was performed in spin columns and the 
washing and elution was performed in a microcentrifuge for short time. For 500 µl 
or 1 ml columns, the washing and elutions were performed in 5 ml syringes and 
under the influence of gravity. In both the cases the purification involved following 
steps. 
The column material was washed 5x with 1 column volume (CV) of Strep wash 
buffer supplemented with 0.1 % DDM, before loading the solubilized protein onto 
the column. This was necessary to prevent the aggregation of the protein on the 
column. After the equilibration, the 1-5 CV of the solubilized sample or the protein 
purified on Ni-NTA column (before concentration) was loaded and incubated on the 
column for 5 min. The unbound fraction called flow through (FT) after the 
incubation was let run and reloaded on the column and incubated again. This 
binding step was repeated 5x for efficient binding of the protein (in case or spin 
columns, the columns were incubated with gentle shaking for 60 min). Following the 
binding step, the column with the bound protein fraction was washed 3x with 1 CV 
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of the Strep wash buffer (with 0.1 % DDM).  After washing of the column, 0.5 CV of 
Strep elution buffer (EB) was loaded on the column and incubated for 5 min. The 
sample after 5 min incubation was collected and labeled as elution fraction (E). The 
elution step was repeated 3-5x in order to elute all the bound protein from the 
column. The compositions of different buffers used for the purification are 
mentioned in the table. 
After the purification, the Strep-tactin column was washed 3x with 1 CV of the Strep 
wash buffer (without 0.1 % DDM) and regenerated by washing the column 2x with 1 
CV of 1x  BufferR (regeneration buffer, IBA) containing HABA (2-[4'-hydroxy-
benzeneazo]benzoic acid). The HABA displaces desthiobiotin (from the elution 
buffer) at the biotin-binding site and regenerate of immobilized Strep-Tactin for the 
next round of purification. The columns were stored at 4 °C in 1x R-buffer until next 
use. 
Composition of  buffers for Strep-tactin 
purification 
  Strep washing buffer  
100 mM Tris 
10 % Glycerol 
0.1 % DDM 
150 mM NaCl 
1 mM EDTA 
  Strep elution buffer  
100 mM Tris 
10 % Glycerol 
0.1 % DDM 
150 mM NaCl 
1 mM EDTA 
2.5 mM Desthiobiotin 
  
 
5.5.6 Purification on Reactive red columns 
Reactive Red is a polyaromatic textile dye which binds to proteins with affinities to 
various nucleotides (Figure 5-3). The reactive chloro groups allow immobilization of 
this dye onto a support matrix such as sepharose or agarose. This immobilized dye 
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can then be used for the affinity purification of any ATP binding protein including 
ABC transporters (Worrall 1996). The bound protein can be eluted from the column 
either by using high salt concentration or by competitive replacement by using a 
substrate of the protein or by nucleotide cofactor. 
 
Figure 5-3: Structure of Reactive Red 120 
A batch-purification method was used for the purification of MRP3 with Reactive 
Red column material (Reactive Red-120, Sigma). 500 µl of the column material was 
taken in a spin column and washed 5x with the binding buffer for the equilibration. 
The solubilized protein sample or the protein purified on Ni-NTA column (before 
concentration) was prepared for the loading by mixing 500 µl of the sample with 
equal volume of 2x Binding buffer. The 1 ml protein sample and was then mixed 
with 500 µl of the equilibrated column material and incubated in 2 ml 
microcentrifuge tube on a shaker for 1 h at 4 °C. After incubation the column 
material was loaded on spin columns and washed 2x with 1 CV of the binding buffer. 
The protein was eluted 2x with 1CV of Elution buffer 1 (EB1) and 3x with 1CV of 
Elution buffer 2 (EV2).  The washing and elution steps were performed in a 
microcentrifuge by spinning down the spin column for short time (30 Sec).  
After the purification the column material was washed 5-10x with 1 CV binding 
buffer (without DDM) and was regenerated by washing 3x with regeneration buffer. 
The resin was stored in storage buffer at 4 °C until the next use.  
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The purification was repeated with different pH values for binding and elution 
buffers. Compositions of different buffers used for the purification of Reactive Red 
column were as mentioned in the table. 
Composition of  buffers for Reactive Red 
purification 
  
Binding buffer  
 10 mM Tris-HCl 
adjust to pH 7 or 8 
 0.1 % DDM 
  
Elution buffer 1 
 10 mM Tris-HCl 
500 mM NaCl 
adjust the pH same as binding buffer 
0.1 % DDM 
  
Elution buffer 2 
 10 mM Tris-HCl 
1 M NaCl 
adjust the pH same as binding buffer 
0.1 % DDM 
  
Regeneration buffer  
100 mM Borate 
1 M NaCl 
adjust the pH to 9.8 using 1M NaOH 
  
Storage buffer   
 2 M NaCl 
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6 Appendix 
6.1 Abbreviations 
AB Antibody 
ABC  ATP-binding cassette  
AOX alcohol dehydrogenase  
ATP adenosine triphosphate 
BBB  blood-brain barrier 
BCRP breast cancer resistance protein  
BSA  bovine serum albumin 
CaCl2  calcium chloride 
cDNA  complementary DNA 
cm  centimetre 
conc. concentration 
CuSO4  copper(II) sulfate 
ddH2O  double distilled water 
DDM n-Dodecyl β-D-Maltopyranoside 
DMSO dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
EDTA  ethylenediaminetetraacetic acid 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
h   hour 
hMRP3 human MRP3 
KCl  potassium chloride 
kDa  kilodalton 
kg  kilogram 
KH2PO4  potassium dihydrogen phosphate 
M  molar 
mA  milliampere 
MDR multidrug resistance 
MgCl2  magnesium chloride 
ml  millilitre 
mRNA  messenger RNA 
MRP Multridrug resistant protein  
MRP  multidrug resistance-associated protein 
Na2HPO4  disodium hydrogen phosphate 
NaCl  sodium chloride 
NaOH sodium hydroxide 
NBD nucleotide binding domain 
ng  nanogram 
nM  nanomolar 
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OD  optical density 
PARS Pichia Autonomous Replication Sequence  
P-gp  P-glycoprotein 
PI Protease inhibitors 
Pi  Inorganic phosphate 
psi pound per square inch 
qRT-PCR  quantitative real-time polymerase chain reaction 
RNA  ribonucleic acid 
rpm   revolutions per minute 
sec second 
SDM site directed mutagenesis  
SDS sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TBS  Tris buffer saline 
TMD transmembrane domains  
U  unit 
UV-Vis  ultraviolet-visible 
V  volt 
v/v  volume per volume 
w/v  weight per volume 
 
Abbreviation     Amino acid name 
  
 
Ala     A    Alanine 
Arg     R   Arginine 
Asn     N   Asparagine 
Asp     D   Aspartic acid (Aspartate) 
Cys     C   Cysteine 
Gln     Q   Glutamine 
Glu     E   Glutamic acid (Glutamate) 
Gly     G   Glycine 
His     H   Histidine 
Ile     I   Isoleucine 
Leu     L   Leucine 
Lys     K   Lysine 
Met     M   Methionine 
Phe     F   Phenylalanine 
Pro     P   Proline 
Ser     S   Serine 
Thr     T   Threonine 
Trp     W   Tryptophan 
Tyr     Y   Tyrosine 
Val     V   Valine 
Asx     B   Aspartic acid or Asparagine 
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Glx     Z   Glutamine or Glutamic acid 
Xaa     X   Any amino acid 
STOP 
 
termination codon 
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6.2 Materials and devices 
Acetic Acid Merck Eurolab 
acrylamide  AppliChem GmbH 
Ampicillin Applichem GmbH 
APS AppliChem GmbH 
BCA  Sigma Aldrich Chemie GmbH 
Bicine Sigma Aldrich Chemie GmbH 
Bradford reagent Sigma Aldrich Chemie GmbH 
Bromophenol Blue AppliChem GmbH 
BSA BIOMOL GmbH 
Chelex Suspension BIO-RAD Laboratories GmbH 
Chymotrypsin AppliChem GmbH 
Copper Sulfate Merck Biosciences GmbH 
DDM AppliChem GmbH 
Desthiobiotin IBA GmbH 
Dextrose AppliChem GmbH 
DMSO Sigma Aldrich Chemie GmbH 
DOC AppliChem GmbH 
DTT AppliChem GmbH 
EACA AppliChem GmbH 
ECL Western Blotting Detection 
Reagent 
GE Healthcare Bio Science 
EDTA Sigma Aldrich Chemie GmbH 
EGTA Merck Biosciences GmbH 
Ethanol Merck Eurolab 
Glycerol AppliChem GmbH 
Glycine AppliChem GmbH 
HCl Sigma Aldrich Chemie GmbH 
HRV 3C Protese Novagen 
Imidazole AppliChem GmbH 
K2HPO4 Sigma Aldrich Chemie GmbH 
KH2PO4 Sigma Aldrich Chemie GmbH 
Leupeptin AppliChem GmbH 
Methanol Merck Eurolab 
Milk Powder AppliChem GmbH 
Na2HPO4 Sigma Aldrich Chemie GmbH 
NaCl AppliChem GmbH 
NaH2PO4 Sigma Aldrich Chemie GmbH 
NaOH  Carl Roth GmbH u. Co. KG  
Ni (II)-NTA Agarose  Qiagen 
Pepstatin AppliChem GmbH 
Peptone AppliChem GmbH 
PMSF AppliChem GmbH 
Ponceau S Sigma Aldrich Chemie GmbH 
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Proteinase-K AppliChem GmbH 
Protogold  Plano GmbH 
Reactive Red 120 Sigma Aldrich Chemie GmbH 
SDS SERVA Electrophoresis GmbH 
Sodium Acetate AppliChem GmbH 
Sorbitol Sigma Aldrich Chemie GmbH 
Strep-Tactin Superflow (50 % 
Suspension) IBA GmbH 
Sucrose GE Healthcare Bio Science 
TCA AppliChem GmbH 
TEMED Fluka 
Tris AppliChem GmbH 
Tris base  AppliChem GmbH 
Tryptone AppliChem GmbH 
Tween-20 Sigma Aldrich Chemie GmbH 
Yeast Extract AppliChem GmbH 
Zeocin Invitrogen GmbH 
β-mercaptoethanol  Sigma Aldrich Chemie GmbH 
 
Kits  
 
  QuikChange XL Site-Directed Mutagenesis Kit Stratagene 
GeneJET Plasmid Miniprep Kit Fermentas 
Zymoclean™ Gel DNA Recovery Kit Zymoresearch 
DNA Clean & Concentrator™ Zymoresearch 
 
Devices 
 
  10.0 ml Deep Well Plate HJ-Bioanalytik GmbH 
96-well microtiter plate Nunc  
96-well plate (MicroAmp) Applied Biosystems 
Agfa Curix 60 Film Processor  Agfa 
autoclave steam sterilizer 3870 EL  Jürgens 
Avanti 300  Beckman 
balance  Sartorius 
BeadBeater TM Model 1107900 BioSpec Products 
centrifuge 5415 D  Eppendorf 
centrifuge 5804 R  Eppendorf 
cryo tubes  Nunc 
electrophoresis power supply EPS 1000  Amersham Biotech  
Electroporation Cuvettes 2.0 mm VWR International 
elektrophoresis power supply PowerPac 2000 BioRad 
EmulsiFlex-C5 high pressure emulsifier Avestin 
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Fermenter Infors HT Minifors Infors HT 
Galss beads 0.45 mm BioSpec Products 
gloves  Roth 
hyperfilms  GE Healthcare 
incubator IG 150  Astel 
incubator Revico Ultimo  Hettich 
Kimwipe paper  Kimberly-Clark 
laminar flow hood Flow BSB 6A and BSB 4A  Gelaire 
Mastercycler personal  Eppendorf 
MicroAmpTM Fast Optical 96-well reaction plates Applied Biosystems 
MicroAmpTM Optical adhesive films Applied Biosystems 
microplate reader MR700  Dynatech 
Milli Q RO 10 Plus clean water device  Millipore 
MiniSpin microcentrifuge Eppendorf 
mocroplate Eppendorf 
Nanodrop 2000 Peqlab 
needle  Fischer 
nitrocellulose membranes (HybondTM ECL) GE Healthcare Biosciences 
petri dish Greiner 
pH meter pH 213  Merck 
PVDF Western blotting Membranes  Roth 
reaction tube Eppendorf 
scalpel  Bayha 
SDS gel electrophoresis device (minigel 10 x 10 cm)  Sigma 
semi-dry blotting equipment  Sigma 
Sepatech Megafuge 1.0  Heraeus 
StepOnePlus™ Real-Time PCR System  Applied Biosystems 
sterile filters Minisart 0.2 μm  Sartorius 
sterilisator UT 6120  Heraeus 
syringe  Henke-Sass/Wolf 
Tecan GENios microplate reader Tecan 
Thermomixer comfort  Eppendorf 
Trans-Blot® Electrophoretic Transfer Cell  Bio-Rad 
TranswellTM filter (3401 and 3402) Costar 
ultra centrifuge Optima-L70 with rotor JA-14  Beckman 
Ultra Yield Flask, 125 ml Thomson Instrument Company 
UV-VIS recording spectrophotometer UV-2401PC Shimadzu 
vortex  IKA Labortechnik 
water bath GFL 1004  GFL 
Whatman paper No.1 and No.3  Whatman 
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6.3 Clone charts 
All the vector maps shown here were created by using clone manager 9.0 software. 
6.3.1 Modified and Unmodified pPicholi vector 
The vector map of the unmodified pPicholi vector from the MoBiTec was as follows. 
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The vector was modified by replacing the sequence between EcoRI and NotI 
restriction sites by a tandem affinity purification tag containing Strep tag II and 8x 
His tag. 
 
This modified vector was used for cloning of different MRP3 sequences as 
mentioned in the section 3.1.2.1.  
The vector map of the modified pPicholi after insertion of MRP3 sequence was as 
follows. 
 
3575 bps
500
1000
1500
2000
2500
3000
3500
AscI
SacII
NotI
Xa Strep 3C 8xHIS
AOX-Terminator
ble (zeoR)
ColE1 ori
AOX1-Promotor
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6.3.2 Map of the pGEM7-MRP3 vector 
The pGEM7-MRP3 vector contained cDNA insert encoding hMRP3 sequence. The 
cloned vector was kindly provided by Prof. P. Borst (The Netherlands Cancer 
Institute, Amsterdam). This vector was transformed into TOP10F’ E.coli and used as 
a template for all the preparatory PCR reactions.  
 
7757 bps
1000
2000
3000
4000
5000
6000
7000
AatII
SphI
MRP3 cDNA
lac prom
pBR322 origin
amp marker
f1 origin
lacZ_a reporter
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6.3.3 Modified and Unmodified pPICZ A vector 
The vector map of the unmodified pPICZ A vector from the Invitrogen was as 
follows. 
 
The vector was modified by replacing the c-myc epitope sequence by Strep tag II 
sequence along with the protease cleavage sites designed for the cloning of MRP3 
from the pPicholi-MRP3 vector.  
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The map of the pPICZ A with Strep tag II and 6xHis tag (PASH) after modification 
was as follows.  
 
This PASH vector was used for cloning of different MRP3 sequences as mentioned in 
the section3.1.2.1. The vector map of the PASH after insertion of MRP3 sequence 
was as follows. 
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6.4 Bacterial and yeast strains used in the project 
6.4.1 Escherichia coli 
The E. coli strain TOP10F´ was used for all the bacterial transformation and plasmid 
isolation experiments. 
Top10 cells are modified E. coli K12 strains from Invitrogen used for cloning and 
plasmid preparation.  They have a high transformation efficiency and have the genes 
for recA (a recombinase) and endA (a DNAse that lowers plasmid yeild) knocked 
out.  The TOP10F´ genotype consists of and additional F´ episome thet carries the 
tetracycline resistance gene. The F’ sequence also allows isolation of single-stranded 
DNA from vectors that have an f1 origin of replication. In addition, the F´ episome 
carries the lacIq repressor for inducible expression from trc, tac, and lac promoters 
using IPTG. Therefore, TOP10F´ cells require induction by IPTG for blue/white 
colony screening. 
Genotype: F  lacIqTn10 (TetR)  - mcrA (mrr-hsdRMS-mcrBC) 80lacZ M15 lacX74 
recA1 ara 139 (ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
6.4.2 Pichia pastoris 
X-33 is a wild-type strain of Pichia pastoris used for selection on antibiotic 
Zeocin™and large-scale growth. It strain grows normally in both YPD and minimal 
media. 
KM71 (his4 arg4 aox1Δ:SARG4) is a strain a mutation in the histidinol 
dehydrogenase gene (his4) that prevents it from synthesizing histidine in the 
argininosuccinate lyase gene (arg4) that prevents the strain from growing in the 
absence of arginine.  However, the chromosomal AOX1 gene is largely deleted and 
replaced with the S. cerevisiae ARG4 gene in this strain which allows the cells to in 
grow in the absence of arginine in media. As a result of the disruption of the AOX1 
gene this strain relies on the much weaker AOX2 gene for the expression of alcohol 
oxidase (AOX) and grows at a slow rate when methanol was used as a sole carbon 
source (MutS). 
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To create KM71H, KM71 was transformed with a gene fragment encoding the HIS4 
gene and the transformants with the ability to grow on a minimal media lacking 
Histidine were isolated. This generated the MutS, Arg+  and His+ KM71H strain. 
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6.6 Sequence of hMRP3 used for cloning and expression 
As mentioned in section 3.1.2.2, the cDNA hMRP3 insert after cloning into pPicholi 
vector was sequenced to ensure that the protein had no alteration in the amino acid 
sequence. The sequence was then transferred into modified pPICZ A vector (section 
3.2.2.2.1). The sequence of the gene and the protein after the ligation into pPICZ A 
vector in was follows. The other truncated versions also had similar amino acid 
sequence.  
               10        20        30        40        50        60            
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ATGGCCTCTTGGTCCCATCCACAATTTGAAAAGATTGAAGGTAGACGGCGCGCCATGGAC  
       M  A  S  W  S  H  P  Q  F  E  K  I  E  G  R  R  R  A  M  D  
 
               70        80        90       100       110       120         
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GCCCTGTGCGGTTCCGGGGAGCTCGGCTCCAAGTTCTGGGACTCCAACCTGTCTGTGCAC  
       A  L  C  G  S  G  E  L  G  S  K  F  W  D  S  N  L  S  V  H  
 
              130       140       150       160       170       180      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ACAGAAAACCCGGACCTCACTCCCTGCTTCCAGAACTCCCTGCTGGCCTGGGTGCCCTGC  
       T  E  N  P  D  L  T  P  C  F  Q  N  S  L  L  A  W  V  P  C  
 
              190       200       210       220       230       240      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ATCTACCTGTGGGTCGCCCTGCCCTGCTACTTGCTCTACCTGCGGCACCATTGTCGTGGC  
       I  Y  L  W  V  A  L  P  C  Y  L  L  Y  L  R  H  H  C  R  G  
 
              250       260       270       280       290       300      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TACATCATCCTCTCCCACCTGTCCAAGCTCAAGATGGTCCTGGGTGTCCTGCTGTGGTGC  
       Y  I  I  L  S  H  L  S  K  L  K  M  V  L  G  V  L  L  W  C  
 
              310       320       330       340       350       360      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GTCTCCTGGGCGGACCTTTTTTACTCCTTCCATGGCCTGGTCCATGGCCGGGCCCCTGCC  
       V  S  W  A  D  L  F  Y  S  F  H  G  L  V  H  G  R  A  P  A  
 
              370       380       390       400       410       420      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CCTGTTTTCTTTGTCACCCCCTTGGTGGTGGGGGTCACCATGCTGCTGGCCACCCTGCTG  
       P  V  F  F  V  T  P  L  V  V  G  V  T  M  L  L  A  T  L  L  
 
              430       440       450       460       470       480      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ATACAGTATGAGCGGCTGCAGGGCGTACAGTCTTCGGGGGTCCTCATTATCTTCTGGTTC  
       I  Q  Y  E  R  L  Q  G  V  Q  S  S  G  V  L  I  I  F  W  F  
 
              490       500       510       520       530       540      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTGTGTGTGGTCTGCGCCATCGTCCCATTCCGCTCCAAGATCCTTTTAGCCAAGGCAGAG  
       L  C  V  V  C  A  I  V  P  F  R  S  K  I  L  L  A  K  A  E  
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              550       560       570       580       590       600      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GGTGAGATCTCAGACCCCTTCCGCTTCACCACCTTCTACATCCACTTTGCCCTGGTACTC  
       G  E  I  S  D  P  F  R  F  T  T  F  Y  I  H  F  A  L  V  L  
 
              610       620       630       640       650       660      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TCTGCCCTCATCTTGGCCTGCTTCAGGGAGAAACCTCCATTTTTCTCCGCAAAGAATGTC  
       S  A  L  I  L  A  C  F  R  E  K  P  P  F  F  S  A  K  N  V  
 
              670       680       690       700       710       720      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GACCCTAACCCCTACCCTGAGACCAGCGCTGGCTTTCTCTCCCGCCTGTTTTTCTGGTGG  
       D  P  N  P  Y  P  E  T  S  A  G  F  L  S  R  L  F  F  W  W  
 
              730       740       750       760       770       780      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TTCACAAAGATGGCCATCTATGGCTACCGGCATCCCCTGGAGGAGAAGGACCTCTGGTCC  
       F  T  K  M  A  I  Y  G  Y  R  H  P  L  E  E  K  D  L  W  S  
 
              790       800       810       820       830       840      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTAAAGGAAGAGGACAGATCCCAGATGGTGGTGCAGCAGCTGCTGGAGGCATGGAGGAAG  
       L  K  E  E  D  R  S  Q  M  V  V  Q  Q  L  L  E  A  W  R  K  
 
              850       860       870       880       890       900      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CAGGAAAAGCAGACGGCACGACACAAGGCTTCAGCAGCACCTGGGAAAAATGCCTCCGGC  
       Q  E  K  Q  T  A  R  H  K  A  S  A  A  P  G  K  N  A  S  G  
 
              910       920       930       940       950       960      
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GAGGACGAGGTGCTGCTGGGTGCCCGGCCCAGGCCCCGGAAGCCCTCCTTCCTGAAGGCC  
       E  D  E  V  L  L  G  A  R  P  R  P  R  K  P  S  F  L  K  A  
 
              970       980       990       1000      1010      1020     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTGCTGGCCACCTTCGGCTCCAGCTTCCTCATCAGTGCCTGCTTCAAGCTTATCCAGGAC  
       L  L  A  T  F  G  S  S  F  L  I  S  A  C  F  K  L  I  Q  D  
 
              1030      1040      1050      1060      1070      1080     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTGCTCTCCTTCATCAATCCACAGCTGCTCAGCATCCTGATCAGGTTTATCTCCAACCCC  
       L  L  S  F  I  N  P  Q  L  L  S  I  L  I  R  F  I  S  N  P  
 
              1090      1100      1110      1120      1130      1140     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ATGGCCCCCTCCTGGTGGGGCTTCCTGGTGGCTGGGCTGATGTTCCTGTGCTCCATGATG  
       M  A  P  S  W  W  G  F  L  V  A  G  L  M  F  L  C  S  M  M  
 
              1150      1160      1170      1180      1190      1200     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CAGTCGCTGATCTTACAACACTATTACCACTACATCTTTGTGACTGGGGTGAAGTTTCGT  
       Q  S  L  I  L  Q  H  Y  Y  H  Y  I  F  V  T  G  V  K  F  R  
 
              1210      1220      1230      1240      1250      1260     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ACTGGGATCATGGGTGTCATCTACAGGAAGGCTCTGGTTATCACCAACTCAGTCAAACGT  
       T  G  I  M  G  V  I  Y  R  K  A  L  V  I  T  N  S  V  K  R  
 
              1270      1280      1290      1300      1310      1320     
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      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GCGTCCACTGTGGGGGAAATTGTCAACCTCATGTCAGTGGATGCCCAGCGCTTCATGGAC  
       A  S  T  V  G  E  I  V  N  L  M  S  V  D  A  Q  R  F  M  D  
 
              1330      1340      1350      1360      1370      1380     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTTGCCCCCTTCCTCAATCTGCTGTGGTCAGCACCCCTGCAGATCATCCTGGCGATCTAC  
       L  A  P  F  L  N  L  L  W  S  A  P  L  Q  I  I  L  A  I  Y  
 
              1390      1400      1410      1420      1430      1440     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TTCCTCTGGCAGAACCTAGGTCCCTCTGTCCTGGCTGGAGTCGCTTTCATGGTCTTGCTG  
       F  L  W  Q  N  L  G  P  S  V  L  A  G  V  A  F  M  V  L  L  
 
              1450      1460      1470      1480      1490      1500     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ATTCCACTCAACGGAGCTGTGGCCGTGAAGATGCGCGCCTTCCAGGTAAAGCAAATGAAA  
       I  P  L  N  G  A  V  A  V  K  M  R  A  F  Q  V  K  Q  M  K  
 
              1510      1520      1530      1540      1550      1560     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TTGAAGGACTCGCGCATCAAGCTGATGAGTGAGATCCTGAACGGCATCAAGGTGCTGAAG  
       L  K  D  S  R  I  K  L  M  S  E  I  L  N  G  I  K  V  L  K  
 
              1570      1580      1590      1600      1610      1620     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTGTACGCCTGGGAGCCCAGCTTCCTGAAGCAGGTGGAGGGCATCAGGCAGGGTGAGCTC  
       L  Y  A  W  E  P  S  F  L  K  Q  V  E  G  I  R  Q  G  E  L  
 
              1630      1640      1650      1660      1670      1680     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CAGCTGCTGCGCACGGCGGCCTACCTCCACACCACAACCACCTTCACCTGGATGTGCAGC  
       Q  L  L  R  T  A  A  Y  L  H  T  T  T  T  F  T  W  M  C  S  
 
              1690      1700      1710      1720      1730      1740     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CCCTTCCTGGTGACCCTGATCACCCTCTGGGTGTACGTGTACGTGGACCCAAACAATGTG  
       P  F  L  V  T  L  I  T  L  W  V  Y  V  Y  V  D  P  N  N  V  
 
              1750      1760      1770      1780      1790      1800     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTGGACGCCGAGAAGGCCTTTGTGTCTGTGTCCTTGTTTAATATCTTAAGACTTCCCCTC  
       L  D  A  E  K  A  F  V  S  V  S  L  F  N  I  L  R  L  P  L  
 
              1810      1820      1830      1840      1850      1860     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  AACATGCTGCCCCAGTTAATCAGCAACCTGACTCAGGCCAGTGTGTCTCTGAAACGGATC  
       N  M  L  P  Q  L  I  S  N  L  T  Q  A  S  V  S  L  K  R  I  
 
              1870      1880      1890      1900      1910      1920     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CAGCAATTCCTGAGCCAAGAGGAACTTGACCCCCAGAGTGTGGAAAGAAAGACCATCTCC  
       Q  Q  F  L  S  Q  E  E  L  D  P  Q  S  V  E  R  K  T  I  S  
 
              1930      1940      1950      1960      1970      1980     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CCAGGCTATGCCATCACCATACACAGTGGCACCTTCACCTGGGCCCAGGACCTGCCCCCC  
       P  G  Y  A  I  T  I  H  S  G  T  F  T  W  A  Q  D  L  P  P  
 
              1990      2000      2010      2020      2030      2040     
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      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ACTCTGCACAGCCTAGACATCCAGGTCCCGAAAGGGGCACTGGTGGCCGTGGTGGGGCCT  
       T  L  H  S  L  D  I  Q  V  P  K  G  A  L  V  A  V  V  G  P  
 
              2050      2060      2070      2080      2090      2100     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GTGGGCTGTGGGAAGTCCTCCCTGGTGTCTGCCCTGCTGGGAGAGATGGAGAAGCTAGAA  
       V  G  C  G  K  S  S  L  V  S  A  L  L  G  E  M  E  K  L  E  
 
              2110      2120      2130      2140      2150      2160     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GGCAAAGTGCACATGAAGGGCTCCGTGGCCTATGTGCCCCAGCAGGCATGGATCCAGAAC  
       G  K  V  H  M  K  G  S  V  A  Y  V  P  Q  Q  A  W  I  Q  N  
 
              2170      2180      2190      2200      2210      2220     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TGCACTCTTCAGGAAAACGTGCTTTTCGGCAAAGCCCTGAACCCCAAGCGCTACCAGCAG  
       C  T  L  Q  E  N  V  L  F  G  K  A  L  N  P  K  R  Y  Q  Q  
 
              2230      2240      2250      2260      2270      2280     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ACTCTGGAGGCCTGTGCCTTGCTAGCTGACCTGGAGATGCTGCCTGGTGGGGATCAGACA  
       T  L  E  A  C  A  L  L  A  D  L  E  M  L  P  G  G  D  Q  T  
 
              2290      2300      2310      2320      2330      2340     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GAGATTGGAGAGAAGGGCATTAACCTGTCTGGGGGCCAGCGGCAGCGGGTCAGTCTGGCT  
       E  I  G  E  K  G  I  N  L  S  G  G  Q  R  Q  R  V  S  L  A  
 
              2350      2360      2370      2380      2390      2400     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CGAGCTGTTTACAGTGATGCCGATATTTTCTTGCTGGATGACCCACTGTCTGCGGTGGAC  
       R  A  V  Y  S  D  A  D  I  F  L  L  D  D  P  L  S  A  V  D  
 
              2410      2420      2430      2440      2450      2460     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TCTCATGTGGCCAAGCACATCTTTGACCACGTCATCGGGCCAGAAGGCGTGCTGGCAGGC  
       S  H  V  A  K  H  I  F  D  H  V  I  G  P  E  G  V  L  A  G  
 
              2470      2480      2490      2500      2510      2520     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  AAGACGCGAGTGCTGGTGACGCACGGCATTAGCTTCCTGCCCCAGACAGACTTCATCATT  
       K  T  R  V  L  V  T  H  G  I  S  F  L  P  Q  T  D  F  I  I  
 
              2530      2540      2550      2560      2570      2580     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GTGCTAGCTGATGGACAGGTGTCTGAGATGGGCCCGTACCCAGCCCTGCTGCAGCGCAAC  
       V  L  A  D  G  Q  V  S  E  M  G  P  Y  P  A  L  L  Q  R  N  
 
              2590      2600      2610      2620      2630      2640     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GGCTCCTTTGCCAACTTTCTCTGCAACTATGCCCCCGATGAGGACCAAGGGCACCTGGAG  
       G  S  F  A  N  F  L  C  N  Y  A  P  D  E  D  Q  G  H  L  E  
 
              2650      2660      2670      2680      2690      2700     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GACAGCTGGACCGCGTTGGAAGGTGCAGAGGATAAGGAGGCACTGCTGATTGAAGACACA  
       D  S  W  T  A  L  E  G  A  E  D  K  E  A  L  L  I  E  D  T  
 
              2710      2720      2730      2740      2750      2760     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
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MRP3  CTCAGCAACCACACGGATCTGACAGACAATGATCCAGTCACCTATGTGGTCCAGAAGCAG  
       L  S  N  H  T  D  L  T  D  N  D  P  V  T  Y  V  V  Q  K  Q  
 
              2770      2780      2790      2800      2810      2820     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TTTATGAGACAGCTGAGTGCCCTGTCCTCAGATGGGGAGGGACAGGGTCGGCCTGTACCC  
       F  M  R  Q  L  S  A  L  S  S  D  G  E  G  Q  G  R  P  V  P  
 
              2830      2840      2850      2860      2870      2880     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CGGAGGCACCTGGGTCCATCAGAGAAGGTGCAGGTGACAGAGGCGAAGGCAGATGGGGCA  
       R  R  H  L  G  P  S  E  K  V  Q  V  T  E  A  K  A  D  G  A  
 
              2890      2900      2910      2920      2930      2940     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTGACCCAGGAGGAGAAAGCAGCCATTGGCACTGTGGAGCTCAGTGTGTTCTGGGATTAT  
       L  T  Q  E  E  K  A  A  I  G  T  V  E  L  S  V  F  W  D  Y  
 
              2950      2960      2970      2980      2990      3000     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GCCAAGGCCGTGGGGCTCTGTACCACGCTGGCCATCTGTCTCCTGTATGTGGGTCAAAGT  
       A  K  A  V  G  L  C  T  T  L  A  I  C  L  L  Y  V  G  Q  S  
 
              3010      3020      3030      3040      3050      3060     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GCGGCTGCCATTGGAGCCAATGTGTGGCTCAGTGCCTGGACAAATGATGCCATGGCAGAC  
       A  A  A  I  G  A  N  V  W  L  S  A  W  T  N  D  A  M  A  D  
 
              3070      3080      3090      3100      3110      3120     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  AGTAGACAGAACAACACTTCCCTGAGGCTGGGCGTCTATGCTGCTTTAGGAATTCTGCAA  
       S  R  Q  N  N  T  S  L  R  L  G  V  Y  A  A  L  G  I  L  Q  
 
              3130      3140      3150      3160      3170      3180     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GGGTTCTTGGTGATGCTGGCAGCCATGGCCATGGCAGCGGGTGGCATCCAGGCTGCCCGT  
       G  F  L  V  M  L  A  A  M  A  M  A  A  G  G  I  Q  A  A  R  
 
              3190      3200      3210      3220      3230      3240     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GTGTTGCACCAGGCACTGCTGCACAACAAGATACGCTCGCCACAGTCCTTCTTTGACACC  
       V  L  H  Q  A  L  L  H  N  K  I  R  S  P  Q  S  F  F  D  T  
 
              3250      3260      3270      3280      3290      3300     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ACACCATCAGGCCGCATCCTGAACTGCTTCTCCAAGGACATCTATGTCGTTGATGAGGTT  
       T  P  S  G  R  I  L  N  C  F  S  K  D  I  Y  V  V  D  E  V  
 
              3310      3320      3330      3340      3350      3360     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTGGCCCCTGTCATCCTCATGCTGCTCAATTCCTTCTTCAACGCCATCTCCACTCTTGTG  
       L  A  P  V  I  L  M  L  L  N  S  F  F  N  A  I  S  T  L  V  
 
              3370      3380      3390      3400      3410      3420     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GTCATCATGGCCAGCACGCCGCTCTTCACTGTGGTCATCCTGCCCCTGGCTGTGCTCTAC  
       V  I  M  A  S  T  P  L  F  T  V  V  I  L  P  L  A  V  L  Y  
 
              3430      3440      3450      3460      3470      3480     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
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MRP3  ACCTTAGTGCAGCGCTTCTATGCAGCCACATCACGGCAACTGAAGCGGCTGGAATCAGTC  
       T  L  V  Q  R  F  Y  A  A  T  S  R  Q  L  K  R  L  E  S  V  
 
              3490      3500      3510      3520      3530      3540     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  AGCCGCTCACCTATCTACTCCCACTTTTCGGAGACAGTGACTGGTGCCAGTGTCATCCGG  
       S  R  S  P  I  Y  S  H  F  S  E  T  V  T  G  A  S  V  I  R  
 
              3550      3560      3570      3580      3590      3600     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GCCTACAACCGCAGCCGGGATTTTGAGATCATCAGTGATACTAAGGTGGATGCCAACCAG  
       A  Y  N  R  S  R  D  F  E  I  I  S  D  T  K  V  D  A  N  Q  
 
              3610      3620      3630      3640      3650      3660     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  AGAAGCTGCTACCCCTACATCATCTCCAACCGGTGGCTGAGCATCGGAGTGGAGTTCGTG  
       R  S  C  Y  P  Y  I  I  S  N  R  W  L  S  I  G  V  E  F  V  
 
              3670      3680      3690      3700      3710      3720     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GGGAACTGCGTGGTGCTCTTTGCTGCACTATTTGCCGTCATCGGGAGGAGCAGCCTGAAC  
       G  N  C  V  V  L  F  A  A  L  F  A  V  I  G  R  S  S  L  N  
 
              3730      3740      3750      3760      3770      3780     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CCGGGGCTGGTGGGCCTTTCTGTGTCCTACTCCTTGCAGGTGACATTTGCTCTGAACTGG  
       P  G  L  V  G  L  S  V  S  Y  S  L  Q  V  T  F  A  L  N  W  
 
              3790      3800      3810      3820      3830      3840     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  ATGATACGAATGATGTCAGATTTGGAATCTAACATCGTGGCTGTGGAGAGGGTCAAGGAG  
       M  I  R  M  M  S  D  L  E  S  N  I  V  A  V  E  R  V  K  E  
 
              3850      3860      3870      3880      3890      3900     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TACTCCAAGACAGAGACAGAGGCGCCCTGGGTGGTGGAAGGCAGCCGCCCTCCCGAAGGT  
       Y  S  K  T  E  T  E  A  P  W  V  V  E  G  S  R  P  P  E  G  
 
              3910      3920      3930      3940      3950      3960     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  TGGCCCCCACGTGGGGAGGTGGAGTTCCGGAATTATTCTGTGCGCTACCGGCCGGGCCTA  
       W  P  P  R  G  E  V  E  F  R  N  Y  S  V  R  Y  R  P  G  L  
 
              3970      3980      3990      4000      4010      4020     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GACCTGGTGCTGAGAGACCTGAGTCTGCATGTGCACGGTGGCGAGAAGGTGGGGATCGTG  
       D  L  V  L  R  D  L  S  L  H  V  H  G  G  E  K  V  G  I  V  
 
              4030      4040      4050      4060      4070      4080     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GGCCGCACTGGGGCTGGCAAGTCTTCCATGACCCTTTGCCTGTTCCGCATCCTGGAGGCG  
       G  R  T  G  A  G  K  S  S  M  T  L  C  L  F  R  I  L  E  A  
 
              4090      4100      4110      4120      4130      4140     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GCAAAGGGTGAAATCCGCATTGATGGCCTCAATGTGGCAGACATCGGCCTCCATGACCTG  
       A  K  G  E  I  R  I  D  G  L  N  V  A  D  I  G  L  H  D  L  
 
              4150      4160      4170      4180      4190      4200     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CGCTCTCAGCTGACCATCATCCCGCAGGACCCCATCCTGTTCTCGGGGACCCTGCGCATG  
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       R  S  Q  L  T  I  I  P  Q  D  P  I  L  F  S  G  T  L  R  M  
 
              4210      4220      4230      4240      4250      4260     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  AACCTGGACCCCTTCGGCAGCTACTCAGAGGAGGACATTTGGTGGGCTTTGGAGCTGTCC  
       N  L  D  P  F  G  S  Y  S  E  E  D  I  W  W  A  L  E  L  S  
 
              4270      4280      4290      4300      4310      4320     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CACCTGCACACGTTTGTGAGCTCCCAGCCGGCAGGCCTGGACTTCCAGTGCTCAGAGGGC  
       H  L  H  T  F  V  S  S  Q  P  A  G  L  D  F  Q  C  S  E  G  
 
              4330      4340      4350      4360      4370      4380     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GGGGAGAATCTCAGCGTGGGCCAGAGGCAGCTCGTGTGCCTGGCCCGAGCCCTGCTCCGC  
       G  E  N  L  S  V  G  Q  R  Q  L  V  C  L  A  R  A  L  L  R  
 
              4390      4400      4410      4420      4430      4440     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  AAGAGCCGCATCCTGGTTTTAGACGAGGCCACAGCTGCCATCGACCTGGAGACTGACAAC  
       K  S  R  I  L  V  L  D  E  A  T  A  A  I  D  L  E  T  D  N  
 
              4450      4460      4470      4480      4490      4500     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CTCATCCAGGCTACCATCCGCACCCAGTTTGATACCTGCACTGTCCTGACCATCGCACAC  
       L  I  Q  A  T  I  R  T  Q  F  D  T  C  T  V  L  T  I  A  H  
 
              4510      4520      4530      4540      4550      4560     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  CGGCTTAACACTATCATGGACTACACCAGGGTCCTGGTCCTGGACAAAGGAGTAGTAGCT  
       R  L  N  T  I  M  D  Y  T  R  V  L  V  L  D  K  G  V  V  A  
 
              4570      4580      4590      4600      4610      4620     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GAATTTGATTCTCCAGCCAACCTCATTGCAGCTAGAGGCATCTTCTACGGGATGGCCAGA  
       E  F  D  S  P  A  N  L  I  A  A  R  G  I  F  Y  G  M  A  R  
 
              4630      4640      4650      4660      4670      4680     
      ....|....|....|....|....|....|....|....|....|....|....|....| 
MRP3  GATGCTGGACTTGCCTCTCCGCGGTTGGAAGTTCTGTTTCAAGGTCCAAATAGCGCCGTC  
       D  A  G  L  A  S  P  R  L  E  V  L  F  Q  G  P  N  S  A  V  
 
              4690      4700  
      ....|....|....|....|.... 
MRP3  GACCATCATCATCATCATCATTGA  
       D  H  H  H  H  H  H  *  
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6.7 Primer sequences  
All the primers used in this project were ordered either from Eurofin MWG Biotech 
or from Biolegio. The sequences of all primers are listed in 5'-3' orientation. For the 
primers containing non complementary sequences, the melting and annealing 
temperature for each primer pair used was found out experimentally by gradient 
PCR. 
Following are the abbreviations used for the designation of primers. 
Tm melting temperature 
TA melting temperature 
For Forward primer 
Rev Reverse primer 
  
Primers used for the generation of different constructs of MRP3 
MRP3 For AGTCTGGCGCGCCATGGACGCCCTGTG (27) 
  MRP3_D203  For AGTCTGGCGCGCCATGGCCTGCTTCAGGGAGAAACCT (37) 
  MRP3_Q250  For GTCTGGCGCGCCATGCATCCCCTGGAGGAGAAGGAC (37) 
  MRP3_S281  For AGTCTGGCGCGCCATGGAGGACGAGGTGCTGCTG (34) 
  MRP3_M904 Rev ACAGTCCGCGGCATAAACTGCTTCTGGACCAC (32) 
  MRP3_R905 For AGTCTGGCGCGCCATGAGACAGCTGAGTGCCCTGT (35) 
  MRP3 Rev ACAGTCCGCGGGAGGCAAGTCCAGCATCTCTG (32) 
  
  GGCGCGCC AscI restriction site at 5' end of the amplified sequence 
CCGCGG SacII restriction site at 3' end of the amplified sequence 
 
  
Primers used for the site directed mutagenesis in the purification tag Tm (°C) 
117_sense  GAAAAGTTGGAAGTTCTGTTTCAAGGTCCACATCATCATCA (41) 69.4 
   117_antis  TGATGATGATGTGGACCTTGAAACAGAACTTCCAACTTTTC (41) 69.4 
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Primers used for the site directed mutagenesis in the SacII 
site Tm (°C) 
MRP3_Mut_Sac_For 
GATGACCCACTGTCTGCGGTGGACTCTCA 
(29) 70.9 
   
MRP3_Mut_Sac_For 
TGAGAGTCCACCGCAGACAGTGGGTCATC 
(29) 70.9 
 
Primers used for colony PCRs 
AOX1 5' For GACTGGTTCCAATTGACAAGC 
  AOX1 3' Rev GCAAATGGCATTCTGACATCC 
  Strep tag II For CCTGGTCCCATCCACAATTTGAAAAG 
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